Exploration of cognitive and neurochemical deficits in an animal model of schizophrenia. Investigation into sub-chronic PCP-induced cognitive deficits using behavioural, neurochemical and electrophysiological techniques; and use of receptor-selective agents to study the pharmacology of antipsychotics in female rats. by McLean, Samantha L.
 University of Bradford eThesis 
This thesis is hosted in Bradford Scholars – The University of Bradford Open Access 
repository. Visit the repository for full metadata or to contact the repository team 
  
© University of Bradford. This work is licenced for reuse under a Creative Commons 
Licence. 
 
i  
 
 
EXPLORATION OF COGNITIVE AND NEUROCHEMICAL DEFICITS IN AN 
ANIMAL MODEL OF SCHIZOPHRENIA 
 
 
Investigation into sub-chronic PCP-induced cognitive deficits using behavioural, 
neurochemical and electrophysiological techniques; and use of receptor-selective agents 
to study the pharmacology of antipsychotics in female rats 
 
 
Samantha Louise MCLEAN 
 
 
submitted for the degree of 
Doctor of Philosophy 
 
 
School of Pharmacy 
 
University of Bradford 
 
2010 
 
 
 
 
ii  
ABSTRACT 
 
Keywords: Rat; Phencyclidine; Antipsychotics; Cognition; Dopamine; 5-HT; GABA 
 
Cognitive dysfunction is a core characteristic of schizophrenia, which can often persist when other 
symptoms, particularly positive symptoms, may be improved with drug treatment.  The non-
competitive NMDA receptor antagonist, phencyclidine (PCP), is a psychomotor stimulant drug that 
has been shown to induce symptoms characteristic of schizophrenia in humans and animals.   
The aim of these studies was to use the sub-chronic PCP model in rats to investigate 
cognitive dysfunction in behavioural tests which have been highlighted as relevance by the 
MATRICS initiative (MATRICS.ucla.edu).  The main tests used were attentional set-shifting, 
operant reversal learning, and novel object recognition tasks.  The pharmacology of antipsychotics 
was studied in the reversal learning task using receptor selective compounds.  Following this, 
experiments were carried out using in vitro electrophysiology and in vivo microdialysis in an attempt 
to investigate the mechanisms underpinning the PCP-induced cognitive deficits. 
The attentional set-shifting task is a test of executive function, the extra-dimensional shift 
(EDS) phase relates to the ability to shift attention to a different stimulus dimension; this is impaired 
in patients with schizophrenia.  The studies presented in chapter 2 showed that sub-chronic PCP 
administration impaired attentional set-shifting performance selectively in the EDS phase, a deficit 
which was significantly attenuated by sub-chronic administration of clozapine and risperidone, but 
not haloperidol.  The effect of PCP was also shown to be more robust in female rats compared to 
males.  A deficit in set-shifting ability was also observed in isolation reared rats.  However, the 
deficits produced by PCP were more robust than the deficit produced by isolation rearing. 
The reversal learning task is another test of executive function.  Chapter 3 reported that sub-
chronic PCP administration impairs reversal learning ability in an operant task, as demonstrated by 
reduced percent correct responding in the reversal phase of the reversal learning task.  It was found 
that a D1 agonist (SKF-38398), a 5-HT1A partial agonist (buspirone), a 5-HT2C antagonist (SB-
243213A) and an agonist and positive allosteric modulator of the alpha 7 nACh receptor (PNU-
282987 and PheTQS respectively) are able to reverse the sub-chronic PCP-induced deficit in 
reversal learning.  Although many antipsychotics have affinity for muscarinic M1 and histamine H1 
receptors, selective agents at these receptors were not able to improve the PCP-induced deficit. 
In chapter 4, the atypical antipsychotics, clozapine and risperidone, when given alone to 
naïve rats had no effect on reversal learning.  Haloperidol when given to naïve rats impaired 
performance at the highest dose.  Sub-chronic PCP was again found to impair reversal learning 
performance.  Investigative experiments revealed that the 2 min time-out could be important as a 
cue.  Following a double reversal, olanzapine-treated rats lost the ability to switch between the rules, 
whereas clozapine and risperidone-treated rats could perform the double reversal.  Experiments with 
the extended (15 min) reversal phase could allow the investigation of the time-course effects of 
antipsychotics or selective compounds.   
The studies presented in chapter 5 found a reduction in gamma oscillations in the CA3 
region of the hippocampus, following sub-chronic PCP treatment (2-5 weeks post treatment) that 
was paralleled by a deficit in parvalbumin immunoreactive (IR) cell density, at a similar time point 
(2 weeks post treatment).  In contrast, a time-dependent increase in gamma oscillations was observed 
(6-8 weeks post treatment), at which point parvalbumin IR cell density was unchanged (8 weeks post 
treatment).  Gamma oscillations were unchanged in the prefrontal cortex (PFC) following the PCP 
treatment regime.  Locomotor activity tests were also carried out to ensure that the sub-chronic PCP 
treatment was successful.  
In-vivo microdialysis revealed that vehicle-treated rats show an increase in dopamine in the 
PFC which is selective for the retention trial of the novel object recognition task.  PCP-treated rats 
were unable to distinguish between the novel and familiar objects and the increase in dopamine 
observed in vehicle rats was absent.  As a control experiment it was also shown that sub-chronic 
PCP did not induce anxiety-like symptoms in the elevated plus maze and open field tests.   
These studies suggest that sub-chronic PCP induces cognitive deficits in behavioural tasks, 
and these deficits may be due to GABAergic mediated processes in the hippocampus and 
dopaminergic dysfunction in the PFC.  These behavioural and neurochemical results are concurrent 
to findings observed in schizophrenia. 
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1.1 Schizophrenia 
Schizophrenia affects approximately 1% of the population.  Schizophrenia is a thought 
disorder, and is characterised by both disturbed form and content of thought (Feldman 
et al., 1997).  It is an accumulation of a wide range of symptoms which are 
characteristically grouped together to simplify diagnosis.  Symptoms were divided into 
positive and negative and stemming from the early work of Kraepelin (1913) and 
Bleuler (1950), a two-syndrome hypothesis was established by Crow (1980).  The 
disorder has now been categorised into more distinct types including catatonic, paranoid 
and disorganised (Stahl, 2002). 
There is strong evidence that there is a genetic predisposition to schizophrenia 
from many twin and adoption studies (Gottesman, 1991).  Current molecular genetic 
research is attempting to uncover a link between schizophrenia and specific genes (see 
Harrison and Owen, 2003).  Chromosome 22 has been associated with the disorder.  
Structural brain abnormalities have been found using CT scans and MRI in 
schizophrenic patients such as diffuse cerebral atrophy and ventricular enlargement 
(Weinberger, 1995; DeLisi, 1999).  These results have been confirmed by post-mortem 
studies (Brown et al., 1986).  There is also strong evidence for neurochemical changes 
to be implicated in schizophrenia (Glantz and Lewis, 2000), with several 
neurotransmitter systems involved, in particular dopamine and glutamate. 
 
1.2 Symptoms of Schizophrenia 
The onset of schizophrenia tends to be 18-25 in males and 25-30 in females, with 
episodes reoccurring throughout life (Buchanan and Carpenter, 2005).  Schizophrenia is 
considered a neurodevelopmental disorder (McGrath et al., 2003).  Many patients are 
unable to work due to the severity of their symptoms; therefore schizophrenia poses a 
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great social problem and is responsible for filling a majority of psychiatric hospital beds 
(Feldman et al., 1997).  Between 25 and 50% of patients attempt suicide, with 10% 
eventually succeeding.  Patients often require chronic treatment as the disorder is in 
many cases progressive.  Currently there is not a known cure for schizophrenia with 
drugs only treating some of the symptoms. 
 
1.2.1 Positive symptoms of Schizophrenia 
The positive symptoms (also named type I symptoms) are characterised by the more 
florid symptoms of the disorder and reflect an excess of normal function.  These 
typically include delusions, auditory hallucinations, distortions or exaggerations in 
language and communication, disorganised speech and behaviour and agitation (Stahl, 
2002).  Patients who suffer from predominantly positive symptoms tend to have had 
acute onset of the disorder.  These patients respond well to antipsychotic treatment, and 
when symptoms are in remission patients social functioning tends to be relatively good 
(Feldman et al., 1997).  
 
1.2.2 Negative symptoms of Schizophrenia 
The negative symptoms (also named type II symptoms) of schizophrenia represent a 
loss or reduction of normal function.  These symptoms are most resistant to 
antipsychotic treatment and symptoms may actually be exacerbated by treatment.  
Unlike patients with positive symptoms, patients with predominantly negative 
symptoms tend to show a long course of progressive deterioration, possibly reflecting 
long-term brain deterioration changes such as ventricular enlargement (Andreasen, 1987; 
Meltzer, 1987).  This symptom cluster has been difficult to model, but there is currently 
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a social withdrawal test which may model some of these deficits (Snigdha and Neill, 
2008a,b). 
 
1.2.3 Cognitive dysfunction in Schizophrenia 
Cognitive dysfunction is a core characteristic of schizophrenia (Sullivan et al., 1994; 
Elvevag and Goldberg, 2000; Kuperberg and Heckers, 2000) and is becoming 
increasingly important as impaired cognition has been implicated in poor long-term 
morbidity (Marder and Fenton, 2004) which can often persist when other symptoms 
may be improved with treatment (Gold et al., 1991).  One reason for the residual 
disability in schizophrenia appears to be the long-standing cognitive deficits of the 
disorder (Green and Nuechterlein, 2004).  Deficits often manifest in a generalised 
decrease in IQ (Elvevag and Goldberg, 2000).  Cognitive impairments appear to be 
stable from first episode through to late middle age (Heaton et al., 2001).   
The National Institute of Mental Health (NIMH) launched the Measurement and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative to 
address the fact that, although there are many antipsychotic drugs that alleviate 
psychotic symptoms, these do not reduce cognitive deficits.  Thus the MATRICS 
initiative was established to facilitate the development of novel pharmacological 
approaches for the treatment of the cognitive deficits in schizophrenia 
(www.matrics.ucla.edu).  One of the major accomplishments of this initiative was the 
identification of 7 primary cognitive domains that are affected in schizophrenia – 
attention/vigilance, speed of processing, working memory, verbal learning and memory, 
visual learning and memory, reasoning and problem solving, and social cognition 
(Green et al., 2004).  
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Whilst impairments have been reported across all of the cognitive domains 
identified by the MATRICS initiative above, impairments in executive function have 
long been considered to be a core feature of schizophrenia (Sullivan et al., 1994).  One 
aspect of executive function is the ability to modify behaviour in response to the 
changing relevance of a stimulus; this is commonly assessed in patients using the 
Wisconsin Card Sorting Test (WCST) (Berg, 1948).   In this test, subjects are presented 
with a set of cards with 3 different features (shape, colour, and number) and instructed 
to sort the cards without being told the relevant feature.  They must learn this based 
upon feedback from the tester.  Once they have established which is the correct feature, 
the rule is switched unannounced, and subjects must learn the new rule based upon 
feedback.  Patients with schizophrenia perform poorly on such tests as they lack the 
ability to inhibit a previously learned rule and are unable to shift their attention to the 
relevant stimulus (Goldberg et al., 1987; Morice and Delahunty, 1996).   
Deficits in working memory are also predominant in schizophrenia.  Working 
memory can be defined as a limited capacity memory system for the temporary storage 
and manipulation of information; this can include verbal material and visuospatial 
images (Keefe, 2000).  Functions of working memory include selective attention, 
maintenance of these selected events and integration of these with the experiences 
stored in long-term memory; these processes are essential for the operation of other 
types of memory, such as episodic or spatial, language, comprehension and reasoning 
(Baddeley, 1986). 
 
1.3 Behavioural tests of cognition 
Behavioural tests or measures are a very useful tool when developing an animal model.  
A major problem in developing an animal model of cognition is that involves several 
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domains, as highlighted by the MATRICS initiative (Green et al., 2004).  As a 
consequence, any one test cannot accurately describe these multiple dimensions of 
cognition.  It is therefore more conceivable to use several behavioural tests to 
characterise different aspects of cognition.  The novel object recognition, reversal 
learning and attentional set-shifting tasks have been highlighted by the MATRICS 
initiative as being relevant translational models for studying visual learning and 
memory and problem solving ability respectively pre-clinically (www.matrics.ucla.edu, 
see table 1.1).  Other cognitive tests highlighted by the MATRICS initiative include 
tests of working memory, for example delayed non-match to sample task, and tests of 
sensorimotor gating, such as pre-pulse inhibition (PPI). 
 
Table 1.1: Mapping animal tests onto cognitive domains affected in schizophrenia. 
Cognitive Domain Animal Models/Tests MATRICS Clinical Battery  
Working memory Operant or T-maze    
DNMTP/ DMTP 
Radial arm maze 
BACS 
WMS-III Spatial Span 
WAIS-III Letter-Number sequence 
UoM Letter-Number Span 
Spatial Delayed Response Task 
Attention/vigilance 
(pre-attentive 
processing) 
5-Choice Serial Reaction 
Time Task 
PPI,  auditory gating  
3-7 CPT 
Identical pairs CPT 
PPI, auditory gating 
Verbal learning and 
memory 
  NAB- Daily Living Memory 
HVLT-Revised 
Visual learning & 
memory 
Novel Object Recognition NAB – Shape Learning 
BVMT-Revised 
Speed of processing 5-Choice Serial Reaction 
Simple Reaction time tasks 
Category fluency 
Trail making A 
WAIS-III Digit Symbol-Coding 
BACS – Symbol Coding 
Reasoning & problem 
solving 
Attentional Set-shifting 
Maze tasks 
Serial Reversal Learning 
WAIS-III Block design 
BACS- Tower of London 
NAB – Mazes 
Social cognition Social interaction/Social 
recognition? 
MSCEIT – Managing emotions 
MSCEIT – Perceiving emotions 
Table 1.1: Tests of cognition highlighted by the MATRICS inititative.  Tests highlighted in yellow will 
be used in this thesis. 
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1.3.1 Novel object recognition 
The novel object recognition task (Ennaceur and Delacour, 1988) is a non-spatial test of 
recognition memory which is ethologically relevant as it relies on the animal‟s natural 
tendency to explore novel environments/objects.  This model is relevant to the disease 
since visual recognition memory is impaired in schizophrenic patients (Calkins et al., 
2005).   The task involves the rat being placed in an arena with 2 novel objects and 
exploration times of each object are scored, this is know as the acquisition trial.  This is 
followed by an inter-trial-interval, which can vary in length from 1 minute to days.  The 
rat is then placed back into the arena with a third copy of the familiar object and a novel 
object, again exploration of each object is timed.  The brain areas involved in object 
recognition depend upon the length of inter-trial interval used.  Following an interval of 
minutes it is believed that the PFC and/or perirhinal cortex are important for recognition 
(this will be further discussed in chapter 6), whereas following an interval in the region 
of hours it is thought that the hippocampus is involved in the recognition of the objects 
(Hammond et al., 2004). 
 
1.3.2 Reversal learning 
In the reversal learning paradigm, animals are required to perform two tasks.  The first 
task requires the animal to inhibit a previously learned rewarded strategy; in the second 
task, the animal must acquire the new strategy (Mackintosh and Little, 1969).  Effective 
performance requires intact cognitive ability; thus animals are required to demonstrate 
flexibility, attention, motivation, and ability to suppress a previously learned response 
and implement a new one (Jones et al., 1991).  In rats this reversal learning ability is 
assessed in operant chambers with two levers, an active lever which when pressed 
produces food from the magazine, and an inactive lever which has no consequence but 
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to end the trial.  The task involves an initial phase for 5 minutes in which one lever is 
active; this is followed by a 2 minute time-out period.  Then in the 5 minute reversal 
phase the opposite lever is now active (Abdul-Monim et al., 2003; 2006; Idris et al., 
2005a).  It has been shown that lesions of the orbital prefrontal cortex impair reversal 
learning ability (McAlonan and Brown, 2003; Tait and Brown, 2007; this will be further 
discussed in chapter 3). 
 
1.3.3 Attentional set-shifting 
The perceptual attentional set-shifting task (Birrell and Brown, 2000) investigates the 
ability of a rat to learn a rule and form an attentional set within the same sorting 
category (intra-dimensional shift - IDS), as well as the ability to shift attentional set 
between different sorting categories (extra-dimensional shift - EDS).  Rats must carry 
out a series of 7 discriminations namely, simple discrimination (SD), compound 
discrimination (CD), reversal 1 (R1), intra-dimensional shift (IDS), reversal 2 (R2), 
extra-dimensional shift (EDS) and reversal 3 (R3).  The attentional set-shifting task 
represents a rat analogue of the human Wisconsin Card Sorting Task (WCST, Berg, 
1948) and CANTAB ID/ED task (Downes et al., 1989) in which schizophrenic patients 
exhibit impaired set-shifting (Kolb and Wishaw, 1983; Haut et al., 1996; Pantelis et al., 
1999; Tyson et al., 2004).  It has been reported that lesions of the medial prefrontal 
cortex (mPFC) produce a selective deficit in the EDS phase in attentional set-shifting 
(Birrell and Brown, 2000; this will be further discussed in chapter 2).    
 
1.3.4 Pre-pulse Inhibition (PPI) 
In pre-pulse inhibition of the startle response (PPI) the animals are exposed to a weak 
stimulus prior to a startling stimulus.  The pre-stimulus causes no startle response but it 
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allows the animal to become aware of the startle stimulus thus reducing the magnitude 
of the startle response (Hert and Ellenbroek, 2000).  Normal individuals are able to filter 
out or inhibit responding to most of the sensory stimuli they receive, thus becoming 
quickly accustomed to the pre-stimulus.  However, schizophrenic patients have an 
abnormality of information processing and more specifically in filtering external stimuli 
(Braff and Geyer, 1990), a deficit of sensorimotor gating.  The deficits in PPI observed 
in patients with schizophrenia can be mimicked in rats via administration of dopamine 
agonists (Swerdlow et al., 1994), serotonin agonists and NMDA receptor antagonists 
(Swerdlow and Geyer, 1998; Geyer et al., 2001).  Furthermore, rats reared in isolation 
also show reduced PPI of the startle response (Geyer et al., 1993; Cilia et al., 2001).  It 
is important to note that deficits in PPI are neither unique to schizophrenia nor 
diagnostic of the disorder (see Geyer et al., 2001). 
 
1.4 Aetiology of schizophrenia 
Population, family and twin studies indicate that schizophrenia is a heritable disorder, 
but no single gene has a strong effect.  Schizophrenia is known to affect approximately 
1% of the population; however this is increased to 10% in first-degree relatives of 
patients with schizophrenia.  In dizygotic twins, one of whom has schizophrenia the 
probability of the other having the illness is 20%; furthermore in monozygotic twins this 
chance is further increased to 50% (Gottesman, 1991, see figure 1.4).  The disorder is 
more likely due to the synergistic interaction of multiple genes and environmental 
factors (Harrison and Weinberger, 2005; genetic models will be discussed in section 
1.6.4). 
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Figure 1.4: Risk of developing schizophrenia (adapted from Gottesman and Erlenmeyer-Kimling, 2001). 
 
 
1.5 Neurochemical hypothesis of schizophrenia 
There is strong evidence to suggest that disturbances of several neurotransmitter 
systems are implicated in schizophrenia.  Significant attention has been directed 
towards the monoamines, such as dopamine and 5-hydroxytryptamine (5-HT).  More 
recently, evidence points towards amino acid neurotransmitters such as gamma-
aminobutyric acid (GABA) and glutamate (Owen and Simpson, 1995).   
 
1.5.1 Dopamine 
There are four dopamine pathways in the brain, all of which mediate different functions.  
The mesolimbic dopamine system projects form the ventral tegmental area to the 
nucleus accumbens, it is thought to have an important role in producing the positive 
symptoms of schizophrenia.  The cell bodies of the mesocorticol dopamine pathway 
also arise in the ventral tegmental area and project to the limbic cortex; this pathway is 
believed to be involved in mediating the cognitive and negative symptoms of 
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schizophrenia (Weinberger et al., 1988).  It has been suggested that the negative 
symptoms of schizophrenia may arise from a dopaminergic deficit in the prefrontal 
cortex (hypofrontality), whereas the positive symptoms may be related to 
hyperdopaminergic activity in mesolimbic dopaminergic neurones (Davis et al., 1991; 
Laruelle et al., 2003).  The nigrostriatal dopamine pathway projects from the substantia 
nigra to the striatum.  This pathway is directly involved in the control of movement, 
therefore disordered function of this pathway whether natural or due to pharmacological 
intervention causes movement disorders (extrapyramidal symptoms).  The 
tuberoinfundibular pathway connects the hypothalamus to the anterior pituitary.  During 
treatment with antipsychotics the dopamine receptors in this pathway can be blocked, 
thus releasing prolactin secretion from inhibition, this can cause symptoms such as 
galactorrhea.       
Spano et al. (1978) proposed the existence of two populations of dopamine 
receptors after it was shown that dopamine both stimulated and inhibited adenylate 
cyclase (AC) activity (Brown and Makman, 1972; Kebabian et al., 1972).  D1 and D5 
receptors belong to the D1-like family in that they stimulate adenylate cyclase (AC), 
whereas D2, D3 and D4 receptors inhibit AC.  D1-like receptors are predominantly found 
in the PFC, while D2-like receptors are expressed in sub-cortical regions (see Guillin et 
al., 2007), although D4 receptors are present in the PFC and hippocampus (Lahti et al., 
1998).  In keeping with the dopaminergic hypothesis of schizophrenia current 
antipsychotics attenuate positive symptoms by blocking sub-cortical D2 receptors 
(Seeman et al., 1975; Creese et al., 1976) but these drugs have, at best, only limited 
efficacy at treating cognitive deficits.  As most current antipsychotics are equipotent for 
D2 and D3 receptors, it is unclear which pharmacological action accounts for their 
clinical profile.  D3 receptors are distributed in the mesocortical but not nigrostriatal 
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regions; therefore, blocking D3 receptors may improve cognitive and negative 
symptoms without producing extrapyramidal adverse effects (Joyce and Millan, 2005). 
 
1.5.2 Serotonin (5-HT) 
5-HT distribution is widespread, the cells occur in several large clusters in the pons and 
upper medulla, which lie close to the midline and are commonly referred to as the raphe 
nuclei.  The rostrally situated nuclei project to the many parts of the cortex, 
hippocampus, basal ganglia, limbic system and hypothalamus.  The caudally situated 
nuclei project to the cerebellum, medulla and spinal cord (Rang et al., 1995).  
Involvement of the serotonergic pathways in the pathophysiology of schizophrenia was 
suggested based on the observation that 5-HT agonists such as lysergic acid 
diethylamide (LSD) can induce or exacerabate schizophrenia-like symptoms in humans 
(see Roth and Meltzer, 1995).  To date all of the 5-HT receptors identified are G-protein 
coupled receptors, with the exception of the 5-HT3 receptor which is a ligand-gated ion 
channel (Barnes and Sharp, 1999; Nichols and Nichols, 2008).  Each receptor is 
subdivided into the following subtypes; 5-HT1A-F, 5-HT2A-C, 5-HT3A/B, 5-HT4A-D, 5-
HT5A/B, 5-HT6 and 5-HT7A-D (see Meneses, 1999).  The ability of atypical antipsychotics 
such as clozapine to reduce extra-pyramidal adverse effects led to the interest in 5-HT2A 
antagonists as potential targets for schizophrenia (Schmidt et al., 1995).  The location 
and pharmacology of the 5-HT receptors will be discussed in detail in section 1.7.3. 
 
1.5.3 Glutamate 
The major excitatory neurotransmitter in the brain, glutamate was first implicated in the 
cause of schizophrenia when it was found that phencyclidine, a glutamate NMDA 
receptor antagonist, induced schizophrenia-like symptoms in man (Luby et al., 1959). 
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Glutamate was also found in decreased concentrations in the cerebrospinal fluid of 
schizophrenic patients together with increased density of glutamate NMDA receptors in 
the corpus striatum (Kim et al., 1980).  Sub-anaesthetic doses of ketamine, another 
NMDA antagonist, in healthy volunteers have also been shown to induce both positive 
and negative-like symptoms of schizophrenia as well as cognitive impairments assessed 
by the WCST (Krystal et al., 1994; Malhotra et al., 1996).   
Selective agonists and antagonists led to the identification of three main 
subtypes of ligand-gated ion channels namely N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), and kainate receptors.  
In 1985, Sladeczek and co-workers reported that a novel glutamate receptor stimulated 
phospholipase C, this gave rise to the concept of metabotropic glutamate receptors.  
Genetic studies indicate the existence of 7 different metabotropic receptors namely 
mGluR1-7 (Schoepp et al., 1994).  These receptors can be subdivided (see table 1.2) 
based on the similarity of their amino acid sequence, pharmacology and second 
messenger coupling (Schoepp et al., 1994). 
 
Table 1.2: Subtypes of metabotropic glutamate receptors 
Receptor Pharmacological 
sensitivity 
Second messenger system 
mGluR1 
mGluR5 
trans-ACPD, quisqualate Positively coupled to phosphor-inositide second 
messenger system 
mGluR2 
mGluR3 
trans-ACPD Negatively coupled to adenylate cyclase 
mGluR4 
mGluR6 
mGluR7 
L-AP4, L-SOP Negatively coupled to adenylate cyclise 
Table 1.2: Subtypes of metabotropic glutamate receptors (Schoepp et al., 1994).  Trans-ACPD (trans-1-
aminocyclopentane-1,3-dicarboxylic acid) is a rigid analogue of glutamate; L-AP4 (L-2-amino-4-
phosphonobutyrate) and L-SOP (L-serine-O-phosphate) are phosphorylated amino acids. 
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1.5.3.1 NMDA receptors 
NMDA receptors show significant permeability to Ca
2+
, Na
+
 and K
+
 ions and are also 
subject to a voltage-dependent blockade by relatively low concentrations of Mg
2+
, i.e. 
when the cell membrane is depolarised the Mg
2+
 block is removed (Feldman et al., 
1997).  The NMDA receptor also requires glycine as a co-agonist; both glycine and 
glutamate have separate binding sites and both must be present for the channel to open 
(see figure 1.4.3).  The NMDA receptor is a heteromeric complex consisting of a 
combination of subunits from 3 subtypes: NR1, NR2, and NR3.  There are 8 different 
NR1 subunits generated from alternative spicing from a single gene, 4 different NR2 
subunits (A-D) and 3 NR3 subunits (A-C); the NR2 and NR3 subunits are encoded by 6 
different genes (Moriyoshi et al., 1991).  Expression of functional recombinant NMDA 
receptors in mammalian cells requires the co-expression of at least 1 NR1 and 1 NR2 
subunit.  Most commonly NMDA receptors consist of 2 NR1 and 2 NR2 subunits of the 
same subtype (Dingledine et al., 1999).   
 
Figure 1.4.3: NMDA Receptor Model (taken from http://abdellab.sunderland.ac.uk) 
 
The dominant hypothesis of the pathophysiology of schizophrenia until recently 
was the dopamine hypothesis as dopamine-releasing drugs such as amphetamine were 
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seen to cause psychosis.  However, a purely dopamine hypothesis is limited as negative 
and cognitive symptoms appear to be untreated by typical antipsychotics.  The 
glutamate hypothesis based on NMDA antagonists producing cognitive impairments 
may be more clinically relevant.  The main glutamate hypothesis arises from the 
NMDA receptor hypofunction hypothesis of schizophrenia of Olney and Farber (1995).  
They postulated that NMDA receptor hypofunction produces a reduction in inhibitory 
firing mediated by GABAergic neurotransmission.  In support of this hypothesis it has 
also been shown that glycine administration to enhance NMDA receptor function can 
improve schizophrenia aetiology when used in conjunction with other antipsychotic 
treatment (Rosse et al., 1989). 
 
1.5.4 GABA 
GABA is an inhibitory neurotransmitter.  GABAergic interneurons can be identified by 
their expression of neurochemical markers such as parvalbumin, calbindin, and 
calretinin, or by assessment of glutamic acid decarboxylase (GAD), the enzyme 
responsible for the breakdown of GABA (Benes and Berretta, 2001).  Post mortem 
studies have found reductions in the concentration of cortical GABA (Perry et al., 1979) 
and the activity of GAD (Bird, 1985), the enzyme that synthesises GABA.  The GABA 
deficit does not affect all cortical GABAergic interneurons equally (Benes et al., 1991) 
but is restricted to the basket and chandelier type of interneurons (Woo et al., 1998; 
Zhang and Reynolds, 2002).  These two types of interneurons contain the Ca
2+
 binding 
protein parvalbumin, and synapse onto pyramidal cells (Hendry et al., 1989).  Although 
there might be a modest reduction in the number of interneurons, the major changes are 
in the concentrations of particular proteins notably GAD67 and parvalbumin (Woo et al., 
1997; Lewis et al., 2005).  There are two isoforms of GAD; GAD65 is primarily 
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localised in axon terminals, while GAD67 is found in the somata and dendrites of 
GABAergic cells (Kauffman et al., 1991). 
 GABA increases Cl
-
 conductance across the membrane, leading to a rapid 
hyperpolarisation of the postsynaptic cell, which accounts for the inhibitory action of 
GABA (Harris and Allan, 1985).  GABA acts on 3 subtypes of receptors, namely 
GABAA-C.  The GABAA and GABAC receptors are ligand-gated ion channels and the 
GABAB receptor is a G-protein coupled receptor.  The Cl
-
-dependent effects of GABA 
are generally mediated by the GABAA receptors as this contains the chloride channel.  
The GABAA receptors have different binding sites, namely the GABA 
(agonist/antagonist) site, benzodiazepine site, steroid site, barbiturate site and the 
picrotoxin site (Olsen et al., 1991).  GABAB receptors are located both post- and pre-
synaptically; those located on the nerve terminal inhibit transmitter release.  GABAB 
receptors are known to utilise at least 4 different effector mechanisms 1) inhibition of 
adenylyl cyclase, 2) stimulation of phospholipase A2, 3) increased K
+
 membrane 
conductance, and 4) inhibition of a voltage-dependent membrane Ca
2+
 conductance 
(Wojcik and Holopainen, 1992). 
 
1.5.5 Involvement of other neurotransmitters in schizophrenia 
Acetylcholine (ACh) is known to play an important role in various domains of cognition, 
particularly attention, learning, and memory (Friedman, 2004).  Indeed, cholinergic 
dysfunction has been shown to be central to the pathophysiology of Alzheimer‟s disease 
and has also been postulated to contribute to the cognitive deficits of various 
neuropsychiatric disorders, including schizophrenia (Friedman, 2004).  The basal 
cholinergic complex sends widely diffuse afferents through 2 projections: the 
septohippocampal and the nucleus basalis of Meynart cortical pathways (Woolf and 
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Butcher, 1989).  The septohippocampal pathway is important in working memory 
processes through hippocampal storage of intermediate-term memory (Brito et al., 1983; 
Fadda et al., 1996) whereas the nucleus basalis of Meynart cortical pathway is involved 
in reference memory through long-term information storage in the neocortex (Dunnett, 
1985; Meck et al., 1987).  Pharmacologically, muscarinic receptor antagonists, such as 
scopolamine, produce learning impairments in healthy subjects (Sitaram et al., 1978).  
The pharmacology of relevant ACh receptors to cognition will be discussed further in 
section 1.6.3 and in chapter 3.   
The central noradrenergic (NA) system projects from the locus coeruleus to the 
prefrontal cortex where α2-adrenoceptors appear to play an important role in cognitive 
functioning (Arnsten, 2004).  Indeed, treatment with the α2-adrenoceptor agonists, 
clonidine and guanfacine, has been shown to improve cognitive performance without 
exacerbating positive symptoms in small trials of patients with schizophrenia (Fields et 
al., 1988; Friedman et al., 2001). 
 
1.6 Animal Models of Schizophrenia 
Animal models are critical in understanding the mechanisms underlying many human 
diseases, and in particular psychiatric disorders.  However, an animal model of 
schizophrenia has proved to be very difficult to develop as it is mainly a thought 
disorder involving complex cortical processes which may not be expected to be found in 
lower mammals.  Consequently, the aetiology of the disease also remains poorly 
understood. 
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1.6.1 Use of pharmacological agents to mimic schizophrenia 
There are many animal models of some of the symptoms of schizophrenia based on 
clinical observations that psychostimulant drugs such as amphetamine and 
phencyclidine (PCP) can produce schizophrenia-like symptoms.  Amphetamine can 
produce the more florid positive symptoms of schizophrenia such as paranoia, 
hallucinations and delusions; this is modelled in animals as hyperactivity (Jentsch et al., 
1998).  In contrast, PCP can produce both positive and negative symptoms as well as 
cognitive deficits (Jentsch and Roth, 1999).  The apparent relationship between 
amphetamine and phencyclidine (PCP) induced psychosis and schizophrenia has made 
these compounds the primary psychotomimetic agents for modelling schizophrenia in 
the laboratory. 
 
1.6.1.1 Amphetamine  
D-amphetamine causes increased dopamine by different mechanisms such as blocking 
reuptake via the dopamine transporter, and via disruption of dopamine‟s vesicular stores; 
this can increase locomotor activity and produce stereotypy.  Stereotypy is a syndrome 
which includes increased sniffing, grooming, and licking (Randrup and Munkurad, 
1967).  These seemingly meaningless behaviours are also observed in humans with 
compulsive repetition in response to high doses of amphetamine.  In humans, psychosis 
following frequent high doses of amphetamine consists of paranoid delusions, various 
forms of stereotyped behaviour, compulsive behaviour and predominantly visual 
hallucinations (Curran et al., 2004; Lieberman et al., 1987).  In animals, treatment with 
amphetamine and apomorphine (a dopamine receptor agonist) increases locomotor 
activity, catalepsy, and stereotyped behaviour (Gambill and Kornetsky, 1976); effects 
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which are successfully antagonised by dopamine antagonists including antipsychotics 
(Ellison and Eison, 1983).  
 
1.6.1.2 Phencyclidine (PCP)  
The non-competitive NMDA receptor antagonist, phencyclidine (PCP), is a 
psychomotor stimulant drug that has been shown to induce symptoms characteristic of 
schizophrenia (Javitt and Zukin, 1991; Jentsch et al., 2007).  PCP and its structural 
analogue ketamine produce inactivation of inhibitory control by decreasing GABA 
release (Yonezawa et al., 1998).  This disinhibition of excitatory neurotransmission is 
referred to as NMDA receptor hypofunction (Jentsch and Roth, 1999; Olney and Farber, 
1995; Olney et al., 1999).  PCP has been shown to disturb dopamine levels in the 
prefrontal cortex and nucleus accumbens.  The reduction of dopamine levels in the PFC 
is associated with negative and cognitive symptoms of schizophrenia (Jentsch and Roth, 
1999), while an increase in dopamine in the nucleus accumbens is associated with 
hyperlocomotion often seen in PCP-treated animals (Jentsch et al., 1998).  Acute 
administration of PCP in rats has been shown to produce deficits in the novel object 
recognition (NOR) task (Grayson and Neill, 2004), an operant reversal learning 
paradigm (Abdul-Monim et al., 2003; Idris et al., 2005a) and attentional set-shifting 
(Egerton et al., 2005).  Acute PCP disrupts PPI of the startle reflex (Geyer et al., 1984), 
a test of relevance to schizophrenia as such deficits are also exhibited by patients with 
schizophrenia (Braff et al., 1978; 1992). 
Acute dosing with PCP has limitations in modelling the chronic psychotic illness 
or the persistent cognitive deficits of schizophrenic patients.  Alternatively, repeated 
sub-chronic exposure to psychomotor stimulant drugs such as PCP, and d-amphetamine, 
produce enduring behavioural, molecular, structural and cellular changes, which are 
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believed to mimic schizophrenia more accurately than acute dosing (Fletcher et al., 
2005; Jentsch and Roth, 1999; Tenn et al., 2003).  Examples of these changes include 
reduced frontal blood flow and glucose utilisation (Hertzman et al., 1990; Wu et al., 
1991) and reduced frontal dopamine transmission (Jentsch et al., 1997).  Sub-chronic 
administration of PCP also produces deficits in social withdrawal (Snigdha and Neill, 
2008a,b).  A table comparing amphetamine, PCP and isolation rearing models is shown 
in table 1.3. 
 
1.6.2 Non-pharmacological models of schizophrenia 
Environmental factors may alter normal processing of information during adulthood 
resulting in a psychotic state (Weinberger and Lipska, 1995).  Abnormal development 
of the brain during gestation or soon after may contribute to the manifestation of 
schizophrenia in later life (Akil, 2000).  There are several non-pharmacological models 
which aim to produce deficits that are caused in development. 
 
1.6.2.1 Isolation rearing model 
Early observations of behaviour in rats reared in isolation led to the description of the 
“isolation syndrome” (Hatch et al., 1965; Sahakian et al., 1977).  Rats reared in 
isolation from weaning until adulthood show several behavioural changes, consistently 
including increased locomotor activity, anxiogenesis, (Puglisi-Allegra and Oliverio, 
1983), enhanced sensitivity to psychoactive drugs such as amphetamine and cocaine 
(Jones et al., 1990; Smith et al., 1997) and sensorimotor gating deficits as measured by 
reduced pre-pulse inhibition (PPI) of the startle response (Geyer et al., 1993; Cilia et al., 
2001).  In addition, administration of sub-chronic PCP was found to enhance the 
locomotor activity observed in isolates (Lapiz et al., 2003).  Rats reared in isolation 
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have been shown to exhibit higher dopamine levels in the nucleus accumbens (NAC) 
and striatum, as well as a reduction in 5-HT levels within the NAC (Fulford and 
Marsden, 1998; Jones et al., 1991; 1992).  Studies have also demonstrated that the 
isolation rearing induced changes in presynaptic dopamine receptor function were also 
accompanied by postsynaptic dopamine changes including a down-regulation of D2 
receptors in the NAC (Hall et al., 1998).  Effects which may be associated with 
decreased presynaptic 5-HT function in the frontal cortex and hippocampus have also 
been demonstrated (Lapiz et al., 2003).  It has also been found that isolation-reared rats 
show decreased dopamine turnover in the mPFC (Heidbreder et al., 2000), a region 
important for cognition (Goldman-Rakic et al., 2000), particularly attentional set-
shifting (Birrell and Brown, 2000).  However, relatively few reports have investigated 
the effect of isolation rearing on cognition of relevance to schizophrenia (Weiss et al., 
2004, Li et al., 2007, Schrijver and Wurbel, 2001; Dalley et al., 2002).  Although, more 
recent studies have shown that rats reared in isolation demonstrate deficits in novel 
object recognition (Bianchi et al., 2006).  Furthermore, treatment with the ampakine, 
aniracetam, or the 5-HT6 antagonist, PRX-07037, both restored novel object recognition 
levels to those seen in socially housed controls (Porkess et al., 2006; King et al., 2007).  
This is due to the theories that AMPA and 5-HT6 receptors are important for cognition 
in schizophrenia.  AMPA receptors work closely with NMDA receptors to maintain 
glutamatergic function (Javitt, 2004).  However, AMPA receptors are prone to rapid 
densenitisation; therefore ampakines have been developed as allosteric modulators of 
AMPA receptors and do not cause desensitisation of the receptor (Yamada et al., 1998).  
Ampakines have been shown to enhance glutamatergic transmission, and to facilitate 
LTP (Hampsen et al., 1998a, b).  5-HT6 receptors have been implicated as having a role 
in learning and memory processes in healthy and disease states (Fone, 2008; Mitchell 
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and Neumaier, 2005; Woolley et al., 2004; see section 1.7.3). A table comparing 
amphetamine, PCP and isolation rearing models is shown in table 1.3. 
 
Table 1.3: Comparison of amphetamine, PCP and isolation rearing animal models. 
 Animal model 
Impaired phenotype Amphetamine PCP Isolation rearing 
Locomotor activity +++ ++ +++ 
Gating + + + 
Cognitive behaviour +/- +++ ++ 
Social behaviour - ++ + 
Schizophrenia pathology + ++ ++ 
Table 1.3: Comparison of amphetamine, PCP and isolation rearing animal models.  The success of each 
model in producing deficits in the phenotype is indicated by +, ++, +++. +/- indicates some deficits 
depending on dosage regimen. Data taken from Schizophrenia Research Forum 
(www.schizophreniaforum.org). 
 
1.6.2.2 Neurodevelopmental and lesion models of schizophrenia 
Early postnatal treatment of rats with PCP on postnatal days (PNDs) 7, 9 and 11 has 
been proposed as a neurodevelopmental model of schizophrenia (Wang et al., 2001).  
This treatment regimen has been reported to produce widespread neurodegeneration in 
brain areas relevant to the cognitive deficits observed in schizophrenic patients, such as 
the hippocampus and frontal cortex (Ikonomidou et al., 1999; Wang and Johnson, 2005).  
Broberg et al. (2008; 2009) showed that this neonatal PCP regimen could impair 
performance in the attentional set-shifting task.  Harich et al., (2007) also showed that 
neonatal PCP produced impairments in social discrimination which was reversed by 
clozapine.  In addition neonatal PCP treatment produces increased locomotor activity 
following an acute PCP challenge and induces deficits in PPI of the startle stimulus and 
delayed spatial alternation task (Wang et al., 2001). 
Disruption of neurogenesis by prenatal treatment with methylazoxymethanol 
(MAM), an anti-mitotic agent, has also been explored as a possible neurodevelopmental 
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model of schizophrenia. Recent studies have reported that MAM administration at 
gestational day 17 produced cognitive deficits as well as behavioural alterations in adult 
rats believed to correspond to certain aspects of the positive and negative symptoms of 
schizophrenia (Flagstad et al., 2004, 2005; Gourevitch et al., 2004; Penschuck et al., 
2006; Moore et al., 2006; Le Pen et al., 2006). Moreover, consistent with the data found 
in schizophrenic subjects, morphological and/or functional abnormalities such as 
disrupted neurogenesis and decreases in parvalbumin expressing neurons have been 
observed in the hippocampus, medial prefrontal cortex (mPFC) and ventral striatum of 
rats prenatally exposed to MAM (Flagstad et al., 2004; Gourevitch et al., 2004; Lavin et 
al., 2005; Penschuck et al., 2006; Moore et al., 2006).  
 Lesions of the ventral hippocampus in neonates, but not in adults, induce the 
same deficits in working memory as medial PFC (mPFC) lesions in adult rats 
performing continuous delayed alternation and variable-delay alternation tasks (Lipska 
et al., 2002). Neonatal ventral hippocampal-lesioned (NVH) rats also show a similar 
deficit prior to puberty in the radial arm maze (Chambers et al., 1996). Following 
lesions of the NVH, rats are also impaired in the Morris water maze (Le Pen et al., 
2000).  Multiple measures of working memory in rodents provide concordant evidence 
that interference with normal development in the functional circuitry of ventral 
hippocampus and PFC induces a postpubertal emergence of cognitive deficits consistent 
with findings in schizophrenia. Evidence for a role for mPFC in this process stems from 
studies that have shown alterations in gene expression, neuronal morphology and 
neurochemistry in mPFC following lesions of the NVH, consistent with the 
neuroanatomical connections between ventral hippocampus and mPFC in the rat 
(Lipska and Weinberger 2000).  NVH lesions also disprupted the extra-dimensional 
shift phase of the attentional set-shifting task, a task known to require intact mPFC 
24  
function (Birrell and Brown, 2000) in juvenile rats (Marquis et al., 2008), and deficits 
are also observed in the five-choice serial reaction time task (LePen et al., 2003).  
Notably, NVH lesions in rodents also induce a postpubertal onset of deficits in 
sensorimotor gating or pre-pulse inhibition (PPI; Chambers et al., 1996; Le Pen et al., 
2000; Daenen et al., 2003), a consistent feature in schizophrenia spectrum disorders 
(Swerdlow et al., 1994; Braff et al., 2001; Geyer et al., 2001). However, 
pharmacological activation/disruption of either ventral hippocampus (Bast et al., 2001) 
or mPFC (Japha and Koch 1999) also produces PPI deficits in adult rats, suggesting that 
a progressive disruption of functional circuitry is not obligatory for induction of this 
deficit. 
 
1.6.3 Pathophysiological changes observed in schizophrenia and similarities with PCP 
and isolation rearing models  
In patients with schizophrenia CT and MRI longitudinal studies have suggested cerebral 
ventricular enlargement and hemisphere volumetric reductions (see DeLisi, 1999).  
Furthermore, positron emission tomography (PET) and fMRI functional measurements 
are often reported to be abnormal in the PFC in schizophrenia (reviewed by Wible et al., 
1995).  Post-mortem analysis of brain tissue from schizophrenic patients has shown a 
reduction in GABAergic interneurons in the frontal cortex (Benes et al., 1991) and 
hippocampus (Benes and Berretta, 2001).  Calcium binding proteins (CBP), namely 
parvalbumin (PV), calbindin (CB) and calretinin (CR) have been used as markers of 
specific subpopulations of non-overlapping GABAergic interneurons in the brain.  The 
GABAergic deficits found in schizophrenia are largely restricted to the PV-containing 
neurons (Lewis et al., 2005).  Reduced density of parvalbumin immuno reactive 
neurons in the hippocampus and M1 (motor area 1) region of the frontal cortex 
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following sub-chronic PCP treatment in the rat was recently shown (Abdul-Monim et 
al., 2007).  It has also been shown that chronic intermittent administration of PCP 
decreases parvalbumin mRNA expression in the prefrontal cortex of rats, and that this 
reduction can be reversed by clozapine but not haloperidol (Cochran et al., 2003).  
These findings provide further support for the theory that sub-chronic PCP treatment in 
the rat provides a good correlate of the clinical condition.   
Schizophrenic patients exhibit decreased dendritic spine density in both the 
hippocampus and medial prefrontal cortex (Glantz and Lewis, 2000).  These structural 
alterations are also seen in rats reared in isolation (Varty et al., 1999; Silva-Gomez et al., 
2003; Day-Wilson et al., 2006).  Reduced density of parvalbumin immuno-reactive 
neurons in the hippocampus were also found following isolation rearing (Harte et al., 
2006).  Levels of N-acetyl aspartic acid (NAA), a marker of neuronal integrity, were 
shown to be decreased in the temporal cortex of isolation-reared rats, while these 
changes were not observed in the hippocampus, striatum or frontal cortex (Harte et al., 
2004); deficits were also found in the temporal cortex only in rats that were chronically 
treated with PCP (Reynolds et al., 2005).  These decreases resemble the pattern 
observed in patients with schizophrenia (Fukuzako et al., 1995).  However, some 
studies have reported reductions in NAA in the frontal cortex in schizophrenia 
(Bertoline et al., 1998; Cecil et al., 1999).  NMDA receptor subunit 1A mRNA 
expression was decreased in isolation-reared rats in the striatum and prefrontal cortex 
(Hall et al., 2002).  However, these results were not similar to those found following 
sub-chronic PCP administration (Snigdha, PhD thesis).  
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1.6.4 Genetic models of schizophrenia 
Construction of mice with targeted mutations via gene knockout or transgenesis has 
demonstrated the ability to identify the functional significance of the targeted gene and 
its encoded protein (Tecott and Wehner, 2001).  Several schizophrenia-susceptibility 
genes have been identified (Harrison and Owen, 2003).  These identified genes may 
impact on the neurodevelopmental aspect of schizophrenia and several are involved in 
glutamatergic transmission particularly via NMDA receptors (Tsai and Coyle, 2002).  
These genes include dysbindin which is involved in the formation and maintenance of 
synapses (Straub et al., 2002), and proline dehyrogenase (PRODH) which affects 
glutamatergic synapses.  RGS4 (regulator of G-protein signalling-4) is a negative 
regulator of glutamate receptors and may have neurodevelopmental roles (De Vries et 
al., 2000). D-aminoacid oxidase (DAAO) and G72 impact directly on NMDA receptors 
as DAAO metabolises D-serine, an endogenous modulator of the receptor (Mothet et al., 
2000), and G72 is believed to be the activator of DAAO (Chumakov et al., 2002).  
Neuregulin-1 (NRG-1) is present in glutamatergic synaptic vesicles, and affects NMDA 
receptors via actions on ErbB receptors and regulation of NMDA receptor expression 
(Buonanno and Fischbach, 2001; Stefansson et al., 2002).  Catechol-O-
methyltransferase (COMT) acts directly on monaminergic neurotransmission (Gogos et 
al., 1998) and can subsequently affect other systems such as the glutamatergic system 
via links with the dopamine system (Grace, 1991).  Disrupted-in-Schizophrenia-1 
(DISC-1) is one of the strongest candidate genes through genetic and clinical 
association studies (Ishizuka et al., 2006; Porteous et al., 2006).  The disruption in this 
gene is cosegregated with schizophrenia, major depression and bipolar disorder in a 
large Scottish family (Millar et al., 2000; Millar et al., 2001).  Since its discovery 
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reproducible linkage between regions of DISC-1 and psychiatric diseases have been 
observed in many populations (see Wang et al., 2008). 
 Despite the merits of genetic models of schizophrenia, it must be emphasised 
that the mutation of a specific susceptibility gene is unlikely to give rise to a phenotype 
that encompasses all aspects of schizophrenia; such mutants should not be considered to 
model schizophrenia, but, rather, to model the functional roles of genes associated with 
risk of schizophrenia.  In addition, as such genetic mutations occur upstream from the 
cellular and physiological mechanisms that give rise to abnormal behaviour, they are 
inevitably subject to environmental influences and compensatory/adaptive effects (see 
Desbonnet et al., 2009). 
 
1.7 Antipsychotics 
Cognitive symptoms can often persist when other symptoms may be improved with 
treatment (Gold et al., 1991).  Novel antipsychotics are required to improve cognition as 
the Clinical Antipsychotic Trials of Invention Effectiveness (CATIE) study revealed 
that atypical antipsychotics, such as clozapine, show little improvement compared to 
typical antipsychotics, against cognitive symptoms (Lieberman, 2006; Keefe et al., 
2007). 
 
1.7.1 Typical antipsychotics 
The classical antipsychotics such as haloperidol, chlorpromazine and thioridazine, act 
via blockade of dopamine D2 receptors, muscarinic cholinergic receptors, α1-adrenergic 
receptors and histamine receptors (Stahl, 2002).  This group of antipsychotics are 
effective in controlling positive symptoms of schizophrenia, but are ineffective in 
treating negative or cognitive symptoms.  Furthermore, typical antipsychotics have 
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significant adverse effects such as tardive dyskinesia and extra-pyramidal symptoms 
due to the blockade of dopamine receptors in the nigrostriatal pathway (Casey, 1996).  
Hyperprolactinemia may also be a side effect when tuberoinfundibular D2 receptors are 
blocked (Windgassen et al., 1996).  Due to these debilitating adverse effects and 
apparent lack of efficacy against many of the symptoms of schizophrenia, much 
research has been focused on developing novel antipsychotics. 
 
1.7.2 Atypical antipsychotics 
The label of “atypical” antipsychotics is usually based on the drugs‟ ability to reduce 
schizophrenic symptoms without causing extra-pyramidal adverse effects.  Benefits of 
atypical antipsychotics include efficacy against positive, negative, and disorganised 
symptoms, improvements of some areas of cognition, lack of development of tardive 
dyskinesia and lack of hyperprolactinaemia.  Some atypical antipsychotics were 
developed to be more selective for the D2 receptor such as sulpiride.  However, most 
new antipsychotics have affinity for multiple receptors, for example risperidone acts as 
an antagonist at 5-HT2A, 5-HT7, α1 and α2-adrenergic, and histamine H1 receptors. 
Atypical antipsychotics improve on the action of the typical antipsychotics by 
blocking 5-HT and dopamine receptors simultaneously.  The significance of 5-HT is 
that it can control the release of dopamine to differing degrees in the four different 
pathways.  In the nigrostriatal pathway 5-HT exhibits significant control over dopamine, 
therefore blocking 5-HT receptors stimulates dopamine release which consequently 
prevents EPS and tardive dyskinesia (Lieberman et al., 1998).  In the mesocortical 
dopamine pathway there is an abundance of 5-HT receptors, thus the atypical 
antipsychotics have a greater effect on 5-HT antagonism therefore increasing dopamine 
release.  Increase in dopamine release in this area of the brain helps to reduce negative 
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symptoms and may also improve cognition (Lieberman et al., 1998).  In the 
tuberoinfundibular pathway dopamine inhibits prolactin release, however when D2 
receptors are blocked, hyperprolactinaemia occurs.  With atypical antipsychotics, there 
is simultaneous inhibition of 5-HT2A receptors, thus there is no longer stimulation of 
prolactin release, and this tends to mitigate the hyperprolactinaemia of D2 receptor 
blockade.  In the mesolimbic pathway, atypical antipsychotics have little impact as they 
fail to prevent D2 receptor blockade.   
 
1.7.3 Pharmacology of antipsychotics and receptor targets for cognition 
Results in this laboratory have shown that atypical but not classical antipsychotics can 
reverse cognitive deficits induced by sub-chronic PCP administration in an operant 
reversal learning paradigm (Abdul-Monim et al., 2006), and in a novel object 
recognition task (Grayson et al., 2007).  Molecular targets for cognitive enhancement in 
schizophrenia were highlighted by Gray and Roth (2007) and are shown in table 1.4. 
Mounting evidence suggests that the D1 receptor in the mPFC may be important 
in regulating cognitive function in schizophrenic patients.  Okubo and colleagues (1997) 
reported a down-regulation of D1 binding in the PFC of treatment-free/-naïve 
schizophrenic patients.  Another study has demonstrated an association between genetic 
risk for schizophrenia and alterations in cortical D1 receptor binding (Hirvonen et al., 
2006). It has also been shown that D1 receptors are more abundant than D2 receptors in 
the PFC of non-human primates (Lidow et al., 1991), and this D1 receptor subfamily has 
been implicated in working memory functions of the PFC (Arnsten et al., 1994, 
Sawaguchi and Goldman-Rakic, 1991) one aspect of cognition impaired in 
schizophrenia. Thus, it is possible that stimulation of the D1 receptor may represent a 
potential strategy for treating cognitive deficits associated with schizophrenia. However, 
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the use of D1 receptor agonists as therapeutic agents pose difficulties for 
pharmacologists as dopamine function in the PFC seems to follow an “inverted-U” 
dose-response relationship whereby increases or decreases from an optimal level result 
in cognitive impairment (Goldman-Rakic et al., 2000). 
There is evidence to show that 5-HT1A receptor density is high in the frontal 
cortices of patients with schizophrenia (Burnet et al., 1997) and a subsequent PET study 
has shown an increase in cortical 5-HT1A receptor binding in schizophrenia (Tauscher et 
al., 2002).  Post-mortem studies have also indicated abnormalities in 5-HT1A receptor-
mediated transmission in the frontal cortex of patients with schizophrenia (Sumiyoshi et 
al., 1996).  5-HT1A receptor agonism has been suggested to contribute to an atypical 
antipsychotic drug profile (Protais et al., 1994).  There are also interactions between 5-
HT2A, 5-HT2C and 5-HT1A receptors (Kapur and Remington, 1996; Meltzer, 1999).  The 
5-HT2A antagonist, M100.907, is efficacious in improving a sub-chronic PCP-induced 
deficit in reversal learning (Neill et al., 2008).  Antagonism at 5-HT2C receptors by 
various atypical antipsychotics (e.g. clozapine, risperidone, sertindole and ziprasidone; 
Roth et al., 2003) may play a role in their beneficial effects and their diminished 
likelihood to produce to neurological adverse effects (Meltzer, 1995; 1999).  Conversely, 
in a recent study, WAY-163909, a selective 5-HT2C agonist, demonstrated anti-
psychotic-like properties by reversing increased locomotor activity induced by PCP and 
amphetamine and reversing MK-801-induced disprution in PPI (Marquis et al., 2007).  
Antagonism at the 5HT2C receptor can increase food intake and body weight in rats 
(Bonhaus et al., 1997), thus this may not be an advantageous strategy for treatment in 
patients as weight gain is a major adverse effect and could affect compliance  (see 
Allison et al., 1999 for meta-analysis).  Furthermore, it had been found that knock-out 
mice lacking the 5-HT2C receptors are hyperphagic and obese (Tecott et al., 1995).  
31  
Antipsychotics that induce body weight gain appear to have combinations of high 
affinities for 5-HT2C, α1, H1 and M1 receptors (Baptista, 2000; Casey and Zorn, 2001; 
Hartfield et al., 2003).  In patients, olanzapine dramatically increases weight gain (Eder 
et al., 2001).  Although ziprasidone also has high affinity for 5-HT2C receptors it was 
shown not to induce ingestive behaviour and intra-abdominal fat deposition in rats (Fell 
et al., 2005).  Indeed, it was demonstrated that ziprasidone, when co-administered with 
olanzapine, attenuated the olanzapine-induced hyperphagia (Kirk et al., 2004).  This 
was suggested to be due to ziprasidone‟s action as a 5-HT1A partial agonist, a property 
which may protect against weight gain (Casey and Zorn, 2001).   
5-HT6 receptors have been implicated as having a role in learning and memory 
processes in healthy and disease states (Mitchell and Neumaier, 2005; Woolley et al., 
2004).  High levels of 5-HT6 receptor mRNA are found in the striatum, nucleus 
accumbens, hippocampus and cortex (Monsma et al., 1993; Ruat et al., 1993).  Many 
atypical antipsychotics are potent antagonists at the 5-HT6 receptor (Roth et al., 2004), 
making it a target of interest.  A selective 5-HT6 receptor antagonist, SB 399885-T, has 
been shown to improve set-shifting ability (Hatcher et al., 2005), this may be via 
facilitation of cortical and hippocampal glutamatergic activity (Dawson et al., 2001). 
Results from this laboratory have reported that the 5-HT6 receptor antagonist, GSK 
742457, and the atypical antipsychotic sertindole a drug with high 5-HT6 receptor 
affinity (Leysen, 2000), are able to reverse a sub-chronic PCP-induced deficit in 
reversal learning (Idris et al., in preparation; Neill et al., 2008).  Antagonism at 5-HT6 
receptors may improve cognition by increasing dopamine (Lacroix et al., 2004) and 
acetylcholine (Riemer et al., 2003) levels in the PFC.  5-HT7 receptors are located in the 
thalamus, hypothalamus, amygdala in addition to limbic and cortical regions (Thomas et 
al., 2002; Varnas et al., 2004).  5-HT7 receptors have been implicated as having a role 
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in learning and memory (Hedlund and Sutcliffe, 2004; Thomas and Hagan, 2004).  The 
5-HT7 receptor is a potential target of relevance to schizophrenia as many atypical 
antipsychotics such as risperidone and ziprasidone have affinity for this receptor (Roth 
et al., 1994; Siegfried et al., 2005; Shahid et al., 2008), and some e.g. clozapine have 
significant inverse agonist activity (Mahe et al., 2004).  It has been hypothesised that 5-
HT7 receptor antagonists may reverse PCP-induced deficits via the prevention of 5-HT 
and/or glutamate release (Semenova et al., 2008). 
Nicotinic acetylcholine receptors (nAChRs) are ionotrophic receptors with a 
pentameric structure composed of α and β subunits, and are highly expressed in the 
hippocampus, cortex, striatum, and thalamus (Freedman et al., 1995; Breese et al., 
2000).  The most prevalent nAChRs are the α4β2 and α7 subtypes, both of which have 
been shown to have reduced numbers in schizophrenia (Freedman et al., 1995; Breese et 
al., 2000).  It has been suggested that these receptor subtypes are involved in cognition 
(Schreiber et al., 2002; Chan et al., 2007; Gray and Roth, 2007; this will be further 
discussed in chapter 3).  Muscarinic ACh receptors are G-protein coupled.  Post mortem 
studies using the selective M1/M4 radioligand [
3
H]pirenzepine have found decreased 
density of M1 and/or M4 receptors in the frontal cortex (Crook et al., 2001) and 
hippocampus (Crook et al., 2000).  The M1 receptor subtype (discussed further in 
chapter 3) is the most abundant muscarinic receptor in the forebrain and hippocampus 
(Levey et al., 1991; Wei et al., 1994).  Furthermore, it has been shown that M1 deficient 
mice demonstrate deficits in working and reference memory (Anagnostaras et al., 2003).  
N-desmethylclozapine (NDMC), a major metabolite of clozapine, has been shown to 
increase ACh and DA in the frontal cortex, an effect due to the stimulation of M1 
receptors, confirming that NDMC had M1 agonistic actions (Li et al., 2005). 
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There are 7 known metabotropic receptors (see section 1.5.4).  Targets of 
importance to cognition and schizophrenia are mGluR2/3 agonists and mGluR5 
agonists. mGluR2 and mGluR3 receptors exhibit moderate to high expression in 
forebrain regions that are commonly associated with schizophrenia such as the frontal 
cortex, hippocampus and nucleus accumbens (Ohishi et al., 1993).  These receptors are 
localised mainly pre-synaptically on glutamate nerve terminals; the mGluR2/3 appear to 
act on a presynaptic site to inhibit glutamate release from the glutamate neurons 
(Schoepp et al., 1999; Kilbride et al., 1998).  Agonists at the mGluR2/3 have been 
reported to attenuate some of the behavioural and neurochemical effects of PCP and 
amphetamine in animal models (Schoepp and Marek, 2002).  The mGlu2/3 receptor 
agonists, LY3792688 and LY404039, have been found to mediate their antipsychotic-
like effects in the mouse PCP and amphetamine hyperlocomotion models of psychosis 
through the selective activation of mGluR2 rather than mGluR3 receptors (Woolley et 
al., 2008; Fell et al., 2008).  mGluR5 is abundant in the striatum, nucleus accumbens, 
olfactory tubercle, hippocampus and cerebral cortex (Testa et al., 1994).  Stimulation of 
mGluR5 enhances NMDA receptor function in cerebral cortex, hippocampus and 
striatum (Benquet et al., 2002; Mannaioni et al., 2001; Pisani et al., 2001).  In support 
of this theory, impairments in PPI have been found in mGluR5 knockout mice (Kinney 
et al., 2003; Henry et al., 1999).    
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Table 1.4: Molecular Targets for Cognitive Enhancement in Schizophrenia. 
Molecular Target 
D1 agonists 
D4 antagonists 
D4 agonists 
COMT inhibitors 
5-HT2A antagonists 
5-HT1A agonists 
5-HT1A antagonists 
5-HT4 agonists 
5-HT6 antagonists 
5-HT7 antagonists 
Cholinesterase inhibitors 
Nicotinic α7 agonists 
Nicotinic α4β2 agonists 
M1 agonists 
M4 agonists 
M5 antagonists 
NMDA enhancers 
GlyT inhibitors 
Ampakines 
mGluR2/3 agonists 
mGluR5 agonists 
α2-adrenergic antagonists 
GABAA (α2) agonists 
GABAA (α5) antagonists 
Sigma agonists 
Table 1.4: Molecular Targets for Cognitive Enhancement in Schizophrenia (adapted from Gray and Roth, 
2007).  Targets highlighted in yellow will be investigated and further described in this thesis. 
 
 
1.8 General Aims 
Phencyclidine is being extensively used to mimic behavioural deficits in different 
rodent tests of cognition.  The principal aim of this work is to study the nature of the 
cognitive and neurobiological deficits in schizophrenia using the sub-chronic PCP 
model in female rats. 
Different behavioural tests will be used to assess different aspects of cognition.  
This thesis will utilise the attentional set-shifting task to assess cognitive deficits in 
executive function using the sub-chronic PCP model and the neurodevelopmental model 
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of isolation rearing.  An operant reversal learning task will be employed to investigate 
the receptor pharmacology of antipsychotics; and this test is will be altered and 
manipulated to elucidate if the task can be made more difficult in order to distinguish 
between antipsychotics.  
An improved knowledge of the mechanisms by which PCP produces its effects 
on cognition will ultimately enhance our understanding of the pathophysiology of 
schizophrenia.  Therefore, the effects of sub-chronic PCP on gamma oscillations in an 
in vitro electrophysiology preparation will be studied as these are believed to be 
disrupted in schizophrenia.  In addition, immunohistochemistry will also carried out to 
determine whether changes in gamma oscillations in the hippocampus are linked to 
changes in parvalbumin immunoreactive neuron cell density.  In order to further 
understand the neurochemical changes in cognition and to investigate the role of 
dopamine, in vivo microdialysis will be performed in behaving rats during the novel 
object recognition test. 
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Chapter 2 
The effect of sub-chronic PCP, 
antipsychotics, and isolation rearing on 
attentional set-shifting performance 
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2.1 Introduction 
Whilst impairments have been reported across all of the cognitive domains identified by 
the MATRICS initiative (see chapter 1), impairments in executive function have long 
been considered to be a core feature of schizophrenia (Elvevag and Goldberg, 2000; 
Nuechterlein and Dawson, 1984; Sullivan et al., 1994).  One aspect of executive 
function is the ability to modify behaviour in response to the changing relevance of a 
stimulus; this is commonly assessed in patients using the Wisconsin Card Sorting Test 
(WCST) (Berg, 1948).  In more recent years a more conclusive battery of tests known 
as CANTAB (Cambridge Neuropsychological Test Battery) has been developed 
(Downes et al., 1989).  The intra-/extra-dimensional (ID/ED) test in CANTAB is 
similar to the WCST.  In the ID/ED task, simple discriminations and reversals are made 
to ensure a rule can be learned and reversed.  This is followed by the addition of a 
distracting variable which establishes an attentional set.  Attentional shifts can then be 
made; firstly in the same dimension as the relevant stimuli (intra-dimensional or ID shift) 
and secondly the relevant dimension changes to the dimension that was previously 
being ignored (extra-dimensional or ED shift; Jazbec et al., 2007, fig 2.1). 
 
Simple Discrimination (SD) 
 
 
Compound Discrimination (CD) 
 
Compound Discrimination 
(overlaid) 
 
Intra-dimensional Shift (IDS) 
 
Extra-dimensional Shift (EDS) 
 
 
Figure 2.1: The ID/ED task without reversal stages, taken from Jazbec et al. (2007). 
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The entire CANTAB battery including the ID/ED test was successfully trialled in 
primates (Weed et al., 1999). The images appeared on a touch screen which primates 
were trained to push to receive a food reward.  However, the use of primates in research 
is extremely expensive and ethically debatable.  Therefore, other animal models of the 
ID/ED task have been developed.  In 2000 Birrell and Brown developed the perceptual 
attentional set-shifting procedure for the rat.  This task (Birrell and Brown, 2000) 
investigates the ability of a rat to learn a rule and form an attentional set within the same 
sorting category (intra-dimensional shift - IDS), as well as the ability to shift attentional 
set between different sorting categories (extra-dimensional shift - EDS).  Rats must 
carry out a series of 7 discriminations namely, simple discrimination (SD), compound 
discrimination (CD), reversal 1 (R1), intra-dimensional shift (IDS), reversal 2 (R2), 
extra-dimensional shift (EDS) and reversal 3 (R3).  In the simple discrimination (SD) 
phase, for example if odour was selected as the relevant dimension, one odour would be 
baited while the other would not, both bowls would be filled with the same digging 
medium.  Successful completion of the SD phase is followed by compound 
discrimination (CD) in which odour remains as the relevant dimension (using the same 
exemplars), along with the introduction of the new digging medium.  The same odour is 
baited as in SD.  Following CD, a reversal (R1) of the established rules in CD is carried 
out, so that the previously unrewarded odour was now baited, irrespective of digging 
media.  Following this rats are presented with new exemplars to assess the intra-
dimensional shift (IDS); the relevant dimension of odour continues to be the positive 
predictor with digging media irrelevant.  The previously rewarded odour is then 
reversed (R2).  For the extra-dimensional shift (EDS) the relevant dimension of odour is 
replaced by digging medium as the positive predictor.  Finally, the EDS is reversed (R3) 
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so that the formerly negative digging medium exemplar becomes the positive predictor 
of the food reward. 
The attentional set-shifting task represents a rat analogue of the human 
Wisconsin Card Sorting Task (WCST, Berg, 1948) and CANTAB ID/ED task (Downes 
et al., 1989) in which schizophrenic patients exhibit impaired set-shifting (Kolb and 
Wishaw, 1983; Haut et al., 1996; Pantelis et al., 1999; Tyson et al., 2004).  The TURNS 
initiative has identified that this test can be used to determine the problem solving 
deficits described in the MATRICS cognitive battery (www.turns.ucla.edu). 
It has been shown that whereas lesions of the orbital prefrontal cortex in rats 
selectively disrupts reversal learning (McAlonan and Brown, 2003), lesions of the 
medial prefrontal cortex (mPFC) produce a selective deficit in the EDS phase in 
attentional set-shifting (Birrell and Brown, 2000).  Rats reared in isolation have been 
shown to exhibit structural abnormalities selectively in the mPFC (Silva-Gomez et al., 
2003; Day-Wilson et al., 2006).  Isolation-rearing also causes reduced levels of 
dopamine in the prefrontal cortex (Jones et al., 1991), a state similar to hypofrontality 
observed in schizophrenia, an effect also mimicked by sub-chronic PCP treatment 
(Jentsch and Roth, 1999).   
Acute administration of PCP in rats has been shown to produce deficits in 
attentional set-shifting (Egerton et al., 2005).  Rodefer and colleagues combined the 
attentional set-shifting test with a sub-chronic PCP dosing regimen (5 mg/kg twice daily 
for seven days followed by a ten-day drug washout period) and found a selective deficit 
in the EDS phase (Rodefer et al., 2005), and have now investigated the pharmacology 
of antipsychotics in this model (Rodefer et al., 2007).  Performance in isolation reared 
rats has previously been described by Schrijver and Wurbel (2001) using an 8-arm 
radial maze with spatial and non-spatial visual discriminations. 
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Haloperidol is still a widely used antipsychotic, and it is the antipsychotic most 
often used to judge the efficacy of newer medications (see Irving et al., 2006).  
Haloperidol relies heavily on its affinity for D2-like receptors (see table 2.1).  Meltzer et 
al., (1989) defined atypical antipsychotic drugs as having higher affinity for 5-HT2A 
receptors than for D2 receptors.  5-HT2A receptor antagonists increase dopamine release 
into the prefrontal cortex (PFC; Ichikawa and Meltzer, 1990).   Although atypical 
antipsychotics such as risperidone and clozapine have high affinity for 5-HT2A receptors, 
it is unlikely that this mechanism alone is responsible for their antipsychotic action, as 
both have been shown to saturate 5-HT2 receptors at sub-therapeutic doses (Kapur et al., 
1999).  Atypical antipsychotics have affinity for a multitude of receptors.  In this 
attentional set-shifting chapter, clozapine, risperidone and haloperidol are to be tested 
against sub-chronic PCP.  The in vitro pharmacology of these antipsychotics is shown 
in table 2.1 and will be further detailed in the discussion of this chapter. 
 
Table 2.1 In vitro receptor binding in man (affinity constants Ki in nM) at receptors for clozapine, 
risperidone and haloperidol.  Values taken from Siegfried et al., 2005. 
Receptor Clozapine Risperidone Haloperidol 
D1 85 430 210 
D2 160 2 1 
D3 170 10 2 
D4 50 10 3 
5-HT1A 200 210 1100 
5-HT2A 16 0.5 45 
5-HT2C 10 25 >10000 
5-HT6 14 2200 9600 
5-HT7 100 2 1200 
NE α1 7 1 6 
NE α2 8 1 360 
H1 1 20 440 
Muscarinic 2 >1000 5500 
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The first aim of this study was to investigate whether a sub-chronic PCP dosing 
regimen could induce a cognitive deficit in male and female rats.  The second aim was 
to investigate whether these deficits induced by PCP in attentional set-shifting could be 
reversed by sub-chronic administration of clozapine, risperidone or haloperidol.  The 
third aim was to investigate whether a non-pharmacological model could also induce a 
cognitive deficit in order to strengthen the validity of the paradigm.  To address this, the 
effects of isolation rearing on cognitive performance in the attentional set-shifting task 
were examined as isolation rearing has been suggested to model some aspects of 
schizophrenia (see chapter 1). 
The aim of the final experiment was to counterbalance the PCP study i.e. half of 
the rats tested on medium first then switching to odour and the second half on odour 
first then switching to medium.  In this experiment the discovery trials were also scored.  
It would be expected that both vehicle and PCP-treated rats would make more incorrect 
discovery trials in the EDS phase. 
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2.2 Materials and Methods 
 
2.2.1 Subjects 
For experiment 1, 20 male and 20 female hooded-Lister rats (Harlan, UK), weighing 
250-280 g and 200-220 g respectively at the start of the study, were used.  For 
experiment 2, 50 female hooded-Lister rats (Harlan, UK), weighing 200-220 g at the 
start of the study, were used and were housed in groups of 4-5 (shown in fig 2.2.1a).  
For experiment 3, 20 female hooded-Lister rats (Harlan, UK) were ordered at post-natal 
day (PND) 14.  At PND 21 rats were randomly allocated to one of two housing 
conditions.  Half were housed in groups of five in clear plastic cages (38 x 59 x 24 cm) 
and half were housed in individual opaque cages (25 x 35 x 24 cm) for a minimum 
period of 6 weeks before testing (shown in fig 2.2.1b).  Rats could hear and smell other 
animals but could not see (due to opaque cages) or come into physical contact with 
them. For experiment 4, 16 female hooded-Lister rats (Harlan, UK), weighing 200-220 
g at the start of the study, were used and were housed in groups of 4-5 (shown in fig 
2.2.1a).   
Animals were housed in a temperature-controlled room (21 ± 2 °C) at humidity 
of 45-55%, and maintained on a 12:12 h light/dark cycle (lights on at 0700 h).  
Experimental procedures were performed in the light phase.  All rats had free access to 
food (Special Diet Services, UK) and water until 1 week before testing began, at which 
point a minimal food restriction was imposed upon them (90% of free feeding 
bodyweight; 12 g food per rat per day) but ad libitum access to water continued.  All 
experimental procedures were carried out in accordance with the Animals (Scientific 
Procedures) Act, UK (1986) and were approved by the University of Bradford ethical 
review process. 
43  
 
Fig. 2.2.1a  Cage of 4-5 social rats.               Fig. 2.2.1b  Isolation-reared housing conditions. 
 
2.2.2 Locomotor activity 
The locomotor activity (LMA) response to a novel environment was assessed using 
automated photocell cages (see fig 2.2.2a and 2.2.2b).  The movement of each animal 
was monitored in 1 of 16 Plexiglas chambers (16 x 26 x 19 cm) covered with a 
compatible Plexiglas lid using AM1052 Activity Monitor (Linton Instrumentation).  
Counts were recorded by AmLogger software (supplied by GSK, Harlow, UK) by 
means of photo beam interruptions within the chamber.  Activity was monitored every 5 
min over a 60 min period and summed to give a total count.  For experiment 1 10 
vehicle and 10 PCP-treated rats were tested in these chambers.  In experiment 2 10 
social and 10 isolation-reared rats were tested.  Rats were randomly allocated across the 
LMA boxes to ensure that all groups were evenly tested on each shelf, and an even 
number of rats from each group were tested at each time point, thus avoiding any 
horizontal placement and/or time of testing bias. For example vehicles were tested 
alongside PCP-treated rats and isolates were tested next to socially housed rats. 
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Fig. 2.2.2a An individual automated photocell cage.        Fig. 2.2.2b 16 automated photocell cages. 
 
2.2.3 Set-shifting apparatus 
The set-shifting apparatus was a modified version of that described originally by Birrell 
and Brown (2000) and was made in-house.  The test box was essentially a modified 
home cage measuring 59 x 35 x 24 cm made of transparent plastic (Fig. 2.2.3a and 
2.2.3b).  A fixed 1 cm thick Plexiglas panel permanently divided 1/3 of the length of the 
box into two separate compartments (choice areas).  These two choice areas could be 
further isolated from each other with the aid of two removable Plexiglas panels that 
were lowered into place along wall mounted vertical sliders.  The digging bowls (glazed 
ceramic pots, Pets at Home, UK) were placed in each choice area, and the rat was given 
access by lifting the divider(s) which could also be used to deny access to the bowls, 
such as when an incorrect choice was made.  A third removable panel divided the 
remaining 2/3 length of the larger compartment into two sections when in place, along 
the horizontal (short) axis of the test box. 
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Figure 2.2.3a: Photograph of the attentional set-shifting test box, plexiglas dividers were inserted into the 
visible slots in the lid. 
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Figure 2.2.3b: Plan view of attentional set-shifting test box, showing gross dimensions, division into 
thirds and then into sixths to create two choice areas.  Dotted lines indicate removable Plexiglas dividers 
and unbroken lines indicate fixed panels and walls.   
 
2.2.4 Habituation and training 
Habituation to specific aspects of the testing paradigm commenced immediately 
following the end of the seven-day drug washout period (see section 2.2.6).  Habituation 
to the testing box occurred for 30 min on 3 consecutive days prior to training.  Two 
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smooth ceramic circular digging pots (measuring 9 cm in diameter by 5 cm internal 
depth) identical to those intended for use during the testing phases were introduced to 
each home cage (figure 2.2.4a).  Each bowl was filled with grade 5 sawdust (also 
covering the home cage floor) and baited with food reward in the form of several 1/4 
honey nut loops (Kellogs, UK).   Digging bowls were continuously re-baited during this 
habituation period and remained in the home cage for the duration of the study.  
Following habituation, all rats had to successfully complete the entire training regime in 
order to proceed to testing.  Rats were first trained to dig quickly and reliably in both 
bowls by progressively covering a single food reward per trial with incrementally 
thicker layers of digging media.  Once a rat had repeatedly demonstrated that it had 
acquired the training procedure, the dividing panels were introduced.  Digging itself 
was defined as a vigorous movement of front paws to displace digging media and obtain 
food reinforcement buried 2-2.5 cm below surface level. 
The second phase of training introduced the concept of simple discrimination 
(SD) between first medium and then, odour.  Rats were presented with identical digging 
bowls that had been anointed (smearing a few drops of oil around the rim of the bowl 
using a tissue) with two aromatic oils (Strawberry and Sandlewood, Bodyshop, UK), 
only one of which was baited with food reward (fig 2.2.4b).  Placement of bowls in 
either the left or right compartment was randomised with the aid of an adapted 
pseudorandom Gellerman schedule.  Rats were permitted to explore both bowls for the 
first four trials irrespective of which bowl they dug in first, thereby allowing the 
associate of a food reward with the positive predictor.  Subsequent incorrect selections 
ended a trial without the opportunity to explore the correct bowl.  A criterion for 
successful learning of each discrimination was set at 6 consecutive correct trials.  All 
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exemplars used in training were not used during testing or at any other point in the 
study. 
             
Fig. 2.2.4a Ceramic bowl used for digging.   Fig.  2.2.4b  Example of aromatic oils used for the odour. 
 
 
2.2.5 Testing paradigm 
In all cases rats were tested in the attentional set-shifting procedure 24 hours after 
training, and following either sub-chronic PCP treatment or 6 weeks of isolation rearing; 
example timelines of these experiments are shown in figures 2.2.5.  A trial was initiated 
by raising both dividers to give access to both digging bowls, only one of which was 
baited.   
1. Experiment 1 (males and females): The first stage was the simple 
discrimination (SD), which was identical to the simple discrimination in the 
training session on the previous day, except new exemplars were used.  Testing 
continued until the rat reached a criterion of six consecutive correct responses.  
In a test session, rats performed a series of discriminations (see Table 2.2.5a).  
For the compound discrimination (CD) a second dimension was introduced 
(digging medium), but the correct and incorrect exemplars remained the same 
(odour).  For the reversals the exemplars and relevant dimensions remained the 
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same (odour) but the rats had to learn that the previously baited odour was now 
incorrect and the other odour was now correct.   New exemplars were used for 
the ID and ED shifts.  The specific exemplars used are shown in table 2.2.5b.  
For the ED shift, the previously irrelevant parameter (i.e. digging medium) was 
now relevant.  It has been shown that rats find the difficulty of each 
discrimination change, i.e. medium to odour or odour to medium, equivalent 
(Birrell and Brown, 2000).  Therefore in simple discrimination, odour was the 
relevant parameter for all rats.   
2. Experiment 2 (sub-chronic PCP and antipsychotics): Rats were tested on 
digging medium in simple discrimination and odour was the parameter used in 
the EDS phase.  For the compound discrimination (CD) a second dimension was 
introduced (odour), but the correct and incorrect exemplars remained the same 
(medium).  For the reversals the exemplars and relevant dimensions remained 
the same (medium) but the rats had to learn that the previously baited odour was 
now incorrect and the other odour was now the correct one.   New exemplars 
were used for the ID and ED shifts.  The specific exemplars used are shown in 
Table 2.2.5b (experiment 1).  For the ED shift, the previously irrelevant 
parameter (i.e. odour) was now relevant.   
3. Experiment 3 (isolation rearing): Rats were tested on odour in simple 
discrimination and digging medium was the parameter used in the extra-
dimensional shift (as in experiment 1).   
4. Experiment 4 (counterbalanced sub-chronic PCP): Rats were trained and 
tested as described in detail in experiments 1 and 2.  Half of each treatment 
group were tested on odour in simple discrimination and half were tested on 
digging medium in simple discrimination, therefore counterbalancing the study.  
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The discovery trials prior to the test trials were scored and then testing continued 
until the rat reached a criterion of six consecutive correct responses. 
 
 
Day     1              8              15                        86
1-7
PCP dosing b.i.d
16-86
Attentional set-shifting
(Habituation, training, testing)
15
Locomotor activity
PND    21                            63                         92
21
Rats housed in 
social isolation 64-92
Attentional set-shifting
(Habituation, training, testing)
63
Locomotor activity
 
Figure 2.2.5: Example timeline of an attentional set-shifting experiment following sub-chronic PCP 
treatment and isolation rearing. 
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Table 2.2.5a  Example order of discriminations presented to rats undertaking the attentional set-shifting 
task.  Only rewarded stimuli were baited with food reward.  [M1 = medium 1; O1 = odour 1].  Table 
adapted from Birrell and Brown (2000).  
Discriminations
Relevant Irrelevant Rewarded Unrewarded
SD Medium Odour M1 M2
CD Medium Odour M1/O1 M2/O1
M1/O2 M2/O2
Rev1 Medium Odour M2/O1 M1/O1
M2/O2 M1/O2
IDS Medium Odour M3/O3 M4/O3
M3/O4 M4/O4
Rev2 Medium Odour M4/O3 M3/O3
M4/O4 M3/O4
EDS Odour Medium O5/M5 O6/M5
O5/M6 O6/M6
Rev3 Odour Medium O6/M5 O5/M5
O6/M6 O5/M6
Dimensions Exemplar combinations
 
 
Table 2.2.5b  Specific exemplars used (presented in pairs) in each phase of the attentional set-shifting 
task.  Odours were applied around the rims of digging bowls which were filled with various digging 
media depending upon the phase being tested.  The significance of pairing within a test phase ensures 
that, for example, rose is always accompanied with white flower within a test trial [O = Odour, M = 
Medium]. 
Dimension Pairing 1 (CD) Pairing 2 (IDS) Pairing 3 (EDS) 
Odour Rose = O1 
White flower = O2 
Green Meadow = O3 
Coconut = O4 
Orange = O5 
Almond = O6 
Medium 
 
Wood shavings = M1 
Cat litter = M2 
Small pebbles = M3 
Aspen = M4 
Fine sawdust = M5 
Wood blocks = M6 
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2.2.6 Drugs 
In experiment 1 half of the males (n=10) and half of the females (n=10) were dosed 
with either 2 mg/kg PCP (Sigma, UK) or vehicle (0.9% saline) by the intraperitoneal 
(i.p.) route twice daily for seven days.  For experiment 2 the study design involved five 
groups (n = 10 per group initially); rats were given either 2 mg/kg PCP (n = 40) or 
vehicle (n = 10).  For experiment 4 half of the rats were given either 2 mg/kg PCP (n = 
8) or vehicle (n = 8).  Dosing with sub-chronic PCP or vehicle was followed by a 
washout period of a further seven days.  In experiment 2 one week following the seven-
day washout period, PCP-treated rats were sub-chronically dosed for seven days (daily, 
i.p. route) with vehicle (0.9% saline), clozapine (2.5 mg/kg), haloperidol (0.05 mg/kg) 
or risperidone (0.2 mg/kg).  Rats were trained 30 minutes after dosing on the seventh 
day, and they were tested on day 8 30 minutes after drug administration.     
The dose of haloperidol was chosen on the basis of a previous study showing 
that 0.05 mg/kg haloperidol significantly attenuated a d-amphetamine-induced reversal 
learning impairment in female hooded-Lister rats (Idris et al., 2005a).  Furthermore, this 
dose of haloperidol has been shown to occupy 50% of dopamine D2 receptors (Kapur 
and Seeman, 2001; Kapur et al., 2003).  The doses of clozapine (2.5 mg/kg) and 
risperidone (0.2 mg/kg) were chosen on the basis of previous work in the laboratory 
showing efficacy against sub-chronic PCP in the reversal learning paradigm (Abdul-
Monim et al., 2006; Neill et al., 2006) and NOR task (Grayson et al., 2007).  PCP HCl 
(Sigma, UK) was dissolved in 0.9% saline (Jentsch et al., 1997b; 1998).  Haloperidol 
(Serenace liquid, 2 mg/kg, Baker, UK) was diluted with distilled water.  Clozapine 
(Tocris, UK) and risperidone (provided by GSK, UK) were dissolved in a minimum 
volume of acetic acid, made up to volume with distilled water and pH adjusted to 6 with 
0.1M NaOH.  Antipsychotics were given sub-chronically as a pilot study showed that 
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acute dosing with clozapine and haloperidol prevented rats from being able to attend to 
the task due to slight sedation.   
 
2.2.7 Pilot antipsychotic study 
A short pilot study was undertaken, during which the training and testing procedures 
were fine-tuned and developed.  During this time 8 rats were tested, of which only 5 
managed to complete the test.  This may have been due to the odours from other rats 
remaining on the testing boxes as they were wiped clean between subjects but it became 
apparent that it would be more beneficial to have the boxes machine cleaned in between 
rats.  The major change was to the dosing of the antipsychotics.  It was originally 
planned to administer the drugs acutely 30 min prior to testing; however, it was soon 
clear that this would not be possible as clozapine and haloperidol were sedating or 
causing motor impairments in the animals too much for them to be able to complete the 
task.  Subsequently, it was decided to give the drugs sub-chronically. Therefore, a 
dosing, training and testing regimen was devised, so that each rat was treated once daily, 
with the drug or vehicle for the 6 days prior to training; the day of training; and the day 
of testing.  Although risperidone at this dose did not cause sedation, in order to make a 
true comparison between the antipsychotics this was also to be dosed sub-chronically.  
 
2.2.8 Data and statistical analysis 
In experiment 1 only total trials to reach criterion and average time per trial were scored.  
In experiments 2 and 3, percentage errors and frequency of both bowl exploration 
before digging were also scored.  LMA data were analysed by Student‟s unpaired t-test 
and are expressed as total counts in a 60 min period.  Data for total trials to criterion 
(TTC), average time per trial (ATT), percentage of errors and exploration of both bowls 
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are expressed as mean ± SEM.  Data were analysed by a two-way ANOVA (set-shifting 
phase x treatment group or housing), followed by post-hoc Student‟s independent t-test.  
If the ANOVA was not significant planned comparisons were still carried out in the 
stage of interest i.e. the EDS phase.  For experiment 4, data were analysed by three-way 
ANOVAs (set-shifting phase x treatment x order of testing [media or odour first]).  All 
analysis was performed using SPSS for Windows software (SPSS Inc., Version 13). 
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2.3 Results 
 
2.3.1 Experiment 1: Effects of sub-chronic PCP in female and male rats in 
attentional set-shifting. 
 
Effects of sub-chronic PCP in female and male rats on total trials to criterion 
A total of 30 rats were successfully trained and tested, rats (3 female vehicle, 2 female 
PCP, 2 male vehicle, 3 male PCP) were excluded from the study due to incompletion of 
the training within a single session as rats were required to complete the simple 
discriminations in training within 30 trials.  Extra trials were not given in order to 
ensure all rats had the same level of training before testing.  Treatment groups were 
female vehicle (n = 7), female PCP (n = 8), male vehicle (n = 8), and male PCP (n = 7).  
Treatment did not have any effect on performance during habituation or training. 
In female rats a two-way ANOVA using phase as a within-subjects factor and 
drug treatment as a between-subjects factor revealed no significant interaction (F1,13 = 
0.48; p=0.50).  A slight increase in trials to criterion in the EDS phase was observed in 
PCP-treated rats to (17.5 ± 2.6) from (12.6 ± 1.8) in the vehicle-treated group, however 
this increase was not significant (p = 0.15).  Post-hoc analysis did not reveal any 
significant differences between the groups (fig. 2.3.1a). 
In male rats a two-way ANOVA using phase as a within-subjects factor and 
drug treatment as a between-subjects factor revealed no significant interaction (F1,13 = 
0.17; p=0.68).  Post-hoc analysis did not reveal any significant differences between the 
groups (fig. 2.3.1b). 
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Figure 2.3.1a  The total trials to criterion in the attentional set-shifting task in female rats. Data are 
expressed as mean ± SEM (vehicle n=7; PCP n=8).  No significant differences between vehicle and PCP-
treated rats at any stage of the task, analysed by Student‟s t-tests. 
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Figure 2.3.1b  The total trials to criterion in the attentional set-shifting task in male rats. Data are 
expressed as mean ± SEM (vehicle n=8; PCP n=7).  No significant differences between vehicle and PCP-
treated rats at any stage of the task, analysed by Student‟s t-tests. 
56  
Effects of sub-chronic PCP in female and male rats on average time taken per trial 
In female rats a two-way ANOVA using phase as a within-subjects factor and drug 
treatment as a between-subjects factor revealed no significant interaction (F1,13 = 1.26; 
p=0.28).  However, post-hoc analysis did reveal a significant increase in the average 
time taken per trial in PCP-treated compared to vehicle-treated rats in the EDS phase 
only (p<0.05; fig. 2.3.1c). 
In male rats a two-way ANOVA using phase as a within-subjects factor and 
drug treatment as a between-subjects factor revealed no significant interaction (F1,13 = 
0.21; p=0.65).  Post-hoc analysis did not reveal any significant differences between the 
groups (fig. 2.3.1d). 
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Figure 2.3.1c  The average time taken per trial in the attentional set-shifting task in female rats. Data are 
expressed as mean ± SEM (vehicle n=7; PCP n=8).  PCP significantly increased the average time taken 
per trial in the EDS phase compared to vehicle-treated rats, *p<0.05. 
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Figure 2.3.1d The average time taken per trial in the attentional set-shifting task. All data are expressed 
as mean ± SEM (vehicle n=8; PCP n=7).  No significant difference between vehicle and PCP-treated rats 
at any stage of the task. 
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2.3.2 Experiment 2: Effects of clozapine, risperidone and haloperidol in sub-chronic 
PCP-treated rats in attentional set-shifting. 
 
Effects of sub-chronic PCP on locomotor activity 
Locomotor activity (LMA) was assessed following the 7-day washout period.  Student‟s 
unpaired t-test showed that PCP-treated rats were not significantly different in total 
LMA over the 60 min test period compared to vehicle-treated rats (p = 0.46; fig. 2.3.2a). 
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Figure 2.3.2a  The effect of sub-chronic PCP (2 mg/kg, i.p. twice daily for 7 days) on locomotor activity 
in a novel environment.  Data are expressed as mean ± SEM activity counts over a 60 min period (n = 10 
per group).  No significant difference between the groups.  
 
 
Effects of antipsychotics on total trials to reach criterion (TTC) 
A total of 42 rats were successfully trained and tested, 8 rats were excluded from the 
study due to inability to complete the training within a single session as rats were 
required to complete the simple discriminations in training within 30 trials.  Extra trials 
were not given in order to ensure all rats had the same level of training before testing.  
Treatment groups were vehicle + vehicle (n = 8), PCP + vehicle (n = 9), PCP + 
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clozapine (n = 9), PCP + haloperidol (n = 7) and PCP + risperidone (n = 9).  Drug 
treatment did not have any effect on performance during habituation or training. 
A two-way ANOVA using phase as a within-subjects factor and drug treatment 
as between-subjects factor revealed a significant interaction (F4,37 = 5.4; p<0.01).  An 
increase in trials to criterion in reversal 1 was observed in all treatment groups, although 
these increases were not significant compared to SD.  PCP+haloperidol-treated rats 
required the most trials in reversal 1 to reach criterion (11.4 ± 1.4) compared to vehicle-
treated rats (7.3 ± 0.6), however this increase was not significant (p = 0.08).  Post-hoc 
analysis within the EDS phase (fig. 2.3.2b) revealed that PCP significantly (p<0.01) 
increased the number of trials to reach criterion when compared to vehicle.  This deficit 
was significantly (p<0.01) attenuated to the same extent by sub-chronic clozapine and 
risperidone, but not by sub-chronic haloperidol.   
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Figure 2.3.2b The effect of sub-chronic PCP (2 mg/kg; i.p. twice daily for 7 days; n = 9) against vehicle-
treated (n = 8) female rats on trials to reach criterion in attentional set-shifting and effects of sub-chronic 
administration of clozapine (2.5 mg/kg; n = 9), haloperidol (0.05 mg/kg; n = 7), risperidone (0.2 mg/kg; n 
= 9) in PCP-treated rats.  Data are expressed as mean ± SEM and were analysed by two-way ANOVA 
and post-hoc Dunnett‟s t-test (p<0.01## compared to vehicle group in EDS; p<0.01** compared to PCP 
group in EDS). 
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Effects of antipsychotics on average time taken per trial (ATT) 
A two-way ANOVA was applied using phase and drug treatment (as previously 
described) and revealed a significant interaction in the ATT (F4,37 = 3.9; p<0.01).  Post-
hoc analysis showed that PCP-haloperidol treated rats required significantly more time 
to complete trials compared to vehicle-treated rats in the SD (p<0.05), CD (p<0.05), 
Rev1 (p<0.001) and Rev3 (p<0.05) phases (fig. 2.3.2c). 
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Figure 2.3.2c The effect of sub-chronic PCP (2 mg/kg i.p. twice daily for 7 days; n = 9) against vehicle-
treated (n = 8) female rats on average time taken per trial (sec) in attentional set-shifting and effects of 
sub-chronic administration of clozapine (2.5 mg/kg; n = 9), haloperidol (0.05 mg/kg; n = 7), risperidone 
(0.2 mg/kg; n = 9) in PCP-treated rats.  Data are expressed as mean ± SEM and were analysed by two-
way ANOVA and post-hoc Dunnett‟s t-test (p < 0.05*; p < 0.001*** compared to vehicle in that phase of 
the task). 
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Effects of antipsychotics on percentage of errors 
A two-way ANOVA revealed a significant interaction (F4,37 = 4.2; p<0.01).  Post-hoc 
analysis revealed significant (p<0.001) increases in the percentage errors in the EDS 
phase in PCP-vehicle and PCP-haloperidol treated rats when compared to the vehicle 
group (fig. 2.3.2d).  The PCP-clozapine and PCP-risperidone groups committed 
significantly (p<0.01) less percentage errors compared to the PCP-vehicle group in EDS 
phase.  In the first reversal the only significant difference was between the PCP-treated 
and PCP-clozapine groups (p<0.05), with the PCP-clozapine group making significantly 
(p<0.05) more percentage errors than the PCP-vehicle group. 
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Figure 2.3.2d The effect of sub-chronic PCP (2 mg/kg, i.p. twice daily for 7 days; n = 9) against vehicle-
treated (n = 8) female rats on percentage errors in attentional set-shifting and effects of sub-chronic 
administration of clozapine (2.5 mg/kg; n = 9), haloperidol (0.05 mg/kg; n = 7), risperidone (0.2 mg/kg; n 
= 9) in PCP-treated rats.  Data are expressed as mean ± SEM and were analysed by two-way ANOVA 
and post-hoc Dunnett‟s t-test (p < 0.001### compared to vehicle group in EDS; p < 0.01** compared to 
PCP group in EDS; p < 0.05
+
 compared to the PCP treated group in reversal 1). 
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Effects of antipsychotics on exploration of both bowls before digging 
A two-way ANOVA was applied; comparing the drug treatment group to the phase of 
the task showed that there was no overall significant difference in the exploration of 
both bowls (F4,37 = 2.1; p=0.101).  Frequency of exploration of both bowls was 
significantly greater in the PCP-treated rats compared to vehicles in the EDS phase 
(p<0.01; fig. 2.3.2e), this effect was significantly attenuated by clozapine [p<0.001]. 
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Figure 2.3.2e The effect of sub-chronic PCP (2 mg/kg, i.p. twice daily for 7 days; n = 9) against vehicle-
treated (n = 8) female rats on frequency of both bowl exploration before digging in attentional set-shifting 
and effects of sub-chronic administration of clozapine (2.5 mg/kg; n = 9), haloperidol (0.05 mg/kg; n = 7), 
risperidone (0.2 mg/kg; n = 9) in PCP-treated rats.  Data are expressed as mean ± SEM and were analysed 
by two-way ANOVA and post-hoc Dunnett‟s t-test (p<0.01## compared to vehicle group in EDS; 
p<0.001*** compared to PCP group in EDS). 
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2.3.3 Experiment 3: Effects of isolation rearing on attentional set-shifting 
performance. 
 
Effects of isolation rearing on locomotor activity 
Locomotor activity (LMA) was assessed following 6 weeks of isolation rearing.  An 
independent Student‟s t-test showed that there was a significantly larger response to a 
novel environment in the isolation-reared rats compared to the socially reared rats 
[p<0.01; Fig. 2.3.3a]. 
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Figure 2.3.3a The response to a novel environment as measured using locomotor activity in isolation-
reared and socially-reared rats.  All data expressed as mean ± SEM (n=10 per group) of total locomotor 
activity counts over a 60 min period.  An independent Student‟s t-test showed that total locomotor activity 
was significantly greater in the isolates compared to the socials (**p<0.01). 
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Effects of isolation rearing on total trials to reach criterion 
A total of 17 rats were successfully trained and tested, 1 isolate and 2 social rats were 
excluded from the study due to non-completion of the training within a single session, 
as rats were required to complete the training of simple discriminations within 30 trials.  
A two-way ANOVA using phase as a within-subjects factor and housing as a between-
subjects factor showed no significant effect (F1,15 = 0.018; p=0.894).  Isolation-reared 
rats showed a selective deficit at the EDS stage of the task requiring significantly more 
trials to reach criterion than socially-housed rats at this stage of testing only (p<0.01; fig. 
2.3.3b).   
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Figure 2.3.3b The total trials to criterion in the attentional set-shifting task in isolation-reared and 
socially reared rats. All data are expressed as mean ± SEM (isolates n=9; socials n=8) of total trials to 
criterion.  Total trials to criterion was significantly greater in the isolates compared to the socials in the 
extra-dimensional shift phase (**p<0.01). 
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Effects of isolation rearing on average time taken per trial 
A two-way ANOVA using phase as a within-subjects factor and housing as a between-
subjects factor showed no significant effect (F1,15 = 0.599; p=0.452). There was a 
significant reduction in the ATT in isolation-reared compared with socially reared rats 
in reversal 3 (p<0.05; fig. 2.3.3c).  
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Figure 2.3.3c The average time taken per trial in the attentional set-shifting task in isolation-reared and 
socially reared rats.  All data are expressed as mean ± SEM (isolates n=9; socials n=8).  Social rats 
required significantly more time per trial than isolation-reared rats in the reversal 3 phase of the task 
(*P<0.05).   
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Effects of isolation rearing on percentage of errors 
A two-way ANOVA with phase as a within subjects factor and housing as a between 
subjects factor showed no significant effect (F1,15 = 0.044; p=0.838).  There were no 
significant differences between socials and isolates at any stage of the task (fig. 2.3.3d). 
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Figure 2.3.3d The percentage of errors made during the attentional set-shifting task in isolation-reared 
and socially reared rats. All data expressed as mean ± SEM (isolates n=9; socials n=8).  No significant 
differences were observed. 
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Effects of isolation rearing on exploration of both bowls before digging 
A two-way ANOVA with phase as a within subjects factor and housing as a between 
subjects factor showed no significance (F1,15 = 1.979; p=0.180).  Frequency of 
exploration of both bowls was significantly greater in the isolates compared to the 
socials in the extra-dimensional shift phase (p<0.01; Fig. 2.3.3e). 
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Figure 2.3.3e The total frequency of exploration of both bowls before digging in the attentional set-
shifting task in isolation-reared and socially reared female rats.  All data are expressed as mean ± SEM 
(isolates n=9; socials n=8) of frequency of exploration.  Frequency of exploration of both bowls was 
significantly greater in the isolates compared to the socials in female rats in the extra-dimensional shift 
phase (**p<0.01). 
 
 
 
 
 
68  
2.3.4 Experiment 4: Effects of sub-chronic PCP in a counterbalanced attentional set-
shifting study, and the effect of discovery trials. 
 
Effect of sub-chronic PCP on trial to reach criterion 
All 16 rats were successfully trained and tested.  Drug treatment did not have any effect 
on performance during habituation or training.  A three-way ANOVA using phase as a 
within-subjects factor and treatment and order of testing (media or odour first) as a 
between-subjects factors showed a significant interaction (F1,12 = 3.3; p<0.01).  PCP-
treated rats showed deficits in the reversal 1 and reversal 3 stages (p<0.05) and a 
significant deficit in the EDS phase (p<0.001), requiring significantly more trials to 
reach criterion (fig. 2.3.4a).  There was no effect of order of testing (F1,12 = 0.02; 
p=0.89). 
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Figure 2.3.4a The total trials to criterion in the attentional set-shifting task. All data are expressed as 
mean ± SEM (n=8).  PCP significantly increased trials to criterion in reversal 1 and 3, *p<0.05, and in the 
EDS phase, ***p<0.001 
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Analysis of the number of correct discovery trials  
A two-way ANOVA using phase as a within-subjects factor and treatment and order of 
testing (media or odour first) as a between-subjects factors showed no significant effect 
(F1,12 = 0.36; p=0.90).  There were no significant differences between vehicle and PCP-
treated rats at any stage of the task (fig. 2.3.4b).  Bonferroni multiple comparisons test 
showed that, in vehicle rats, the number of correct discovery trials was significantly 
decreased from IDS to EDS (p<0.01) and this effect was also observed in PCP-treated 
rats (p<0.001).  In both vehicle and PCP-treated groups the number of correct discovery 
trials were significantly increased in SD when compared to the Rev1 and EDS phases of 
the task (p<0.001).  There was no effect of order of testing (F1,12 = 0.47; p=0.51). 
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Figure 2.3.4b The number of correct discovery trials in the attentional set-shifting task. All data are 
expressed as mean ± SEM (n=8).  No significant difference between vehicle and PCP-treated rats at any 
stage of the task.  In both PCP and vehicle-treated rats the number of correct discovery trials was 
significantly lower in the EDS phase compared to IDS; **p<0.01, ***p<0.001.  In both vehicle and PCP-
treated groups the number of correct discovery trials was significantly increased in SD when compared to 
the Rev1 and EDS phases of the task ***p<0.001.   
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Effect of sub-chronic PCP on average time taken per trial 
A two-way ANOVA using phase as a within-subjects factor and treatment and order of 
testing (media or odour first) as a between-subjects factors showed no significant effect 
(F1,12 = 0.76; p=0.61).  There were no significant differences between vehicle and PCP-
treated rats at any stage of the task (fig. 2.3.4c).  However there was a significant effect 
of order of testing (F1,12 = 7.54; p<0.01). 
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Figure 2.3.4c The average time taken per trial in the attentional set-shifting task. All data are expressed 
as mean ± SEM (n=8).  No significant difference between vehicle and PCP-treated rats at any stage of the 
task. 
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Effects of sub-chronic PCP on percentage of errors 
A two-way ANOVA using phase as a within-subjects factor and treatment and order of 
testing (media or odour first) as a between-subjects factors showed a significant 
interaction (F1,12 = 3.12; p<0.05).  PCP-treated rats had increased percent errors with 
respect to trials to criterion in the reversal 1 and reversal 3 stages (p<0.05) and in the 
EDS phase compared with the vehicle group (p<0.001; Fig. 2.3.4d).  There was no 
effect of order of testing (F1,12 = 1.89; p=0.19). 
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Figure 2.3.4d The percentage of errors made during the attentional set-shifting task. All data are 
expressed as mean ± SEM (n=8).  Percent errors were significantly increased in reversal 1 and 3, *p<0.05; 
and in the EDS phase, ***p<0.001. 
 
 
 
72  
Effects of sub-chronic PCP on exploration of both bowls before digging 
A two-way ANOVA using phase as a within-subjects factor and treatment and order of 
testing (media or odour first) as a between-subjects factors showed an interaction 
approaching significance (F1,12 = 3.84; p=0.07).  Frequency of exploration of both bowls 
was significantly greater in the PCP-treated rats compared to the vehicle group in the 
EDS phase (p<0.05; Fig. 2.3.4e).  There was no effect of order of testing (F1,12 = 1.68; 
p=0.24). 
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Figure 2.3.4e The total frequency of exploration of both bowls before digging in the attentional set-
shifting task. All data are expressed as mean ± SEM (n=8).  Frequency of exploration of both bowls was 
significantly increased in PCP-treated rats compared to the vehicle group; *p<0.05. 
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2.4 Discussion 
The aim of these studies was to examine the effects of isolation rearing and a sub-
chronic PCP treatment regimen on attentional set-shifting ability in female rats and to 
investigate the effects of sub-chronic administration of antipsychotics.  An initial study 
aimed to assess the effect of sub-chronic PCP in male and female rats.  The aim was 
also to investigate the effect of counterbalancing a study and to score the discovery 
trials to assess whether these could have an impact on the task.  The rodent version of 
this test was adapted by Birrell and Brown (2000) from a previous version used in 
primates (Roberts et al., 1988) and is a useful analogue of the WCST (Berg, 1948).  
This task requires rats to initially learn a rule, and then switch their attention to a new 
stimulus dimension, demonstrating cognitive flexibility.   
 
2.4.1 Experiment 1: Effects of sub-chronic PCP in attentional set-shifting in female and 
male rats 
In female rats there was an increase in trials required to reach criterion in PCP-treated 
rats for the EDS stage, suggesting sub-chronic PCP causes a deficit in attentional set-
shifting ability, although this was not significant.  A difference in trials to criterion was 
not observed in male rats.  Female rats also required significantly more time to complete 
the trials within the EDS phase, suggesting an impairment; again, this effect was not 
observed in the male rats.  The results from experiment 1 suggest that sub-chronic PCP 
produces more pronounced effects in female rats compared to male rats; this may be due 
to differing sensitivity to PCP.  Therefore, subsequent experiments were only carried 
out using female rats.  A recent study from the laboratory has shown that males are less 
sensitive to acute PCP treatment compared to females, as measured using the novel 
object recognition task (Grayson et al., 2005).  Several studies have shown female rats 
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to be more sensitive to the behavioural effects of PCP (Nabeshima et al., 1984a; 
Nabeshima et al., 1984b; Hönack and Löscher, 1993; Wessinger et al., 1995). 
These behavioural differences may be due to differences in pharmacokinetics.  
Nabeshima et al. (1984b) and Gartlon et al. (2006) found higher levels of PCP in the 
plasma and brain tissue of female rats given the same dose as male rats.  Shelnutt and 
colleagues (1999) found significantly lower in vitro formation of PCP metabolites in 
female rats when compared to males.  Furthermore pharmacokinetic studies in SD rats 
showed that, in females, the systemic clearance and non-renal clearance were 
significantly reduced and terminal elimination half-life was significantly increased 
when compared to male rats (Shelnutt et al., 1999); this could account for the 
behavioural differences observed in female rats.  Hönack and Löscher (1993) suggested 
that increased sensitivity to MK-801 in females did not simply reflect differences in 
drug metabolism but could be due to differences in the number and/or affinity of PCP 
binding sites, or differences in endogenous modulators of the NMDA receptor.  
Together, these findings suggest that differential responsiveness to PCP in males and 
female rodents can be explained by pharmacokinetic and possibly pharmacodynamic 
differences. 
 
2.4.2 Experiment 2 (and 4): Effects of clozapine, risperidone and haloperidol on sub-
chronic phencyclidine-induced deficits in attentional set-shifting 
Sub-chronic PCP produced a deficit in the ability to switch from one attentional set to 
another, indicated by a poor performance in the EDS stage of the task.  The PCP-
induced deficit was not significant in the first experiment, but there was an increase in 
trials to reach criterion in the female rats.  The lack of a significant deficit in the first 
experiment may be due to the fact that it was the first time the task had been trialled in 
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the laboratory.  Due to having more experience with the task, in the second experiment 
the PCP-induced deficit was significant; these deficits were reversed by sub-chronic 
administration of clozapine and risperidone, but not haloperidol.  There was no 
significant difference in locomotor activity observed between vehicle and sub-chronic 
PCP-treated groups; therefore it may be assumed that the cognitive deficit produced by 
sub-chronic PCP was independent of effects on locomotor activity.   
In this study rats readily learned to discriminate food bowls based on the digging 
medium and odour, and also refrained from digging in the un-baited bowls, therefore 
making few incorrect decisions.  In both vehicle and PCP-treated rats the first reversal 
(R1) required more trials to reach criterion compared to earlier stages of the task.  This 
is supported by data showing a significant increase in trials to criterion in control rats in 
reversal 1 (Hatcher et al., 2005); however, other studies have shown more modest 
increases (Birrell and Brown, 2000; Egerton et al., 2005; Fletcher et al., 2005). 
 
Vehicle rats 
Vehicle-treated rats required fewer trials to reach criterion in the IDS phase than the 
EDS phase and completed the IDS trials faster, suggesting that an attentional set was 
formed.  However, lack of a significant increase in trials to criterion from IDS to EDS 
does not support the idea that an attentional set had been formed in the control rats. One 
aspect of this study that may have influenced the data set is that, before each new 
discrimination begins, all rats have 4 discovery trials to learn the new rule; it is 
therefore possible that vehicle rats learned the EDS rule within these 4 trials thus 
improving their performance; this may also explain the occurrence of minimum trials to 
criterion without any apparent errors in certain discriminations.    
76  
Therefore, the aim of experiment 4 was to counterbalance a PCP attentional set-
shifting study; and to examine the effects of the discovery trials in order to establish if 
the inclusion of 4 discovery trials at the start of each phase was the reason for the lack 
of significance in vehicle rats in ID/ED shift.  Analysis of the number of correct 
discovery trials showed that in both vehicle and PCP-treated groups the number of 
correct discovery trials was reduced when comparing SD to the Rev1 and EDS phases 
of the task, indicating that these stages are more difficult.  Also, in vehicle and PCP-
treated rats the number of correct discovery trials was significantly decreased from IDS 
to EDS.  This suggests that if the discovery trials were not included, i.e. scoring started 
from trial 1, both vehicle and PCP treated rats would find the EDS phase much harder 
than the IDS phase.   This may also suggest that within the discovery trials it is possible 
for the rats to learn the new correct rule before the scoring starts; therefore the discovery 
trials could be masking potential errors that would be scored if the discovery trials were 
omitted. 
 
Effects of PCP 
There were no significant differences in time taken to complete the trials at any stage of 
the test between vehicle and PCP-treated rats.  In the EDS phase PCP-treated rats 
showed an increase in percentage errors and frequency of exploring both bowls before 
digging, this could be a measure of indecision or could be an indication that they cannot 
remember which is the correct parameter from the discovery trials.  In the literature, set-
shifting ability is measured by recording the number of trials to reach criterion, however 
in the current experiments additional measures (time taken, percentage errors and both 
bowl exploration) were taken in order to determine whether PCP affected any other 
behaviours.   
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There was a significant increase in trials required to reach criterion in PCP-
treated rats only in the EDS stage, suggesting that sub-chronic PCP causes a selective 
deficit in attentional set-shifting ability.  These results are supported by a previous study 
where PCP at 5 mg/kg twice daily for seven days followed by a ten-day drug washout 
period, in male Long-Evans rats, selectively impaired the EDS without affecting other 
discrimination tasks or reversals (Rodefer et al., 2005, 2007).  Acute PCP (2.58 mg/kg) 
also produces a deficit in set-shifting ability in rats (Egerton et al., 2005).  However, 
repeated exposure i.e. sub-chronic administration of PCP is believed to mimic 
schizophrenia more closely than acute administration (Jentsch and Roth, 1999, see 
chapter 1).  The success of the treatment regime used in this investigation is further 
supported by a comparative study of sub-chronic PCP dosing regimes by Gartlon et al. 
(2006) who reported that a bi-daily (7-day) regime, but not a 26-day intermittent regime, 
produces cognitive deficits in the NOR task.  Furthermore, recent studies have shown 
that long-term intermittent administration of PCP (3 mg/kg once per day administered 
Monday, Wednesday and Friday for 5 weeks, and 10 mg/kg daily for 14 days) did not 
impair set-shifting ability in male rats (Deschênes et al., 2006; Fletcher et al., 2005).  
These data would suggest that continual dosing with PCP is more effective than an 
intermittent regime.  It is important to note that PCP is not the only pharmacological 
means of producing schizophrenia-like impairments, for example amphetamine 
sensitised rats show deficits in sensorimotor gating, in addition to cognitive impairment 
in tasks such as attentional set-shifting (Fletcher et al., 2005; Tenn et al., 2003). 
In experiment 4 PCP-treated rats required more trials to reach criterion in the 
EDS phase but this effect was also observed in the Rev1 and Rev3 phases.  No 
differences were observed in the time taken per trial.  The percent errors were increased 
in PCP-treated rats in the Rev1, EDS, Rev3 stages when compared to vehicle rats.  
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PCP-treated rats also explored both bowls before digging more frequently than vehicle-
treated rats only in the EDS phase.  The results from this experiment closely correspond 
to those in experiment 2.  The only difference is that trials to criterion were increased in 
two of the reversal phases in the current experiment; this may be due to the orbital PFC 
being relied upon in reversals as well as the medial PFC in the EDS phase.  Sub-chronic 
PCP does cause reliable deficits in reversal learning in an operant task (Abdul-Monim et 
al., 2006), so it is not surprising that deficits in reversals are also observed during the 
attentional set-shifting task.  These deficits in operant reversal learning will be explored 
further in the next chapter. 
 
Effects of antipsychotics 
It has been widely reported that atypical antipsychotics have some beneficial effect on 
cognitive deficits (Buchanan et al., 1994; Hagger et al., 1993; Harvey et al., 2004; 
Meltzer and McGurk, 1999; Rossi et al., 1997).  However, it is important to appreciate 
the limitations of models such as this one as; although clozapine and risperidone 
effectively reversed the cognitive deficits observed in this experiment, the CATIE study 
highlights the fact that these antipsychotics do not provide consistent improvement of 
cognitive symptoms in patients (Lieberman, 2006).  This could indicate a need to 
develop more robust cognitive deficit models which are only partially improved by 
currently available antipsychotics, in order to correspond more closely with the clinical 
situation and allow for assessment of improved therapies.  It could also suggest that a 
full reversal of induced deficits is a limitation of the animal model.  Full reversals with 
current antipsychotics may be gained in animals as compliance is not an issue as it can 
be in patients, in that it is known exactly how much of the drug is administered and that 
there are no interactions with other medications as can be the case in patients with 
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schizophrenia.  In addition it is important to note that patients involved in clinical trials 
can often be on long-term medication which could interfere with the efficacy of 
potential new therapies. 
The use of only one dose of antipsychotics is a limitation of this study, a dose 
response should ideally have been conducted; however, in order to limit the number of 
animals used, and length of testing, one active dose of each antipsychotic was carefully 
selected.  The doses of clozapine (2.5 mg/kg) and risperidone (0.2 mg/kg) were chosen 
on the basis of recent experiments from this laboratory showing efficacy against sub-
chronic PCP-induced deficits in reversal learning (Abdul-Monim et al., 2006; Neill et 
al., 2006) and NOR (Grayson et al., 2007).  The dose of haloperidol was chosen on the 
basis of previous work showing that 0.05 mg/kg haloperidol significantly attenuated a 
d-amphetamine-induced reversal learning impairment in female hooded-Lister rats 
(Idris et al., 2005a).  It is unlikely that a higher dose of haloperidol would have been 
any more effective as a dose of 0.075 mg/kg haloperidol was less efficacious to reverse 
the amphetamine deficit in reversal learning when compared to the dose of 0.05 mg/kg 
(Idris et al., 2005a) and a dose of 0.1 mg/kg was shown to impair performance (Abdul-
Monim et al., 2003).  Indeed in this experiment 0.05 mg/kg haloperidol significantly 
increased the time taken to complete trials in 4 phases of the task.  Furthermore, 0.05 
mg/kg haloperidol has been shown to occupy 50% of dopamine D2 receptors (Kapur 
and Seeman, 2001; Kapur et al., 2003). 
The current study shows that the PCP-induced deficit in percentage errors and 
trials to reach criterion was improved by sub-chronic administration of clozapine and 
risperidone, but not haloperidol.  The increase in frequency of both bowl exploration in 
PCP-treated rats was also improved by clozapine, although not risperidone. As 
mentioned above, these results are in agreement with previous studies in this laboratory.  
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In addition, a recent study has shown that sub-chronic administration of clozapine (5 
mg/kg) but not haloperidol (0.05 mg/kg) can prevent the PCP-induced cognitive deficit 
when administered in conjunction with the daily sub-chronic PCP treatment regimen 
(Idris et al., 2005b).  
Antipsychotics were given sub-chronically as initially a pilot study showed that 
acute dosing with clozapine and haloperidol prevented rats from being able to complete 
the task, therefore for rats to complete the task, sub-chronic dosing with clozapine and 
haloperidol was required.  In order to make a direct comparison, risperidone was also 
given sub-chronically.  Didriksen and colleagues used doses of 0.63 and 1.3 mg/kg of 
clozapine for a reversal learning study as their pilot study showed worsening of 
performance with higher doses of clozapine in combination with PCP (Didriksen et al., 
2007).  It has also been shown that tolerance can develop to the sedative effects of 
clozapine after repeated dosing (Chesler and Salamone, 1996).  These data are 
supported by a study by Hashimoto and colleagues who showed that acute 
administration of clozapine (5 mg/kg) and haloperidol (0.1 mg/kg) did not improve a 
sub-chronic PCP-induced cognitive deficit in the NOR task in mice; however, they 
found that sub-chronic administration of clozapine (5 mg/kg daily for 14 days) 
significantly improved the deficit, whereas sub-chronic haloperidol (0.1 mg/kg daily for 
14 days) did not (Hashimoto et al., 2005). 
The results from this experiment show that sub-chronic administration of 
haloperidol did not significantly improve the deficit in set-shifting performance induced 
by PCP as indicated by the inability to improve the deficit in trials to reach criterion and 
the percentage of errors.  This is supported by clinical data as patients chronically 
treated with haloperidol have shown impaired performance in tests of working memory 
and executive function (Gilbertson and van Kammen, 1997).  Haloperidol-treated rats 
81  
also required significantly more time to complete their trials in the SD, CD, Rev l and 
Rev 3 phases of the task, indicating that the rats were impaired behaviourally.  The 
inability of haloperidol to reverse the PCP-induced deficit may be due to its high D2 
receptor affinity and minimal 5-HT2A receptor affinity (Siegfried et al., 2005). 
The current study does not provide direct evidence for specific receptor 
mechanisms involved in mediating the efficacy of the antipsychotics against the PCP 
effect.   Selective agents will be used in chapter 3 to identify which receptors are 
involved in reversing the PCP-induced deficit in an operant reversal learning task.  Data 
from receptor binding studies in other laboratories allows the suggestion of potential 
receptor mechanisms which may be involved.   Risperidone was highly effective in 
reversing the PCP-induced deficit and has high 5-HT2A and D2 receptor affinity (Leysen 
et al., 1993) as well as high 5-HT7 affinity (Shahid et al., 2008).  5-HT7 receptors have 
been implicated as having a role in learning and memory (Hedlund and Sutcliffe, 2004; 
Thomas and Hagan, 2004).  Risperidone is suggested to be the most effective atypical 
antipsychotic to improve working memory and executive function in the clinic (Meltzer 
and McGurk, 1999), although, in this study in rats, clozapine was equally effective.  
Clozapine has a lower affinity for D2 receptors than risperidone (Arnt and Skarsfeldt, 
1998).  It is believed that a 40-80% threshold of D2 receptor occupancy is required to 
achieve an antipsychotic response (Kapur et al., 2003).  Clozapine is able to reach its 
antipsychotic effect at 45-65% D2 receptor occupancy levels (Kapur et al., 2003).  
Risperidone is only effective at occupancy levels above the threshold of 65%, 
suggesting that risperidone is more reliant upon its D2 receptor affinity than clozapine.  
Although risperidone and clozapine have high affinity for 5-HT2A receptors, it is 
unlikely that this mechanism alone is responsible for their antipsychotic action, as both 
have been shown to saturate 5-HT2 receptors at sub-therapeutic doses (Kapur et al., 
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1999).  Risperidone also has high affinity for D3, D4 and α2-adrenoceptors, which may 
add to its therapeutic effect (Siegfried et al., 2005).  Clozapine has affinity at a wide 
range of receptors including 5-HT6 receptors.  Activity at 5-HT6 receptors has been 
postulated to be involved in cognitive dysfunction (Woolley et al., 2004; Mitchell and 
Neumaier, 2005).  A selective 5-HT6 receptor antagonist has been shown to improve 
set-shifting ability (Hatcher et al., 2005), this may be via facilitation of cortical and 
hippocampal glutamatergic activity (Dawson et al., 2001). 
 
2.4.3 Experiment 3: Effects of isolation rearing and attentional set-shifting 
The results demonstrate that isolation reared rats showed hyperactivity when compared 
to socially housed controls. Since this is in agreement with previous results in this 
(Smith et al., 1997) and many other laboratories (Bakshi and Geyer, 1999; Lapiz et al., 
2003; Elliott and Grunberg, 2005; Bianchi et al., 2006) this validated the isolation 
rearing paradigm used.  It has been widely suggested that increases on LMA in rats 
reared in isolation may be due to increased dopamine in the mesolimbic pathway (see 
Fone and Porkess, 2008), with some reported increases in dopamine turnover in the 
nucleus accumbens (Hall et al., 1998).  Although rats reared in isolation demonstrated 
hyperactivity in the automated photocell cages, there were no significant differences in 
time taken to complete the trials during attentional set-shifting, except in reversal 3 of 
the task in which isolation reared rats were quicker to complete the trials.  This may be 
an observed effect as the isolation reared rats appear to be getting progressively quicker 
over the phases, except in the EDS phase where due to the increased difficulty rats take 
longer per trial, so that by reversal 3 they are significantly quicker than their social 
counterparts.  The social rats may not complete the trials quicker as they could be less 
motivated than the isolates as it has been shown that in progressive ratio isolates will 
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respond much more for food than social animals (Smith et al., 1997).   The principal 
findings show that isolation reared rats exhibit impaired set-shifting ability when 
compared with socially reared controls.  Thus, isolates required significantly more trials 
to reach criterion selectively at the EDS phase of testing, when compared with socially 
housed animals indicative of a selective deficit in set-shifting ability.  An additional 
finding in the current study was that isolates explored both bowls more before making a 
decision to dig.  This effect was also observed in PCP-treated rats, demonstrating that it 
is a consistent finding.  This was measured by an increased number of visits to both 
bowls and could suggest that isolates are more indecisive or could be an indication that 
they cannot remember which is the correct parameter from the discovery trials.  The 
deficit produced by sub-chronic PCP in experiments 1 and 3 is more robust than the 
deficit produced by isolation rearing.  This may be due to more variation between the 
isolates as the errors bars are larger in the isolation rearing experiment compared to 
those in the PCP experiments, and that the isolates are difficult to test due to changes in 
their behaviour including being more susceptible to distraction produced by housing in 
isolation.  
Patients with schizophrenia also exhibit selective deficits in the ED shift of the 
ID/ED task and WCST (Haut et al., 1996; Tyson et al., 2004; Jazbec et al., 2007).  The 
data herein show a similar profile in rats reared in isolation.  Notably there were no 
differences between isolates and socials in any other stage of the task including reversal 
learning, showing that reversal learning is not affected by isolation rearing.  This is in 
agreement with previous data in an operant lever pressing task (Abdul-Monim et al., 
2006).  This data is also supported by a study using an 8 arm radial maze to assess 
attentional set-shifting ability showing that isolates performed similarly in the 
acquisition and reversal phases but were impaired in attentional shifts (Schrijver and 
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Wurbel, 2001).  This may be due to the different regions of the frontal cortex involved 
in reversal learning and attentional set-shifting.  It has been shown that whereas lesions 
of the orbital prefrontal cortex in rats selectively disrupts reversal learning (McAlonan 
and Brown, 2003), lesions of the medial prefrontal cortex (mPFC) produce a selective 
deficit in the EDS phase (Birrell and Brown, 2000).  Consistent with a selective deficit 
in the EDS phase, rats reared in isolation have been shown to exhibit structural 
abnormalities selectively in the mPFC (Silva-Gomez et al., 2003; Day-Wilson et al., 
2006).  
It is not surprising that early separation from cage-mates alters brain 
development as most of the monoamine neurotransmitters and their associated receptor 
compliment only reach the adult composition between PND 30-50 in the rat (Lapiz et 
al., 2003).  The cognitive deficit shown in this study could be attributed to structural 
and neurochemical abnormalities previously demonstrated in rats reared in isolation.  
Isolation rearing decreases dopamine turnover in the medial prefrontal cortex 
(Heidbreder et al., 2000), which is similar to the hypofrontality in schizophrenia.  
Schizophrenic patients exhibit decreased dendritic spine density in both the 
hippocampus and medial prefrontal cortex (Glantz and Lewis, 2000).  These structural 
alterations are also seen in rats reared in isolation (Varty et al., 1999; Silva-Gomez et al., 
2003; Day-Wilson et al., 2006) and are regions suggested to be involved in the 
attentional set-shifting task (Birrel and Brown, 2000).  Rats reared in isolation also 
show a decrease in mPFC volume (Day-Wilson et al., 2006).  
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2.4.4 Conclusions 
Sub-chronic PCP administration and isolation rearing impairs attentional set-shifting 
ability as demonstrated by poor performance in the EDS stage of the task.  The findings 
of this study support NMDA antagonist administration and isolation rearing as useful 
models for mimicking cognitive dysfunction with relevance to schizophrenia.  It was 
also shown that sub-chronic treatment with the atypical antipsychotics, clozapine and 
risperidone, is effective in reversing the PCP-induced cognitive deficit in the attentional 
set-shifting task, and that, the typical antipsychotic, haloperidol, is ineffective.  The data 
from experiment 4 suggests that counterbalancing is not essential but preferred, and 
analysis of the number of correct discovery trials showed that in both vehicle and PCP-
treated groups the number of correct discovery trials was significantly decreased from 
IDS to EDS.  This suggests that, if an attentional shift is to be observed in vehicle rats, 
the discovery trials should not be disregarded and should be scored and incorporated as 
normal trials. 
 
This chapter demonstrates that deficits in attentional set-shifting ability can be produced 
by sub-chronic PCP administration and isolation rearing.  However, the deficits 
produced by PCP in experiments 2 and 4 were more robust than the deficit produced by 
isolation rearing.  Thus, in other tests of cognition it would be more beneficial to use the 
sub-chronic PCP model to induce cognitive deficits as these appear to be robust and 
reproducible.  It was also shown that clozapine and risperidone improved the PCP-
induced deficit; however, this does not give an indication of the specific receptors that 
are involved in the mediation of the reversal of the PCP-induced deficit.  The next 
chapter will use an operant reversal learning task to elucidate the receptors involved in 
the PCP-induced deficit and which receptors are important for antipsychotic activity. 
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Chapter 3 
Effects of antipsychotics and receptor 
selective agents against sub-chronic  
PCP-induced deficits in reversal learning 
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3.1 Introduction 
The dominant hypothesis of the pathophysiology of schizophrenia until recently was the 
dopamine hypothesis as dopamine-releasing drugs such as amphetamine were seen to 
cause psychosis and D2 antagonists were shown to have some efficacy.  However, a 
purely dopamine hypothesis is limited as negative and cognitive symptoms appear to be 
untreated by typical antipsychotics.  The glutamate hypothesis based on NMDA 
antagonists, such as phencyclidine (PCP), producing cognitive impairments may be 
more clinically relevant.  The main glutamate hypothesis arises from the NMDA 
receptor hypofunction hypothesis of schizophrenia of Olney and Farber (1995).  They 
postulated that NMDA hypofunction produces a reduction in inhibitory firing mediated 
by GABAergic neurotransmission (see chapter 1).  In support of this hypothesis it has 
also been shown that glycine administration to enhance NMDA receptor function can 
improve schizophrenic symptoms when used in conjunction with other antipsychotic 
treatment (Rosse et al., 1989). 
Sub-chronic phencyclidine (PCP) dosage regimens are believed to induce 
cognitive impairments to mimic those seen in schizophrenia (Javitt and Zukin, 1991).  It 
was previously shown that PCP selectively impaired performance in the reversal phase 
of the reversal learning task (Abdul-Monim et al., 2006), and that the atypical 
antipsychotic ziprasidone, but not the classical antipsychotic haloperidol, was able to 
prevent the PCP-induced disruption of the task (Abdul-Monim et al., 2006).  Sub-
chronic PCP has also produced deficits in other cognitive tests such as attentional set-
shifting (see chapter 2) and a novel object recognition test (Grayson et al., 2007).  In 
both of these studies the PCP-induced deficit was reversed by atypical antipsychotics, 
but not classical agents.   
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In the reversal learning paradigm, animals are required to perform two tasks.  
The first task requires the animal to inhibit a previously learned rewarded strategy; in 
the second task, the animal must acquire the new strategy (Mackintosh and Little, 1969).  
Effective performance requires intact cognitive ability; thus animals are required to 
demonstrate flexibility, attention, motivation, and ability to suppress a previously 
learned response and implement a new one (Jones et al., 1991).  In rats this reversal 
learning ability is assessed in operant chambers with two levers, an active lever which 
when pressed produces food from the magazine, and an inactive lever which has no 
consequence but to end the trial.  The task involves an initial phase for 5 min in which 
one lever is active; this is followed by a 2 min time-out period.  Then in the 5 min 
reversal phase the opposite lever is now active.  The experiments in this chapter utilised 
an operant reversal learning test and this was combined with our sub-chronic PCP 
dosage regimen to produce a cognitive deficit similar to those seen in schizophrenia.  
Similar tests in schizophrenia patients, such as the Wisconsin Card Sorting Test, require 
intact functioning of the prefrontal cortex (Deicken et al., 1995; Dias et al., 1997).  It 
has been shown more specifically that lesions of the orbital prefrontal cortex impair 
reversal learning ability (McAlonan and Brown, 2003; Tait and Brown, 2007). 
The principal aim of this chapter is to further validate the reversal learning task 
with sub-chronic PCP and antipsychotics, and to determine which receptor mechanisms 
may be implicated in cognitive dysfunction associated with schizophrenia by using 
selective compounds (see chapter 1 section 1.6.3).  Receptor affinities of these selective 
compounds are detailed in table 3.1.  The drugs selected were based on the receptor 
pharmacology of clozapine and risperidone; and on the emerging roles of the dopamine 
D1 and α7 nACh receptors in cognitive enhancement in schizophrenia, as well as the 
conflicting role of 5-HT1A receptors (Gray and Roth, 2007, see chapter 1 table 1.4). 
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Table 3.1: Receptor affinities for the selective compounds to be used in this chapter. 
Drug Receptor affinity Dose (mg/kg) Reference 
clozapine 
5-HT2A, 5-HT2C, 5-
HT6, α1 and α2-
adrenergic, H1, M1 
5 Siegfreid et al., 2005 
risperidone 
D2, D3, D4, 5-HT2A, 
5-HT7, α1 and α2-
adrenergic, H1 
0.2 Siegfreid et al., 2005 
haloperidol 
D2, D3, D4, α1-
adrenergic 
0.05 Stahl, 2002 
SKF-38393 D1, D5 0.75, 1.5, 3, 6 
Neumeyer et al., 
2003, Qandil et al., 
2003 
SCH-23390 D1, D5 0.05 Lawler et al., 1999 
buspirone 5-HT1A 0.15625-2.5 Hamik et al., 1990 
WAY-100635 5-HT1A 0.3, 1.0 Hamon et al., 1990 
77-LH-28-1 M1 1, 3, 10 
Langmead et al., 
2008b 
SB-243213A 5-HT2C 1, 3, 10 Bromidge et al., 2000 
PNU-282987 nicotinic α7 5, 10, 20 Waring et al., 2008 
PheTQS nicotinic α7 PAM 3, 10, 30 GSK in house data 
pyrilamine 
(mepyramine) 
H1 10, 20, 40 
Soria-Jasso et al., 
1997 
Table 3.1: See table 3.3 for details of source and administration. 
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3.2 Materials and Methods 
 
3.2.1 Subjects and housing conditions 
Two groups of 50 female hooded-Lister rats (Harlan, UK) housed in groups of four or 
five were used as subjects.  Animals were maintained under standard laboratory 
conditions at a temperature of 21°C (±2°C) and humidity of 40–50%.  They were 
maintained on a 12 h/12 h light/dark cycle (lights on at 0700 h) and experimental 
procedures were performed during the light phase.  Rats were gradually food deprived 
to approximately 90% of free-feeding body weight before training; reduced body weight 
was maintained by restricting the amount of food (standard laboratory chow, Special 
Diet Services, Essex, UK) given to each rat per day (12 g/day). The availability of water 
was not restricted.  Experiments were conducted in accordance with the Animals 
Scientific Procedures Act, UK, 1986, and approved by the University of Bradford 
ethical review process. 
 
3.2.2 Reversal learning training and testing 
All rats were tested in one of eight operant chambers (constructed in-house, shown in 
fig 3.2.2a).  Each chamber (29 × 30 × 30 cm) consisted of Plexiglas walls and ceiling, 
and a metal grid floor over sawdust (see fig 3.2.2b).  A hinged Plexiglas panel (6 × 6 cm) 
provided access to a food hopper containing food pellets (45 mg Noyes pellets, 
Sandown Scientific, UK).  Two retractable levers (4 × 2 cm) were positioned on either 
side of the food hopper.  A light emitting diode (LED) was positioned centrally above 
each lever and a house light was located in the ceiling of each chamber.  The chambers 
were placed individually within ventilated sound-attenuating hardboard boxes (69 × 38 
× 42 cm) containing a Perspex window to allow viewing.  A small fan was built into 
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each chamber to mask external noise.  All boxes were controlled by Med-PC software 
(Version 2.0 for DOS or Med-PC for Windows, Med Associates, Inc. Lafayette, 
Indiana).  Programmes were written using Medstate notation. 
 
 
 
 
 Figure 3.2.2a Identical Skinner boxes in test room. 
Figure 3.2.2b Individual Skinner box. 
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Following habituation to the operant chambers, rats were trained on a continuous 
reinforcement (CR) schedule, whereby a food pellet was delivered every 30 s for a 20 
min period.  This training period was (for approximately 5 days) followed by the 
introduction of the two retractable levers using the FR1 (fixed ratio 1) schedule of 
reinforcement so that one press of either lever resulted in the delivery of a food pellet.  
This process was conducted for approximately 2 weeks for all rats to acquire the lever 
pressing response.  When responding had stabilised, rats were trained to press either the 
left or right lever for food delivery according to a visual cue (LED on or off).  The 
experimental session was terminated following a total of 128 lever presses, which took 
approximately 30 min.  The active lever was varied between days using the 
pseudorandom Gellerman schedule, which randomly assigned either the left or right 
lever as active, thus avoiding the generation of lever bias.  The experimental session 
began with the illumination of the house-light.  After 3 s, the levers were extended to 
the chamber together with the cue light.  Following a lever press the levers were 
retracted and the house-light was extinguished for a 3 s time-out period.  A correct 
response on the active lever resulted in the delivery of a food pellet, and an incorrect 
response resulted in no food delivery.  The house-light was then illuminated and the 
cycle was repeated.  The experimental session was terminated following 128 lever 
presses (on either the correct or incorrect levers).  Rats were trained once daily and this 
was repeated until rats had reached criterion, i.e. 90% correct responding for three 
consecutive days. 
The day before each reversal task session, a full 30-min operant training session 
(as described above) was conducted in order to ensure stable responding, i.e. 90% 
correct responding.  The reversal-learning session involved animals being first exposed 
to a 5 min period during which the active lever was the same as on the previous training 
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day.  During this period, responses on both correct and incorrect levers were recorded.  
This part of the session was termed the initial phase.  This was followed by a 2 min 
time-out period, which was signalled by the house light being turned off. In the 
subsequent 5 min period, the active lever was reversed.  Responses made on the correct 
and incorrect levers were again recorded.  This second period was termed the reversal 
phase.  Animals undertook several of these reversal learning sessions before beginning 
the drug studies in order to ensure that they attained a stable level of performance, i.e. 
90% correct responding and at least 25 lever presses in total, in both the initial and 
reversal phases of the task.  
 
3.2.3 Experimental design 
Rats were tested on a cycle of 4 days (see table 3.2.2).  On day 1 each animal had a 30-
min operant training session. The following day, animals received the appropriate 
drug(s) and undertook a reversal-learning session. On day 3 and day 4, each animal 
underwent a further operant training session and reversal task session, respectively, in 
order to ensure that responding was back to normal after the drug treatment.  Following 
sub-chronic PCP treatment and a 7-day washout period the following drug experiments 
were carried out.  The drug and vehicle treatment given to each PCP-treated rat was 
pseudo-randomised over the course of these experiments to ensure that the highest dose 
or vehicle treatment was not given to the same rats in successive experiments.  In the 
experiments in this chapter, normal responding was restored following each drug 
treatment, if performance was not fully restored, the cycle shown in table 3.2.2 would 
be repeated with no drug treatments until baseline performance in the reversal test was 
restored. 
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Table 3.2.2: The experimental design for each drug study. 
Day 1 Day 2 Day 3 Day 4 Day 5 + 
Training 
session 
 
Drug test day, reversal 
test session. Data 
shown in results section 
Training 
session 
Reversal 
test session, 
drug-free 
The cycle 
repeated 
as needed 
 
3.2.4 Drugs 
For each cohort, the study design involved groups of 10 rats initially; rats were given 
either 2 mg/kg PCP (n = 40) or vehicle (0.9 % saline; n = 10) by the intraperitoneal (i.p.) 
route twice daily for seven days.  Dosing with sub-chronic PCP or vehicle was followed 
by a washout period of a further seven days.  PCP hydrochloride (Sigma, UK) was 
dissolved in 0.9 % saline.  Drugs and respective vehicles used in the experiments are 
shown in table 3.2.3.  The effects of drugs were examined in PCP-treated rats only.  The 
order of experiments is shown is figure 3.2.3. 
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Figure 3.2.3: Timeline of experiments 
 
Experiment 1: Rats were treated with vehicle (0.9% saline), risperidone (0.2 mg/kg), 
clozapine (5.0 mg/kg), and haloperidol (0.05 mg/kg).  Haloperidol (Serenace liquid, 2.0 
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mg/ml, Baker, UK) was diluted with distilled water.  Clozapine (Tocris, UK) and 
risperidone (provided by GSK, UK) were dissolved in 10μl of acetic acid, made up to 
volume with distilled water and pH adjusted to 6 with 0.1M NaOH.  All drug doses 
were calculated as base equivalent weight and were administered via the intraperitoneal 
(i.p.) route in a volume of 1 ml/kg 30 min before testing. 
Experiments 2 and 3: A dose-response was carried out to the dopamine D1 
receptor agonist, SKF-38393, and this was followed by a further experiment where the 
D1 receptor antagonist, SCH-23390 was also administered in the presence of SKF-
38393.  The dose-response to SKF-38393 was carried out over 2 experiments, in the 
first experiment 0.75, 1.5, and 3.0 mg/kg (i.p.) were tested followed by a later 
experiment with 6.0 mg/kg (i.p.) subsequently the data were combined which meant 
there were 20 rats in the vehicle and PCP groups.  SKF-38393 hydrochloride (Research 
Biochemicals International, MA, USA) and SCH-23390 hydrochloride (Tocris, UK) 
were dissolved in saline (0.9 %) and were administered via the i.p. route in a volume of 
1 ml/kg.  SCH-23390 or vehicle was given 20 min prior to SKF-38393 or vehicle and 
rats were tested 30 min following this treatment.  All drug doses were calculated as base 
equivalent weight.  It was determined that 0.05 mg/kg of SCH-23390 reversed the effect 
of SKF-38393 in novel object recognition (Idris et al., 2008); therefore this dose was 
tested in the second reversal learning experiment.  
Experiments 4 and 5: The doses of buspirone were selected based on previous 
dose-response experiments carried out in this reversal learning task.  WAY-100635 was 
shown to have selective 5-HT1A antagonist activity at the doses used in this study 
(Prinssen et al., 1999).  Buspirone hydrochloride (Sigma, UK) and WAY-100635 
(Sigma, UK) were dissolved in 0.9% saline and injected in a volume of 1 ml/kg via the 
i.p. route; buspirone was administered 30 min prior testing and WAY-100635 or vehicle 
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was administered 30 min prior to buspirone.  WAY-100635 alone was administered 60 
min prior to testing. 
Experiment 6: The doses of SB-243213A (5-methyl-1-[[2-[92-methyl-3-
pyridyl0oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindone hydrochloride) were 
selected based on effects observed in a study by Wood et al., (2001).  SB-243213 was 
shown to have high affinity for the human 5-HT2C receptor with greater than 100-fold 
selectivity over 5-HT2A and 5-HT2B receptors (Wood et al., 2001).  SB-243213A 
(generously supplied by GSK, Harlow, UK) was dissolved in vehicle containing 
cyclodextrin (8% by weight) plus 25mM citric acid, and was administered 30 min prior 
to testing via the i.p. route in a volume of 2 ml/kg.   
Experiment 7: 77-LH-28-1 (1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-
2(1H)-quinolinone) was generously supplied by GSK (Harlow, UK) was prepared in 
0.9% saline, given in a volume of 2 ml/kg via the s.c. route, and was administered 30 
min before testing.  The doses and route of administration of 77-LH-28-1 were selected 
according to internal GSK DMPK and additional in-house behavioral data.  
Experiments 8 and 9: PheTQS ((3aR,4S,9bS)-4-(4-methylphenyl)-3a,4,5,9b-
tetrahydro-3H cyclopenta[c]quinoline-8-sulfonamide)) was generously supplied by 
GSK (Harlow, UK) and was prepared in 1 % methylcellulose, given in a volume of 1 
ml/kg via the p.o. route, and was administered 1 hour before testing.  The doses and 
route of administration of PheTQS were selected according to internal GSK DMPK and 
additional in-house behavioral data.  PNU-282987 ([N-[(3R)-1-Azabicyclo[2.2.2]oct-3-
yl]-4-chlorobenzamide Hydrochloride]) (Tocris, UK) was dissolved in 0.9% saline and 
given in 2 ml/kg volume via the s.c. route, and was administered 1 hour before testing. 
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Experiment 10: Pyrilamine maleate salt (Sigma, UK) was prepared in 0.9% 
saline, given in a volume of 2 ml/kg via the s.c. route, and was administered 45 min 
before testing.  
 
3.2.5 Data and statistical analysis 
Data for percent correct responding in the reversal learning task was calculated using 
the number of presses on the correct lever divided by the total number of presses 
multiplied by 100.  The percent correct responding data was arcsine transformed and 
analysed by one-way ANOVA followed by post-hoc Dunnett‟s t-test.  The total number 
of lever presses was calculated by adding the number of correct and incorrect presses 
together within the 5 min test session, this was used to assess whether drugs had caused 
any sedation or behavioural impairment. 
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Table 3.2.3: Routes of administration and vehicles of the drugs used in this chapter. 
Drug Source Receptor Dose (mg/kg) 
Volume 
(ml/kg) Route Vehicle 
Treatment time 
(min) 
Clozapine Tocris, UK See table 3.1 5 1 i.p. 
distilled water + 10μl acetic acid  
and pH balanced with NaOH (1M) 30 
Risperidone GSK, UK See table 3.1 0.2 1 i.p. 
distilled water + 10μl acetic acid  
and pH balanced with NaOH (1M) 30 
Haloperidol Baker, UK See table 3.1 0.05 1 i.p. distilled water 30 
SKF-38393 RBI, MA, USA D1 agonist 0.75, 1.5, 3, 6 1 i.p. 0.9% saline 30 
SCH-23390 Tocris, UK D1 antagonist 0.05 1 i.p. 0.9% saline 
20 before SKF,  
30 before testing 
Buspirone Sigma, UK 
5-HT1A partial 
agonist 0.15625-2.5 1 i.p. 0.9% saline 30 
WAY-100635 Sigma, UK 5-HT1A antagonist 0.3, 1.0 1 i.p. 0.9% saline 
20 before 
buspirone,  
30 before testing 
77-LH-28-1 GSK, UK M1 agonist 1, 3, 10 2 s.c. 0.9% saline 30 
SB-243213A GSK, UK 5-HT2C antagonist 1, 3, 10 2 i.p. 
0.9% saline containing cyclodextrin  
(8% by weight) plus 25mM citric acid  30 
PNU-282987 Tocris, UK alpha 7 agonist 5, 10, 20 2 s.c. 0.9% saline 60 
PheTQS GSK, UK alpha 7 PAM 3, 10, 30 1 p.o. 1% methyl cellulose 60 
Pyrilamine Sigma, UK H1 antagonist 10, 20, 40 2 s.c. 0.9% saline 45 
 
Table 3.2.3: Routes of administration: intraperitoneal (i.p.), sub-cutaneous (s.c), per os (p.o). 
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3.3 Results 
 
3.3.1 Effect of antipsychotics 
A one-way ANOVA on the initial phase showed a significant effect of drug (F4,46=3.36, 
P<0.05) and post-hoc Dunnett‟s t-test showed that haloperidol significantly impaired 
responding (P<0.01, fig 3.3.1) compared to the vehicle group.  A paired t-test showed a 
significant deficit in the reversal phase in the PCP group compared to the initial phase 
(P<0.05).  A one-way ANOVA on the reversal phase showed a significant effect of drug 
(F4,46=3.77, P<0.01).  Post-hoc Dunnett‟s t-test revealed that risperidone significantly 
improved performance of PCP-treated rats compared to PCP alone (P<0.05, fig 3.3.1a), 
while clozapine and haloperidol did not improve performance (P=0.16 and P=1.0 
respectively).  There was no effect on total lever pressing in the reversal phase; however, 
in the initial phase clozapine significantly reduced the total lever pressing (P<0.05, table 
3.3.1).  
 
Table 3.3.1: The effect of clozapine (5.0 mg/kg), risperidone (0.2 mg/kg), haloperidol (0.05 mg/kg) and 
sub-chronic PCP (2.0 mg/kg, twice a day for 7 days, i.p.) on the total number of lever presses in a reversal 
learning paradigm. Data are expressed as the mean  SEM total number of lever presses (n=8-10 per 
group) in the initial and reversal phase of the task.  Post-hoc Dunnett‟s t-test revealed that the total 
number of lever presses was significantly decreased in the initial phase in clozapine-treated rats when 
compared to the vehicle-treated group; *P<0.05.  
Drug treatment     Initial phase   Reversal phase 
vehicle + vehicle      27.1 0.4     27.6 0.3 
vehicle + sub-chronic PCP 2mg/kg      27.4 0.5     27.2 0.4 
5.0 mg/kg clozapine + sub-chronic PCP       24.3 1.4*     26.0 1.0 
0.2 mg/kg risperidone + sub-chronic PCP      26.4 0.6     26.8 0.7 
0.05 mg/kg haloperidol + sub-chronic PCP      27.5 0.3     26.9 0.3 
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Figure 3.3.1a: The effect of clozapine (5.0 mg/kg), risperidone (0.2 mg/kg) and haloperidol (0.05 mg/kg) 
on the deficit produced by sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the 
reversal phase of the reversal learning task.  Data are shown as mean ± SEM. percentage correct 
responding (n=8-10).  Post-hoc Dunnett‟s t-test in the initial phase showed a significant reduction in 
correct responding in the haloperidol-treated group compared to vehicle; 
++
P<0.01.  A paired t-test 
showed a significant deficit in the reversal phase in the PCP-group compared to the initial phase; *P<0.05.  
#P<0.05 Dunnett‟s t-test showed risperidone significantly improved responding compared to PCP alone. 
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Figure 3.3.1b: The influence of clozapine (5.0 mg/kg), risperidone (0.2 mg/kg) and haloperidol (0.05 
mg/kg) on the effect of sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the 
initial and reversal phase of the reversal learning task. Data are shown as the mean total number of lever 
presses, correct responses are shown as clear bars and incorrect responses are shown as shaded bars (n=8-
10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
 
3.3.2 Effects of the D1 receptor agonist SKF-38393 alone and in conjunction with the 
D1 receptor antagonist SCH-23390 
For percent correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.001) and following SKF-38393 (0.75, 1.5 mg/kg, i.p.; P<0.05).  A one-way 
ANOVA in the reversal phase showed a significant interaction (F5,78 = 7.38, P<0.001).  
Post-hoc analysis revealed that SKF-38393 at 6.0 mg/kg (i.p.) significantly improved 
the PCP-induced deficit (P<0.05; Fig 3.3.2).  There was no significant effect on total 
lever pressing in the initial or reversal phases, suggesting that neither locomotor 
capacity nor motivation were affected (table 3.3.2).   
In the SKF-38393 and SCH-23390 combination study a paired t-test showed a 
significant impairment in responding in the reversal phase compared to the initial phase 
in the PCP-treated group (P<0.001; Fig 3.3.3).  A one-way ANOVA in the reversal 
phase showed a significant interaction (F4,47 = 14.63, P<0.001).  Post-hoc analysis 
showed that SKF-38393 (6.0 mg/kg, i.p.) significantly improved the PCP-induced 
deficit (P<0.001), and that SCH-23390 (0.05 mg/kg, i.p.) significantly antagonised this 
effect (P<0.001).  A one-way ANOVA on total lever pressing in the reversal phase 
showed a significant interaction (F4,47 = 6.14, P<0.01) and post-hoc analysis showed a 
significant (P<0.001) reduction in lever pressing following SCH-23390 treatment 
compared to the vehicle group (table 3.3.3).   
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Figure 3.3.2a: The effect of SKF-38393 (0.75, 1.5, 3.0, 6.0 mg/kg) on the deficit produced by sub-
chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal 
learning task.  Data are shown as mean ± SEM. of percent correct responding (n=20 for vehicle and 
PCP+vehicle, n=9 for all doses of SKF-38393).  A paired t-test showed a significant reduction in 
performance of the reversal phase compared with the initial phase; ***P<0.001, *P<0.05.  Dunnett‟s t-
test showed significant improvement in responding compared to PCP alone in the reversal phase at 6.0 
mg/kg of SKF-38393; 
#
P<0.05. 
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Figure 3.3.2b: The influence of SKF-38393 (0.75, 1.5, 3.0, 6.0 mg/kg) on the effect of sub-chronic PCP 
(2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the reversal 
learning task.  Data are shown as the mean total number of lever presses, correct responses are shown as 
clear bars and incorrect responses are shown as shaded bars (n=20 for vehicle and PCP+vehicle, n=9 for 
all doses of SKF-38393). 
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Table 3.3.2: The effect of sub-chronic PCP (2.0 mg/kg, twice a day for 7 days, i.p.) and SKF-38393 (0.75, 
1.5, 3.0, 6.0 mg/kg) and on total lever pressing.  Data are expressed as the mean  SEM total number of 
lever presses (n=20 for vehicle and PCP+vehicle, n=9 for all doses of SKF-38393) in the initial and 
reversal phase of the task. 
Drug treatment Initial phase Reversal phase 
vehicle + vehicle 27.0 0.3 27.0 0.2 
vehicle + sub-chronic PCP 26.9 0.2 26.6 0.2 
0.75 mg/kg + sub-chronic PCP 25.9 0.3 26.3 0.2 
1.5 mg/kg + sub-chronic PCP 26.1 0.2 26.1 0.2 
3.0 mg/kg + sub-chronic PCP 25.8 0.3 26.0 0.1 
6.0 mg/kg + sub-chronic PCP 26.8 0.5 27.3 0.4 
 
 
 
 
Table 3.3.3: The effect of sub-chronic PCP (2.0 mg/kg, twice a day for 7 days, i.p.), SKF-38393 (6.0 
mg/kg) and SCH-23390 (0.05 mg/kg) on total lever pressing. Data are expressed as the mean  SEM total 
number of lever presses (n=9-10 per group) in the initial and reversal phase of the task.  Dunnett‟s t-test 
showed a significant reduction in lever pressing compared to vehicle (*P<0.05, ***P=0.001). 
Drug treatment Initial phase Reversal phase 
vehicle + vehicle 27.9 0.5 26.9 0.3 
vehicle + sub-chronic PCP 27.0 0.4 26.9 0.4 
6.0 mg/kg SKF-38393 + sub-chronic PCP 26.1 0.6 27.8 0.4 
0.05 mg/kg SCH23390 + sub-chronic PCP   24.2 1.5*       20.2 2.1*** 
0.05 mg/kg SCH23390 + 6.0 mg/kg SKF-
38393 + sub-chronic PCP 
25.0 0.9 24.6 1.6 
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Figure 3.3.3a: The effect of SKF-38393 (6.0 mg/kg) and SCH-23390 (0.05 mg/kg) on the deficit 
produced by sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal 
phase of the reversal learning task.  Data are shown as mean ± SEM of percent correct responding (n=9-
10).  Significant reduction in performance of the reversal phase compared with the initial phase 
(***P<0.001).  Post-hoc Bonferroni‟s multiple comparison test showed that SKF-38393 (6.0 mg/kg) 
significantly improved the PCP-induced deficit (
###
P<0.001), and that this deficit was significantly 
antagonised by SCH-23390 (0.05 mg/kg); 
+++
P<0.001. 
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Figure 3.3.3b: The influence of SKF-38393 (6.0 mg/kg) and SCH-23390 (0.05 mg/kg) on the effect of 
sub-chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase 
of the reversal learning task. Data are shown as the mean total number of lever presses, correct responses 
are shown as clear bars and incorrect responses are shown as shaded bars (n=9-10). 
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3.3.3 Effects of the 5-HT1A receptor partial agonist, buspirone, alone and in conjunction 
with the antagonist, WAY-100635 
For percent correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.001), and following treatment with buspirone at 0.15625 mg/kg (P<0.05).  A one-
way ANOVA in the reversal phase showed a significant interaction (F6,75 = 5.70, 
P<0.001).  Post-hoc analysis revealed that buspirone at 0.3125 and 0.625 mg/kg 
significantly improved reversal learning compared to the PCP alone group (P<0.01; fig 
3.3.4).  Pre-treatment with WAY-100635 (0.3 and 1.0 mg/kg) partially antagonised the 
effect of buspirone (0.3125 mg/kg), but this effect was not significant as buspirone in 
the presence of WAY-100635 did not significantly improve the PCP-induced deficit 
(P=0.208 and P=0.082 respectively).  There was no significant effect on total lever 
pressing in the initial or reversal phases (table 3.3.4). 
 
 
Table 3.3.4: The effect of sub-chronic PCP (2.0 mg/kg, twice a day for 7 days, i.p.), buspirone (0.15625, 
0.3125, 0.625 mg/kg), and WAY-100635 (0.3, 1.0 mg/kg) against buspirone (0.3125 mg/kg) on total 
lever pressing in the reversal learning paradigm.  Data are expressed as the mean  SEM (n=20 for 
vehicle, PCP + vehicle and PCP + buspirone at 0.3125 mg/kg, n=8-10 for other doses of buspirone and 
WAY-100635 groups ) in the initial and reversal phase of the task. 
Drug treatment     Initial phase   Reversal phase 
vehicle + vehicle 27.4 0.2 27.8 0.1 
vehicle + sub-chronic PCP 26.9 0.4 26.8 0.2 
0.15625 mg/kg + sub-chronic PCP  27.6 0.3 27.0 0.2 
0.3125 mg/kg + sub-chronic PCP 27.4 0.4 27.4 0.2 
0.625 mg/kg + sub-chronic PCP 26.6 0.7 27.1 0.5 
0.3125 mg/kg + WAY-100635 (0.3 mg/kg) + 
sub-chronic PCP 
28.8 0.3 27.6 0.3 
0.3125 mg/kg + WAY-100635 (1.0 mg/kg) + 
sub-chronic PCP 
27.6 0.3 27.0 0.3 
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Figure 3.3.4a: The effect of buspirone (0.15625, 0.3125, 0.625 mg/kg), and WAY-100635 (0.3, 1.0 
mg/kg) in combination with buspirone (0.3125 mg/kg) on the deficit produced by sub-chronic PCP (2.0 
mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal learning task.  
Data are shown as mean ± SEM percentage correct responding (n=20 for vehicle, PCP + vehicle and PCP 
+ buspirone at 0.3125 mg/kg, n=8-10 for other doses of buspirone and WAY-100635 groups).  A paired t-
test showed a significant reduction in performance of the reversal phase compared with the initial phase; 
***P<0.01, *P<0.05. Dunnett‟s t-test showed significant improvement in responding compared to PCP 
alone in the reversal phase at 0.3125 mg/kg and 0.625 mg/kg; 
##
P<0.01.  Pretreatment with WAY-100635 
at 0.3 and 1.0 mg/kg produced a partial reversal of buspirone but did not significantly alter the effect of 
0.3125 mg/kg buspirone (P=0.208 and P=0.082 respectively). 
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Figure 3.3.4b: The influence of buspirone (0.15625, 0.3125, 0.625 mg/kg), and WAY-100635 (0.3, 1.0 
mg/kg) against buspirone (0.3125 mg/kg) on the effect of sub-chronic PCP (2.0 mg/kg, twice daily for 7 
days, i.p.) on performance of the initial and reversal phase of the reversal learning task.  Data are shown 
as the mean total number of lever presses, correct responses are shown as clear bars and incorrect 
responses are shown as shaded bars (n=20 for vehicle, PCP + vehicle and PCP + buspirone at 0.3125 
mg/kg, n=8-10 for other doses of buspirone and WAY-100635 groups). 
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3.3.4 Effect of WAY-100635 alone 
For percent correct responding, a paired t-test showed a significant reduction in 
performance of the reversal phase compared with the initial phase in the PCP-group 
(P<0.001), and in both WAY-100635 groups (P<0.05). A one-way ANOVA in the 
reversal phase showed a significant interaction (F3,33 = 4.58, P<0.01).  Post-hoc analysis 
revealed that WAY-100635 at 0.3 and 1.0 mg/kg did not significantly improve 
performance compared to PCP alone in the reversal phase (P=0.541 and P=0.422 
respectively, fig 3.3.5).  There was no significant effect on total lever pressing in the 
initial phase of the task, however, WAY-100635 at 1.0 mg/kg did significantly reduce 
lever pressing in the reversal phase of the task (P<0.01, table 3.3.5). 
 
 
 
Table 3.3.5: The effect of WAY-100635 (0.3, 1.0 mg/kg), and sub-chronic PCP (2.0 mg/kg, twice a day 
for 7 days, i.p.) on total lever pressing in the reversal learning paradigm.  Data are expressed as the mean 
 SEM (n=8-10) in the initial and reversal phase of the task. 
Drug treatment     Initial phase   Reversal phase 
vehicle + vehicle 27.5 0.2 27.9 0.2 
vehicle + sub-chronic PCP 2mg/kg 27.4 0.3 26.7 0.3 
0.3 mg/kg + sub-chronic PCP  28.3 0.4 27.2 0.3 
1.0 mg/kg + sub-chronic PCP 27.8 0.2     26.0 0.8** 
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Figure 3.3.5a: The effect of WAY-100635 (0.3, 1.0 mg/kg) alone on the deficit produced by sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal learning 
task.  Data are shown as mean ± SEM percentage correct responding (n=8-10).  A paired t-test showed a 
significant reduction in performance of the reversal phase compared with the initial phase; ***P<0.001, 
*P<0.05.  Dunnett‟s t-test showed no significant improvement in responding compared to PCP alone in 
the reversal phase at 0.3 mg/kg and 1.0 mg/kg WAY-100635 (P=0.541 and P=0.422 respectively).   
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Figure 3.3.5b: The influence of WAY-100635 (0.3, 1.0 mg/kg) alone on the effect of sub-chronic PCP 
(2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the reversal 
learning task.  Data are shown as the mean total number of lever presses, correct responses are shown as 
clear bars and incorrect responses are shown as shaded bars (n=8-10). 
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3.3.5 Effects of the 5-HT2C receptor antagonist, SB-243213A 
For percentage correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.001), 1.0 mg/kg SB-243213A treated group (P<0.01) and 3.0 mg/kg SB-243213A 
treated group (P<0.001).  A one-way ANOVA in the reversal phase revealed a 
significant interaction (F4,49 = 7.27, P<0.001).  Post-hoc analysis revealed that SB-
243213A at 10 mg/kg significantly (P<0.05) improved the PCP-induced deficit (fig 
3.3.6).  There was no significant effect on total lever pressing in the initial or reversal 
phases, suggesting that neither locomotor capacity nor motivation were affected (table 
3.3.6). 
 
Table 3.3.6: The effect of SB-243213A (1.0, 3.0, 10.0 mg/kg) and sub-chronic PCP (2.0 mg/kg, twice a 
day for 7 days, i.p.) on the total number of lever presses in a reversal learning paradigm. Data are 
expressed as the mean  SEM total number of lever presses (n=10) in the initial and reversal phase of the 
task. 
Drug treatment     Initial phase   Reversal phase 
vehicle + vehicle      28.2 0.4     27.6 0.3 
vehicle + sub-chronic PCP 2mg/kg      27.2 0.3     27.5 0.3 
1.0 mg/kg + sub-chronic PCP       28.8 0.3     26.9 0.9 
3.0 mg/kg + sub-chronic PCP      28.2 0.4     27.4 0.4 
10.0 mg/kg + sub-chronic PCP      27.8 0.4     27.4 0.3 
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Figure 3.3.6a: The effect of SB-243213A (1.0, 3.0, 10.0 mg/kg) on the deficit produced by sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal learning 
task.  Data are shown as mean ± SEM percentage correct responding (n=10).  Paired t-tests showed a 
significant deficit in the reversal phase compared to the initial phase; **P<0.01, ***P<0.001.  Post-hoc 
Dunnett‟s t-test showed that SB-243213A at 10.0 mg/kg significantly improved responding compared to 
PCP alone in the reversal phase; 
#
P<0.05. 
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Figure 3.3.6b: The influence of SB-243213A (1.0, 3.0, 10.0 mg/kg) on the effect of sub-chronic PCP (2.0 
mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the reversal 
learning task. Data are shown as the mean total number of lever presses, correct responses are shown as 
clear bars and incorrect responses are shown as shaded bars (n=10). 
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3.3.6 Effect of the M1 receptor agonist, 77-LH-28-1 
For percent correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.05), 1.0 mg/kg treated group (P<0.05), 3.0 mg/kg treated group (P<0.05) and 10.0 
mg/kg treated group (P<0.01).  A one-way ANOVA in the reversal phase showed a 
significant interaction (F4,41 = 4.21, P<0.01); however, post-hoc analysis did not reveal 
any significant improvements with 77-LH-28-1 (fig 3.3.7).  There was no significant 
effect on total lever pressing in the initial or reversal phases, suggesting that neither 
locomotor capacity nor motivation were affected (table 3.3.7).   
 
Table 3.3.7: The effect of 77-LH-28-1 (1.0, 3.0, 10.0 mg/kg) and sub-chronic PCP (2.0 mg/kg, twice a 
day for 7 days, i.p.) on total lever pressing. Data are expressed as the mean  SEM total number of lever 
presses (n=7-10) per group) in the initial and reversal phase of the task.  
Drug treatment     Initial phase   Reversal phase 
Vehicle + vehicle      27.0 0.5     27.7 0.2 
Vehicle + sub-chronic PCP 2mg/kg      27.1 0.4     28.8 0.3 
1.0 mg/kg + sub-chronic PCP       27.6 0.4     28.0 0.6 
3.0 mg/kg + sub-chronic PCP      26.4 0.6     26.0 1.6 
10.0 mg/kg + sub-chronic PCP      24.9 2.2     26.0 1.0 
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Figure 3.3.7a: The effect of 77-LH-28-1 (1.0, 3.0, 10.0 mg/kg) on the deficit produced by sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal learning 
task.  Data are shown as mean ± SEM percentage correct responding (n=7-10).  Significant reduction in 
performance of the reversal phase compared with the initial phase; *P<0.05, **P<0.01. 
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Figure 3.3.7b: The influence of 77-LH-28-1 (1.0, 3.0, 10.0 mg/kg) on the effect of sub-chronic PCP (2.0 
mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the reversal 
learning task. Data are shown as the mean total number of lever presses, correct responses are shown as 
clear bars and incorrect responses are shown as shaded bars (n=7-10). 
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3.3.7 Effects of activating α7 nAChR with PheTQS and PNU-282987 
In the PheTQS experiment, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.05) and 10 mg/kg treated group (P<0.05).  A one-way ANOVA in the reversal 
phase showed a significant interaction (F4,46 = 5.82, P<0.01).  Post-hoc analysis revealed 
that PheTQS at 30 mg/kg significantly (P<0.01) improved the PCP-induced deficit (fig 
3.3.8a).  There was no significant effect on total lever pressing in the initial or reversal 
phases, suggesting that neither locomotor capacity nor motivation were affected (table 
3.3.8).   In the PNU-282987 experiment, a paired t-test showed a significant impairment 
in responding in the reversal phase compared to the initial phase in the PCP-treated 
group (P<0.001).  A one-way ANOVA in the reversal phase showed a significant 
interaction (F4,47 = 10.69, P<0.001).  Post-hoc analysis revealed that PNU-282987 
significantly improved the PCP-induced deficit at 10 mg/kg (P<0.01) and 20 mg/kg 
(P<0.001, fig 3.3.9a).  There was no significant effect on total lever pressing in the 
initial or reversal phases, suggesting that neither locomotor capacity nor motivation 
were affected (table 3.3.9). 
 
Table 3.3.8: The effect of PheTQS (3.0, 10.0, 30.0 mg/kg; p.o.) and sub-chronic PCP (2.0 mg/kg, twice a 
day for 7 days, i.p.) on total lever pressing. Data are expressed as the mean  SEM total number of lever 
presses (n=9-10) in the initial and reversal phase of the task. 
Drug treatment Initial phase Reversal phase 
Vehicle + vehicle 27.6 0.2 27.3 0.3 
Vehicle + sub-chronic PCP 27.2 0.4 27.6 0.5 
3.0 mg/kg + sub-chronic PCP  27.9 0.3 27.0 0.8 
10.0 mg/kg + sub-chronic PCP 28.3 0.5 28.1 0.3 
30.0 mg/kg + sub-chronic PCP 28.3 0.4 28.1 0.2 
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Figure 3.3.8a: The effect of PheTQS (3.0, 10.0, 30.0 mg/kg; p.o.) on the deficit produced by sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal learning 
task.  Data are shown as mean ± SEM percent correct responding (n=9-10).  Paired t-test showed a 
significant deficit in the reversal phase compared to the initial phase; *P<0.05.  Post-hoc Dunnett‟s t-test 
showed a significant improvement in responding compared to PCP alone in the reversal phase at 30.0 
mg/kg (
##
P<0.01). 
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Figure 3.3.8b: The influence of PheTQS (3.0, 10.0, 30.0 mg/kg; p.o.) on the effect of sub-chronic PCP 
(2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the reversal 
learning task. Data are shown as the mean total number of lever presses, correct responses are shown as 
clear bars and incorrect responses are shown as shaded bars (n=9-10). 
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Table 3.3.9: The effect of PNU-282987 (5.0, 10.0, 20.0 mg/kg; s.c.) and sub-chronic PCP (2.0 mg/kg, 
twice a day for 7 days, i.p.) on total lever pressing. Data are expressed as the mean  SEM total number 
of lever presses (n=9-10) in the initial and reversal phase of the task. 
Drug treatment Initial phase Reversal phase 
Vehicle + vehicle 27.6 0.4 27.5 0.2 
Vehicle + sub-chronic PCP 27.8 0.1 28.0 0.3 
5.0 mg/kg + sub-chronic PCP  27.1 0.3 27.6 0.4 
10.0 mg/kg + sub-chronic PCP 27.1 0.3 27.4 0.3 
20.0 mg/kg + sub-chronic PCP 27.3 0.3 27.4 0.4 
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Figure 3.3.9a: The effect of PNU-282987 (5.0, 10.0, 20.0 mg/kg; s.c.) on the deficit produced by sub-
chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal 
learning task.  Data are shown as mean ± SEM percentage correct responding (n=9-10).  Paired t-test 
showed a significant deficit in the reversal phase compared to the initial phase; ***P<0.001.  Post-hoc 
Dunnett‟s t-test showed PNU-282987 significantly improved responding compared to PCP alone in the 
reversal phase at 10.0 mg/kg (
##
P<0.01) and 20.0 mg/kg (
###
P<0.001). 
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Figure 3.3.9b: The influence of PNU-282987 (5.0, 10.0, 20.0 mg/kg; s.c.) on the effect of sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the 
reversal learning task. Data are shown as the mean total number of lever presses, correct responses are 
shown as clear bars and incorrect responses are shown as shaded bars (n=9-10). 
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3.3.8 Effect of the H1 receptor antagonist, pyrilamine 
For percent correct responding, a paired t-test showed a significant impairment in 
responding in the reversal phase compared to the initial phase in the PCP-treated group 
(P<0.01).  A one-way ANOVA in the reversal phase showed a significant interaction 
(F4,45 = 3.50, P<0.05); however, post-hoc analysis did not reveal any significant 
improvements with pyrilamine (fig 3.3.10).  A one-way ANOVA revealed a significant 
effect of pyrilamine on total lever pressing in the initial and reversal phases 
(F(4,45)=10.35, P<0.001) and (F(4,45)=5.55, P<0.01) respectively.  Post-hoc Dunnett‟s test 
showed that pyrilamine at 40.0 mg/kg significantly reduced lever pressing compared to 
vehicle-treated rats in the initial and reversal phases (p<0.001; table 3.3.10). 
 
Table 3.3.10: The effect of pyrilamine (10.0, 20.0, 40.0 mg/kg; s.c.) and sub-chronic PCP (2.0 mg/kg, 
twice a day for 7 days, i.p.) on total lever pressing. Data are expressed as the mean  SEM total number 
of lever presses (n=8-10) in the initial and reversal phase of the task. Post-hoc Dunnett‟s t-test revealed 
that the total number of lever presses was significantly decreased in rats treated with 40 mg/kg when 
compared to the vehicle-treated group; ***P<0.001.  
Drug treatment     Initial phase   Reversal phase 
vehicle + vehicle      27.2 0.2     28.1 0.2 
vehicle + sub-chronic PCP 2mg/kg      26.7 0.3     27.3 0.3 
10.0 mg/kg + sub-chronic PCP       27.4 0.3     27.2 1.0 
20.0 mg/kg + sub-chronic PCP      25.3 0.9     26.4 0.8 
40.0 mg/kg + sub-chronic PCP      16.4 3.4***     22.3 1.9*** 
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Figure 3.3.10a: The effect of pyrilamine (10.0, 20.0, 40.0 mg/kg; s.c.) on the deficit produced by sub-
chronic PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the reversal phase of the reversal 
learning task.  Data are shown as mean ± SEM percentage correct responding (n=8-10).  Paired t-test 
showed a significant deficit in the reversal phase compared to the initial phase; **P<0.01.  Post-hoc 
Dunnett‟s t-test showed no significant improvement following drug treatment. 
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Figure 3.3.10b: The influence of pyrilamine (10.0, 20.0, 40.0 mg/kg; s.c.) on the effect of sub-chronic 
PCP (2.0 mg/kg, twice daily for 7 days, i.p.) on performance of the initial and reversal phase of the 
reversal learning task. Data are shown as the mean total number of lever presses, correct responses are 
shown as clear bars and incorrect responses are shown as shaded bars (n=8-10). 
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3.4 Discussion 
In the reversal learning task, the PCP-treated rats were unaffected in the initial phase, 
but demonstrated reduced correct responding in the reversal phase, suggesting that when 
the rule changes PCP-treated rats do not switch to respond on the now correct lever.  
This is supported by previous results using this sub-chronic PCP model (Abdul-Monim 
et al., 2006; Abdul-Monim et al., 2007).  The advantages of using this sub-chronic 
model and the pathological effects have previously been discussed in chapters 1 and 2. 
 
3.4.1 PCP-induced disruption and antipsychotic reversal 
The present results show that vehicle-treated rats can be trained to an equivalent level of 
accuracy in both the initial and reversal phases of the task.  Following treatment with 
sub-chronic PCP rats continually demonstrated reduced performance which was 
selective for the reversal phase.  This is in agreement with other results from this 
laboratory (Abdul-Monim et al., 2006) and also this effect is observed following acute 
treatment with PCP (Abdul-Monim et al., 2003).  Sub-chronic PCP treatment did not 
affect total lever pressing, suggesting locomotor activity nor motivation were affected, 
thus the apparent cognitive deficits in the reversal phase were not due to any other non-
specific effects of PCP.  Results from other laboratories have also shown deficits in 
reversal learning following sub-chronic PCP administration (Jentsch and Taylor, 2001).  
The use of sub-chronic PCP treatment is believed to more closely mimic cognitive 
deficits associated with schizophrenia compared to acute treatment (Jentsch and Roth, 
1999).   
 The single doses of clozapine and risperidone were chosen on the basis of 
previous work showing efficacy against sub-chronic PCP-induced deficits in reversal 
learning (Abdul-Monim et al., 2006; Neill et al., 2006) and NOR (Grayson et al., 2007).   
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The effect of clozapine to improve the PCP-induced deficit in this study failed to reach 
statistical significance; however, risperidone was effective in reversing the PCP-induced 
deficit at 0.2 mg/kg.  Clozapine did in fact improve performance in sub-chronic PCP-
treated rats to an equivalent level as the vehicle rats, with vehicle-treated rats 
performing at 77% and clozapine rats performing at 76% correct responding.  However, 
the performance of clozapine was not sufficient to reach statistical significance 
compared to the PCP-treated rats, which responded at a level of 59%.  Whereas the 
level of correct responding following risperidone treatment improved the performance 
of PCP-treated rats to a higher level than the vehicle group.  Risperidone is suggested to 
be the most effective atypical antipsychotic to improve working memory in the clinic 
(Meltzer and McGurk, 1999) and unlike in the attentional set-shifting study (chapter 2) 
where clozapine was equally effective, these results from reversal learning would 
appear to be consistent with the clinic.  As in chapter 2 the inability of haloperidol to 
reverse the PCP-induced deficit may be due to its high D2 receptor affinity and minimal 
5-HT2A receptor affinity (Siegfried et al., 2005).  A selective 5-HT2A receptor antagonist 
was shown to be efficacious in this model (Neill et al., 2008). 
 
3.4.2 Dopamine D1 receptor compounds 
Both ligands shall be referred to as D1-like throughout as SKF-38393 and SCH-23390 
have been reported to have similar Ki values at D1 and D5 receptors; SKF-38393 having 
reported Ki values of 26nM and 80nM at D1 and D5 receptors respectively (Neumeyer et 
al., 2003; Qandil et al., 2003), whilst SCH-23390 has reported Ki values of 0.37nM and 
0.47nM for D1 and D5 receptors respectively (Lawler et al., 1999).  The data show that 
SKF-38393 significantly improved a sub-chronic PCP-induced deficit in the reversal 
learning test, an improvement which was subsequently antagonised by the D1-like 
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receptor antagonist, SCH-23390.  Hersi and colleagues (1995) showed that a dose of 3.0 
mg/kg (i.p.) of SKF-38393 in male Long-Evans rats increased acetylcholine release by 
two-fold over baseline, thus dose response was carried out with 3.0 mg/kg as the middle 
dose (0.75, 1.5, 3.0, 6.0 mg/kg) in the reversal learning task.  Experiment 2 showed that 
6.0 mg/kg was the most efficacious dose, and was also shown to improve a 
scopolamine-induced impairment in a T-maze working memory test (Amico et al., 
2007).    0.05 mg/kg SCH-23390 has also been shown to inhibit acetylcholine release in 
the hippocampus in male Long-Evans rats (Hersi et al., 1995). 
This data is in agreement with a study by Granon and colleagues (2000), 
whereby infusions into the PFC of SKF-38393 (0.06 μg/side) and SCH-23390 (0.3 
μg/side) improved and then respectively attenuated accuracy in the five-choice 
attentional task in male Lister-hooded rats.  Hersi and co-workers (1995) found that 
SKF-38393 improved cognitive performance in the Morris water maze in rats with age-
related impairments.  In the present experiments we have used a sub-chronic PCP 
regimen to induce schizophrenia-like deficits in cognition, however, amphetamine can 
also induce cognitive impairments in tests of working memory (Castner et al., 2005), 
attentional set-shifting (Fletcher et al., 2005), and reversal learning (Idris et al., 2005a).  
A study by Fletcher and colleagues found that amphetamine-induced impairments were 
reversed by infusing SKF-38393 into the medial PFC (Fletcher et al., 2007).  This effect 
of SKF-38393 to improve cognitive function in amphetamine-treated rats is in 
agreement with the effect observed in our sub-chronic PCP-treated rats. 
It is important to note that the effect of SCH-23390 alone in PCP-treated rats 
was investigated in order to eliminate the possibility that SCH-23390 could have 
affected cognitive performance alone.  It appears that SCH-23390 (0.05 mg/kg) 
impaired performance in the initial phase, an effect not observed following sub-chronic 
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PCP treatment alone, although this effect was not statistically significant.  This trend 
was supported by a study showing that intracortical infusions of SCH-23390 impaired 
performance accuracy in the five-choice attentional task (Granon et al., 2000).  
Therefore, blockade of D1-like receptors with SCH-23390 alone may impair cognition, 
but this was not observed in the current experiments. 
SKF-38393 also has an affinity for 5-HT2C receptors (then classified as 5-HT1C; 
Briggs et al., 1991), albeit reduced affinity compared with D1-like receptors.  It is 
unlikely that 5-HT2C receptors play a critical role in the effects of SKF-38393 as its 
effect was fully reversed by SCH-23390 which has been shown to be selective for D1-
like receptors, however further experiments would be required to investigate this 
possibility since 5-HT2C receptor agonists do show efficacy in pre-clinical tasks of 
cognition (Siuciak et al., 2007) and in the current studies the 5-HT2C antagonist, SB-
243213A significantly improved the PCP-induced deficit.  It was previously shown that 
3.0 mg/kg of SKF-38393 increased acetylcholine (ACh) release by two-fold over 
baseline (Hersi et al., 1995).  However, the most efficacious dose in the reversal 
learning experiment was 6.0 mg/kg; this dose was also shown to improve a 
scopolamine-induced impairment in a T-maze working memory test (Amico et al., 
2007).  The dose of SCH-23390 used here (0.05 mg/kg) has been shown to transiently 
inhibit acetylcholine release (Hersi et al., 1995).  
Cognitive impairments observed in the Wisconsin Card Sorting Task (Kashima, 
1991) have been positively correlated with a down-regulation of D1 receptor binding in 
the PFC of treatment-free/-naïve schizophrenic patients (Okubo et al., 1997); thus 
identifying the D1 receptor as a particularly relevant target for improving cognition in 
schizophrenia (Gray and Roth, 2007).  As previously mentioned in chapter 1, the 
prefrontal cortex is critically involved in reversal learning (McAlonan and Brown, 2003; 
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Tait and Brown, 2007).  Damage to the PFC has also been shown to impair performance 
in recognition memory tasks (Kolb et al., 1994; Meunier et al., 1997).  The 
hippocampus is also a critical brain region for learning and memory.  The density of D1 
receptors is considerably higher than D2 receptors throughout the cortex with 
differential distribution in the rat mPFC (Vincent et al., 1995), and low levels of D2 
receptors have been detected in the hippocampus (Meador-Woodruff et al., 1989; Levey 
et al., 1993).  The majority of dopamine receptors in the hippocampus are from the D1-
like subfamily of receptors (Dawson et al., 1986), with a high density of the D5 receptor 
(Ciliax et al., 2000).  Furthermore, it has been reported that administration of SKF-
38393 increased hippocampal acetylcholine (ACh) release in young and aged rats (Hersi 
et al., 1995), which improved performance in the Morris Water Maze, thus suggesting a 
mechanism for the cognitive enhancing effects of SKF-38393.  Dihydrexidine, a full 
D1-like receptor agonist has been shown to increase extracellular concentrations of 
cortical ACh to around 300% of baseline values; an effect which was completely 
blocked by SCH-23390, and coincided with an improvement in cognitive performance 
assessed using a passive-avoidance paradigm (Steele et al., 1997).  Indeed, it has also 
been demonstrated that atypical antipsychotics such as clozapine, olanzapine, 
risperidone and ziprasidone can increase levels of ACh in the mPFC (Ichikawa et al., 
2002).  This suggests a beneficial mechanism of action in that D1-like agonists could 
improve cognition in a similar manner to some atypical antipsychotics. 
Positive symptoms are induced by elevation of dopamine in the limbic system, 
whereas negative and cognitive symptoms are due, at least in part, to decreased 
prefrontal dopamine function (Davis et al., 1991).  As agents which increase prefrontal 
dopamine turnover may have beneficial effects on cognition it would seem profitable to 
explore direct stimulation of the D1 receptor in the PFC.  Indeed, D1 agonists have been 
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highlighted as a molecular target for cognitive enhancement in schizophrenia (see Gray 
and Roth, 2007).  Subsequently, a single administration of the full D1-like receptor 
agonist, dihydrexidine, produced increased perfusion in D1 rich PFC regions in patients 
with schizophrenia (Mu et al., 2007); suggesting that agents increasing transmission at 
dopamine D1 receptors could have potential in the pharmacotherapy of schizophrenia 
through a variety of mechanisms.  However, the use of D1 receptor agonists as 
therapeutic agents pose difficulties for pharmacologists as dopamine function in the 
PFC seems to follow an “inverted-U” dose-response relationship whereby increases or 
decreases from an optimal level result in cognitive impairment (Goldman-Rakic et al., 
2000).  In addition, chronic treatment with D1 agonists may lead to the down-regulation 
of D1 receptors which could in turn worsen cognition. 
 
3.4.3 5-HT1A receptor agents 
In the current experiments, the efficacy of buspirone to improve the PCP-induced 
reversal learning deficit was partially reversed by the 5-HT1A antagonist, WAY-100635.  
There is evidence to show that 5-HT1A receptor density is high in the frontal cortices of 
patients with schizophrenia (Burnet et al., 1997) and a subsequent PET study has shown 
an increase in cortical 5-HT1A receptor binding in schizophrenia (Tauscher et al., 2002).  
Post-mortem studies have also indicated abnormalities in 5-HT1A receptor-mediated 
transmission in the frontal cortex of patients with schizophrenia (Sumiyoshi et al., 
1996).  
Buspirone is a 5-HT1A receptor partial agonist with weak D2 receptor antagonist 
properties compared to typical antipsychotic drugs, with Ki values of 20nM and 240nM 
respectively (Hamik et al., 1990).  WAY-100635 may not have fully antagonised the 
effects of buspirone as buspirone is rapidly converted to its metabolite 1-(2-
pyrimidinyl)-piperazine (1-PP; Caccia et al., 1986), a potent α2-adrenoceptor antagonist, 
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which is able to stimulate cortical dopamine release (Gobert et al., 1999). The effect of 
buspirone is unlikely to be due to D2 receptor blockade as haloperidol is ineffective in 
reversing the PCP-induced deficit (Abdul-Monim et al., 2006).  It is important to 
highlight that WAY-100635 administered alone at both 0.3 and 1.0 mg/kg did not 
improve the PCP-induced deficit.  This is in agreement with a study in mice using a 
novel object recognition task whereby WAY-100635 at 1.0 mg/kg did not produce any 
improvement in the PCP-induced cognitive deficit (Hagiwara et al., 2008).  However, 
there are conflicting studies surrounding the effects of WAY-100635 and other 5-HT1A 
receptor antagonists; Wedzony et al. (2000) reported that WAY-100135 attenuated the 
deficit induced by MK-801 in tests of working memory and selective attention in rats.  
In addition, WAY-100635 has been shown to prevent learning deficits induced by 
blockade of AMPA receptors (Schiapparelli et al., 2006).  An explanation for the 
conflicting effects of WAY-100635 and WAY-100135 could be due to the acute 
administration of MK-801 (an NMDA receptor antagonist) and NBQX (an AMPA 
receptor antagonist) in comparison to the sub-chronic PCP administration in this thesis, 
and also both of these studies were performed in male Wistar rats compared to the 
female hooded-Lister rats used throughout this thesis.  
The antipsychotics clozapine, quetiapine, and ziprasidone have partial agonist 
properties at 5-HT1A receptors, like buspirone (Newman-Tancredi et al., 1998; Ichikawa 
et al., 2001).  There are conflicting pre-clinical results with 5-HT1A compounds with 
selective agonists, partial agonists, and antagonists being highlighted as potential 
molecular targets for cognitive enhancement in schizophrenia (see Gray and Roth, 
2007).  As previously mentioned there is a high concentration of 5-HT1A receptors on 
cortical and hippocampal pyramidal neurons (Azmitia et al., 1996).  There is also a 
population of 5-HT1A receptors on raphe neurons, where 5-HT1A receptors function as 
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somatodendritic autoreceptors providing inhibitory feedback control of 5-HT release 
(Barnes and Sharp, 1999).  It is thought that this is the mechanism by which 5-HT1A 
antagonists improve cognition, while the beneficial effects on cognition in animal 
studies of 5-HT1A partial agonists are thought to be mediated via an action at pyramidal 
neurons (Roth et al., 2003; Schechter et al., 2002).  In schizophrenic patients, the 5-
HT1A agonist, tandospirone, has been shown to improve executive function and verbal 
memory when added to ongoing typical antipsychotic treatment (Sumiyoshi et al., 
2001). 
 The results from the present experiments are supported by another investigation 
in a social interaction test (Snigdha and Neill, 2008b).  It was demonstrated that co-
administration of WAY-100635 with aripiprazole, another antipsychotic with partial 5-
HT1A agonist properties (Shapiro et al., 2003), successfully prevented the beneficial 
effects of aripiprazole in PCP-treated rats following the same regime in a social 
interaction model of negative symptoms.  It was suggested that 5-HT1A receptor 
activation selectively augments cortical dopamine levels which results in improvement 
in the social behaviour deficits.  This suggestion is in agreement with a previous report 
by Ichikawa and colleagues (2001) suggesting that 5-HT1A induced dopamine release in 
the mPFC may be the potential basis for the mechanism of action of at least some of the 
atypical antipsychotics.    
 
3.4.4 5-HT2C receptor antagonist 
SB-243213A was effective in reversing the sub-chronic PCP-induced deficit at 10 
mg/kg, without having any adverse effects on behaviour.  SB-243213A is a selective 5-
HT2C receptor antagonist (Bromidge et al., 2000).  5-HT2C receptors are located in a 
variety of brain regions including the neocortex, amygdala, hippocampus, nucleus 
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accumbens, substantia nigra and the ventral tegmental area (Pompeiano et al., 1994; 
Abramowski et al., 1995; Eberle-Wang et al., 1997).  5-HT2C receptor activation has 
been suggested to reduce dopamine release in the nucleus accumbens and prefrontal 
cortex (Di Matteo et al., 2001).  The 5-HT2C antagonist, SB242084, enhances dopamine 
release in the nucleus accumbens (Di Matteo et al., 1999) and cortex (Gobert et al., 
2000).  Antagonism at 5-HT2C receptors by various atypical antipsychotics (e.g. 
clozapine, risperidone, sertindole and ziprasidone; Roth et al., 2003) may play a role in 
their beneficial effects and their diminished likelihood to produce to neurological 
adverse effects (Meltzer, 1995; 1999).  However, antagonism at the 5HT2C receptor can 
increase food intake and body weight in rats (Bonhaus et al., 1997), thus this may not be 
an advantageous strategy for treatment in patients as weight gain is a major adverse 
effect and could affect compliance (see chapter 1 section 1.6.3). 
SB-243213 is active in preclinical models of anxiety and has an improved 
anxiolytic profile compared with benzodiazepines (Wood et al., 2001; Blackburn et al., 
2002).  SB-243213A may also have antidepressant-like activity as it increased deep 
slow wave sleep quantity and reduced paradoxical sleep quantity with similar efficacy 
to paroxetine (Smith et al., 2002).  There is limited data concerning the efficacy of SB-
243213A in tests of cognition.  The current data show that SB-243213A at 10.0 mg/kg 
selectively and significantly improved the PCP-induced deficit in the reversal phase of 
the task.  This is supported by recent data showing improvements in spatial learning by 
the 5-HT2C antagonist, SB242084, suggesting that the facilitatory effects of 5-HT2C 
antagonists are mediated by the OFC (Boulougouris et al., 2008).   
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3.4.5 Activation/ positive modulation of α7 nACh receptors 
The most prevalent nicotinic acetylcholine receptors nAChRs are the α4β2 and α7 
subtypes, both of which have been shown to have reduced numbers in schizophrenia 
(Freedman et al., 1995; Breese et al., 2000).  It has been suggested that these receptor 
subtypes are involved in cognition (Schreiber et al., 2002; Chan et al., 2007; Gray and 
Roth, 2007).   
Much of the α7 nAChR research in vivo has focused on sensory gating with 
antagonists at the α7 nAChR inducing deficits (Luntz-Leybam et al., 1992), while 
agonists at this receptor have been shown to normalise sensory gating in rodents 
(Simosky et al., 2001).  Both PheTQS and PNU-282987 attenuated the sub-chronic 
PCP-induced deficit in the reversal phase of the task. PheTQS significantly reversed the 
PCP-induced deficit at the highest dose of 30 mg/kg, and did not have any effect on 
lever pressing, indicating that PheTQS did not cause sedation.  PNU-282987 dose-
dependently attenuated the impairment produced by PCP with significant improvements 
in performance at 10 and 20 mg/kg without causing any impairment in lever pressing.  
The role of α7 nACh receptors in cognition is supported by evidence showing 
that α7 knock-out mice were impaired in 5-choice serial reaction time task (Hoyle et al., 
2006).  The α7 nAChR agonist AR-R 17779 improved scopolamine-induced social 
recognition deficits in rats; in addition, this reversal was blocked by the α7 nAChR 
antagonist methyllycaconitine (van Kampen et al., 2004).  SSR180711 is a selective α7 
nAChR partial agonist which was shown to enhance object recognition memory 
following a 1 hour inter-trial interval (at 0.3 mg/kg) and at 1-3 mg/kg SSR180711 was 
shown to reverse deficits in the Morris water maze induced by MK-801 and PCP 
(Pichat et al., 2007).  Furthermore, SSRI80711 (1 mg/kg) was found to increase 
extracellular dopamine in the PFC (Pichat et al., 2007). 
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PNU-282987 has been shown to enhance amphetamine-induced theta and 
gamma oscillations in the CA3 region of the hippocampus and enthorinal cortex (Hajόs 
et al., 2005; Hoffmann et al., 2005).  PNU-282987 has also been shown to increase c-
Fos dose-dependently in the PFC and the NAc shell, while the NAc core and the 
dorsolateral striatum were unaffected (Hansen et al., 2007). 
 
3.4.6 Activation of muscarinic M1 receptors  
The M1 agonist, 77-LH-28-1, was ineffective in improving the PCP-induced deficit at 
1.0, 3.0 and 10.0 mg/kg.  There was also no significant effect on lever pressing 
behaviour, although in the initial phase there does appear to be a difference at 10.0 
mg/kg compared to vehicle, this effect was not statistically significant.  The M1 receptor 
is located primarily in postsynaptic terminals in the cortex, hippocampus and striatum.  
Furthermore, the M1 receptor subtype is the most abundant muscarinic receptor in the 
forebrain and hippocampus (Levey et al., 1991; Wei et al., 1994).   
There is an emerging role for M1 receptors in cognition.  It has been shown that 
M1 deficient mice demonstrate deficits in working and reference memory (Miyakawa et 
al., 2001; Anagnostaras et al., 2003).  In addition, a major metabolite of clozapine, N-
desmethylclozapine, is a muscarinic M1 agonist (Davies et al., 2005).  N-
desmethylclozapine has been found to increase acetylcholine and dopamine release in 
the mPFC and hippocampus, an effect which is believed to contribute to the ability of 
N-desmethylclozapine and clozapine to improve cognitive dysfunction in patients with 
schizophrenia (Weiner et al., 2004; Li et al., 2005).   
Xanomeline, a potent M1/4 receptor agonist (Shannon et al., 1994), has been 
reported to improve cognition in Alzheimer‟s disease, and to improve cognition and 
decrease psychotic symptoms in a small placebo-controlled trial in patients with 
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schizophrenia (Bodick et al., 1997; Bymaster et al., 2002).  AC260584 is a potent 
muscarinic M1 receptor agonist and a newly developed atypical antipsychotic (Spalding 
et al., 2006).  AC260584 significantly increased acetylcholine and dopamine in the 
mPFC and hippocampus, these increases were significantly blocked by telenzepine, a 
M1 antagonist (Li et al., 2007). 
Although the M1 receptor is a target for the treatment of cognitive dysfunction, 
many of the developed M1 receptor agonists, including sabcomeline and xanomeline, 
actually demonstrate little selectivity for the M1 receptor subtype amongst the other 
mACh receptors (see Langmead et al., 2008a).  Therefore, the identification of a 
selective M1 receptor agonist would be an advantage for mACh receptor pharmacology.  
Spalding et al. (2002) described a novel compound, AC-42, which activated human 
recombinant M1 receptors without activating hM2-hM5 receptors.  Subsequently it was 
found that the regions of the M1 receptor required for the activation by AC-42 were 
regions distinct from the orthosteric site of the M1 receptor.  This newly described 
binding site was termed the allosteric site (Langmead et al., 2006).   
77-LH-28-1 is a structural analogue of the allosteric M1 receptor agonist AC-42, 
and has selective agonist activity for the M1 receptor subtype in both human 
recombinant and naïve rat tissue (Langmead et al., 2008b).  Furthermore, 77-LH-28-1 at 
3.0 mg/kg (s.c.) was shown to increase network oscillations relevant to cognitive 
processing (Langmead et al., 2008b).  However, in contrast to other M1 receptors 
agonists, in the current experiment, 77-LH-28-1 (1.0, 3.0, 10.0 mg/kg s.c.) did not 
reverse the sub-chronic PCP-induced deficit in reversal learning.  The pharmacokinetic 
profile of 77-LH-28-1 suggested that the s.c. route was preferable to the i.p. route, and 
that brain concentrations of the drug were highest at 15 min after administration.  
Therefore, it may have been necessary to test the rats 15 min after dosing rather than 30 
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min.  Furthermore, the pharmacokinetic profile of 77-LH-28-1 was carried out in male 
Sprague-Dawley rats, whereas the reversal learning experiments was conducted using 
female hooded-Lister rats, therefore the lack of behavioural effect may be due to 
differences in metabolism or pharmacokinetic profile of the drug. 
 
3.4.7 Activation of histamine H1 receptors 
Pyrilamine was selected for use in these experiments due to many antipsychotic having 
affinity for the histamine H1 receptor, including clozapine, risperidone, olanzapine and 
quetiapine (Siegfreid et al., 2005).  Pyrilamine at 40 mg/kg caused a significant 
reduction in lever pressing in both the initial and reversal phases of the task.  In support 
of this finding, it has been suggested that sedation induced by clozapine and risperidone 
at higher doses is attributed to their affinity for the H1 receptor (Richelson and Souder, 
2000).  At 10 and 20 mg/kg pyrilamine does appears to produce a slight improvement of 
the PCP-induced deficit in the reversal phase, however this does not reach statistical 
significance. 
 On the basis of their pharmacology and signal transduction mechanisms 
histamine receptors have been subdivided into H1, H2 and H3 subtypes (Hill et al., 1990).  
Activation of histamine H1 receptors leads to the breakdown of phosphatidylinositol 
4,5-biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (Hill et 
al., 1990).  Histaminergic neurons are exclusively located in the tuberomamillary 
nucleus (TMN) of the posterior hypothalamus (Watanabe et al., 1984).  A high density 
of H1 receptors are found in the frontal and temporal cortex, hippocampus, thalamus and 
limbic system (Kanba and Richelson, 1984; Yanai et al., 1992). 
 In the present study, 10 and 20 mg/kg pyrilamine does appear to produce a slight 
improvement of the PCP-induced deficit in the reversal phase; however this did not 
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reach statistical significance. Pyrilamine at 40 mg/kg did not affect the PCP-induced 
deficit.  Pyrilamine alone at 10, 20 and 40 mg/kg did not impair PPI; in addition it was 
shown that 10 and 20 mg/kg reversed a dizocilpine-induced deficit in PPI (Roegge et al., 
2007).  The same study found that 20 and 40 mg/kg impaired reference memory in the 
radial arm maze and 40 mg/kg impaired working memory (Roegge et al., 2007).  In 
support of this, chronic treatment with pyrilamine (20 mg/kg) impaired reference and 
working memory in the radial arm maze (Chen et al., 2001).  These data suggest that 
pyrilamine alone may have an impairing effect on cognition, but may improve NMDA-
induced deficits, although the reversal in the current experiment was not significant. 
 
3.4.8 Conclusions 
From the experiments in this chapter it is evident that D1 receptor agonists, 5-HT1A 
receptor partial agonists, 5-HT2C receptor antagonists and positive modulators of the 
alpha 7 nACh receptor are able to reverse the sub-chronic PCP-induced deficit in 
reversal learning.  Although many antipsychotics have affinity for muscarinic M1 and 
histamine H1 receptors, selective agents at these receptors were not able to improve the 
PCP-induced deficit.  From previous experiments in the literature it is possible that 
these agents may improve cognition via increasing dopamine or acetylcholine levels in 
the prefrontal cortex (see fig 3.4), the region thought to be involved in reversal learning 
ability. 
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Figure 3.4: Summary diagram of the possible mechanisms involved in the attenuation of the sub-chronic 
PCP-induced deficit in reversal learning.  Abbreviations: acetylcholine (ACh), dopamine (DA), prefrontal 
cortex (PFC); nucleus accumbens (NAcc), substantia nigra (SN), ventral tegmental area (VTA). Solid 
lines indicate agonism or activation, dotted lines indicate antagonism.  Red highlights increases in ACh 
and blue highlights increases in DA. 
 
 
This chapter has demonstrated that deficits in reversal learning are robust and very 
reproducible using sub-chronic PCP administration; the results with antipsychotics 
support the findings of the previous attentional set-shifting chapter.  This chapter has 
indicated possible receptors involved in the PCP-induced deficit.  The next chapter will 
aim to validate the operant reversal learning task to investigate whether the task can be 
developed to increase the difficulty of the task, therefore making the deficit harder to 
reverse by antipsychotics.  The aim is also to investigate the temporal effects of 
compounds to potentially distinguish antipsychotics by efficacy.  
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Chapter 4 
Validation of the reversal  
learning task 
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4.1 Introduction 
The previous chapter established that sub-chronic PCP produces robust deficit in 
reversal learning.  Selective compounds suggested that D1, 5-HT1A, 5-HT2C and 
nicotinic α7 acetylcholine receptors are involved in the attenuation of this PCP-induced 
deficit.  Following the demonstration of these deficits in reversal learning in the 
previous chapter, the aim of this chapter was to validate the reversal learning task and to 
improve our understanding of how sub-chronic PCP produces the cognitive deficits 
observed in chapter 3.  The atypical antipsychotics risperidone and clozapine were 
shown to fully reverse and partially reverse (respectively) the sub-chronic PCP induced 
deficit.  However, the UK Cost Utility of the Latest Antipsychotic Drugs in 
Schizophrenia Study (CUtLASS; Jones et al., 2006; Lewis et al., 2006) and the CATIE 
study (Keefe et al., 2007) highlight the fact that atypical antipsychotics do not provide 
consistent improvement of cognitive symptoms in patients.  Furthermore, clinical 
studies have in fact noted that classical antipsychotics such as haloperidol can impair 
working memory performance (Gilbertson and van Kammen, 1997).  However, like 
many pre-clinical studies, the effect of the antipsychotics in drug naïve rats on baseline 
levels of performance has not been previously investigated.  Therefore, the first aim was 
to investigate the effect of clozapine, risperidone and haloperidol on reversal learning 
ability in naïve rats. 
The second aim was to explore the nature of the sub-chronic PCP-induced 
deficit.  In the reversal learning task used in chapter 3, there is a 2 min time-out period 
prior to the reversal phase, which is believed to act as a cue.  Orbitofrontal cortex (OFC) 
damage in varying species causes reversal learning deficits while preserving the normal 
ability to learn initial contingencies (McAlonan and Brown, 2003; Chudasama and 
Robbins, 2003; Dias et al., 1996; Izquierdo et al., 2004).  There is a hypothesis that the 
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OFC drives behaviour according to associative information representing the 
significance of a particular cue (Rolls et al., 1996; Thorpe et al., 1983).  An aim of this 
chapter is to assess performance of vehicle and sub-chronic PCP-treated rats in the 
absence of the 2 min cue normally employed between the initial and reversal phases of 
the reversal learning task.   
The temporal profile of the sub-chronic PCP-induced deficit in this model will 
also be determined by extending the reversal phase of the experiment and recording the 
results at each minute, this would allow determination of how long it takes the rats to 
adapt to the new rule.  Following this, a double reversal experiment will also be carried 
out in an attempt to make the task more difficult, or rather more difficult to reverse by 
antipsychotics.  Olanzapine will also be tested in this double reversal as it has also been 
shown to improve a sub-chronic PCP-induced deficit (Abdul-Monim et al., 2006).  
Therefore, the aim of this chapter is two-fold; A) to test antipsychotics in naïve rats and 
B) to explore the nature of the sub-chronic PCP-induced deficit. 
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4.2 Material and Methods 
 
4.2.1 Subjects and housing conditions 
One cohort of thirty and a second cohort of fifty female hooded-Lister rats (Harlan, UK) 
housed in groups of four or five were used as subjects.  Animals were housed and food 
restricted as in chapter 3. 
 
4.2.2 Reversal learning 
Rats were trained as detailed in chapter 3. 
 
4.2.3 Antipsychotic validation experiments 
Cohort 1 was tested once weekly with a vehicle control group and dose responses to the 
antipsychotics risperidone (0.1, 0.2, 0.4 mg/kg), clozapine (1.25, 2.5, 5.0 mg/kg) and 
haloperidol (0.025, 0.05, 0.1 mg/kg) were carried out.  The drug treatment and vehicle 
treatment given to each rat (and within each home cage) over the course of these 
experiments was pseudo-randomised to ensure the highest dose of drug and vehicle 
were not given to the same rats in successive experiments.  The order of experiments is 
shown in figure 4.2.1.   
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Figure 4.2.1:  Timeline of experiments in cohort 1. 
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4.2.4 Experiments with sub-chronic PCP 
Cohort 2 was trained to perform the reversal learning task and then sub-chronically 
dosed with PCP (see chapter 2).  Training was not continued throughout the PCP dosing 
or the 7 day washout period.  Following the washout period rats underwent the time-out 
experiment, this involved a 5 min initial phase followed by a 2 min time-out period (or 
not in the time-out experiment) and then a 5 min reversal phase.  The order of 
experiments is shown in figure 4.2.2.  Cohort 2 were tested using a cross-over study as 
there were only 10 vehicle-treated rats, i.e. in the first week 5 vehicle rats and 5 PCP-
treated rats were given the 2 min time-out period and the other 5 of each group went 
straight into the reversal phase without the time-out (shown in table 4.2.1).  In the 
second week the same rats were used but whether the rats received the time-out or not 
was reversed from the previous week, this gave a total of 10 per group. 
 
Table 4.2.1: Cross-over study for the time-out experiment.  Rats in red were tested with a time-out in 
week 1 and without the time-out in week 2.  Rats in blue were tested vice versa.  
Experiment Time-out No time-out 
Week 1 5 Vehicle + 5 PCP 5 Vehicle + 5 PCP 
Week 2 5 Vehicle + 5 PCP 5 Vehicle + 5 PCP 
 
 
The extended reversal experiment involved a 5 min initial phase followed by a 2 min 
timeout period, and then the reversal phase was extended for 15 min and recordings of 
correct and incorrect lever presses were carried out at every minute of this reversal 
phase.  Minute by minute recordings were only carried out in the reversal phase and not 
in the initial phase, as results from the previous chapter showed that the deficit is only 
present in the reversal phase. 
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The double reversal experiment involved a 5 min initial phase followed by a 2 
min time-out period and a 5 min reversal phase followed by a 4 min time-out period and 
a second 5 min reversal.  A 4 min time-out was selected in an attempt to make the 
second reversal more difficult.  Rats were treated with vehicle (0.9% saline), risperidone 
(0.2 mg/kg), clozapine (5.0 mg/kg), olanzapine (1.5 mg/kg) and haloperidol (0.05 
mg/kg).  The drug treatment given to each rat (and within each home cage) over the 
course of these experiments was randomised.  The doses of antipsychotics were selected 
based on previous studies in our laboratory (Abdul-Monim et al., 2006; Garyson et al., 
2007; Idris et al., 2005a).  
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Figure 4.2.2:  Timeline of experiments in cohort 2. 
 
4.2.5 Drugs 
Cohort 1 were injected with increasing doses of clozapine (Tocris, UK), risperidone 
(provided by GSK, UK) and haloperidol (Serenace liquid, 2.0 mg/ml, Baker, UK) based 
on doses used in previous experiments (Idris et al., 2005a; Abdul-Monim et al., 2006; 
Neill et al., 2006; Grayson et al., 2007; chapter 2).  These doses have also been shown 
to correspond to clinical doses (Kapur et al., 2003). Clozapine and risperidone were 
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dissolved in 10μl of acetic acid, made up to volume with distilled water and pH adjusted 
to 6 with 0.1M NaOH.  Haloperidol was diluted with distilled water.   
From cohort 2 40 rats were dosed 2 mg/kg PCP and 10 with vehicle by the 
intraperitoneal (i.p.) route twice daily for seven days.  Dosing with sub-chronic PCP or 
vehicle was followed by a washout period of a further seven days.  PCP hydrochloride 
(Sigma, UK) was dissolved in 0.9 % saline.  For the double reversal experiment doses 
of antipsychotics were selected based on previous experiments and from the data from 
cohort 1.  Olanzapine (provided by GSK, UK) was made as described for clozapine and 
risperidone.  All drug doses were calculated as base equivalent weight and were 
administered via the i.p. route in a volume of 1 ml/kg 30 min before testing. 
 
4.2.6 Data and statistical analysis 
Data for percent correct responding was calculated using the number of presses on the 
correct lever divided by the total number of presses multiplied by 100.  The percent 
correct responding data was arcsine transformed and analysed by one-way ANOVA 
followed by post-hoc Dunnett‟s t-test.  The total number of lever presses was calculated 
by adding the correct and incorrect presses together within the 5 min test session, this 
was used to assess whether drugs had caused any sedation or behavioural impairment. 
Paired t-tests were used to compare performance in the reversal phase to the 
initial phase.  For the extended reversal experiments data for percent correct responding 
at each time point in the reversal learning task was calculated.  Area under the curve 
was calculated for the extended reversal phase and was analysed by a one-way ANOVA 
followed by post-hoc Dunnett‟s t-test. 
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4.3 Results 
 
4.3.1 Antipsychotics in vehicle rats 
 
Effect of risperidone alone 
There were no significant effects of risperidone on reversal learning performance in the 
initial or reversal phases of the task (fig 4.3.1a).  However, a one-way ANOVA revealed 
a significant effect of risperidone on total lever pressing in the initial and reversal 
phases (F(3,28)=6.36, P<0.01) and (F(3,28)=13.61, P<0.001) respectively.  Post-hoc 
Dunnett‟s test showed that risperidone at 0.4 mg/kg significantly reduced lever pressing 
compared to vehicle-treated rats in the initial (P<0.01; table 4.1) and reversal phases 
(P<0.001; table 4.3.1). 
 
 
Table 4.3.1: The effect of risperidone (0.1, 0.2, 0.4 mg/kg; i.p.) on the total number of lever presses in a 
reversal learning paradigm. Data are expressed as the mean  SEM total number of lever presses (n=7-8) 
per group) in the initial and reversal phase of the task. Significant reduction in lever pressing compared 
with vehicle group; **P<0.01, ***P<0.001. 
Drug treatment     Initial phase   Reversal phase 
Vehicle      27.7 0.2     28.4 0.2 
0.1 mg/kg      26.3 0.4     27.8 0.4 
0.2 mg/kg      27.1 0.3     27.6 0.2 
0.4 mg/kg      21.0 2.4**     20.9 1.9*** 
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Figure 4.3.1a: The effect of risperidone (0.1, 0.2, 0.4 mg/kg; i.p.) on performance of the initial and 
reversal phases of the reversal learning task.  Data are shown as mean ± SEM percent correct responding 
(n=7-8). 
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Figure 4.3.1b: The influence of risperidone (0.1, 0.2, 0.4 mg/kg; i.p.) on performance of the initial and 
reversal phase of the reversal learning task. Data are shown as the mean total number of lever presses, 
correct responses are shown as clear bars and incorrect responses are shown as shaded bars (n=7-8). 
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Effect of clozapine alone 
There were no significant effects of clozapine on reversal learning performance in the 
initial or reversal phases of the task (fig 4.3.2a).  However, a one-way ANOVA revealed 
a significant effect of clozapine on total lever pressing in the initial and reversal phases 
(F(3,28)=6.67, P<0.01) and (F(3,28)=4.60, P<0.05) respectively.  Post-hoc Dunnett‟s t-test 
showed that clozapine at 5.0 mg/kg significantly reduced lever pressing compared to 
vehicle-treated rats in the initial (P<0.01; table 4.3.2) and reversal phases (P<0.05; table 
4.3.2). 
 
 
Table 4.3.2: The effect of clozapine (1.25, 2.5, 5.0 mg/kg; i.p.) on the total number of lever presses in a 
reversal learning paradigm. Data are expressed as the mean  SEM total number of lever presses (n=7-8 
per group) in the initial and reversal phase of the task.  Significant reduction in lever pressing compared 
with vehicle group; *P<0.05, **P<0.01. 
Drug treatment     Initial phase   Reversal phase 
Vehicle      28.0 0.2     28.0 0.4 
1.25 mg/kg      27.4 0.4     27.5 0.3 
2.5 mg/kg      24.9 1.2     27.3 0.6 
5.0 mg/kg      23.0 1.3**     20.6 3.3* 
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Figure 4.3.2a: The effect of clozapine (1.25, 2.5, 5.0 mg/kg; i.p.) on performance of the initial and 
reversal phases of the reversal learning task.  Data are shown as mean ± SEM percent correct responding 
(n=7-8). 
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Figure 4.3.2b: The influence of clozapine (1.25, 2.5, 5.0 mg/kg; i.p.) on performance of the initial and 
reversal phase of the reversal learning task. Data are shown as the mean total number of lever presses, 
correct responses are shown as clear bars and incorrect responses are shown as shaded bars (n=7-8). 
 
 
 
 
 
 
 154 
 
Effect of haloperidol alone 
There were no significant effects of haloperidol in the initial phase (F(3,28)=2.64, P = 
0.071).  However, a one-way ANOVA in the reversal phase showed a significant effect 
(F(3,28)=3.54, P<0.05;).  Post-hoc Dunnett‟s t-test revealed that haloperidol at 0.1 mg/kg 
significantly impaired reversal learning performance compared to vehicle rats (P<0.05; 
fig 4.3.3a).  A one-way ANOVA on total lever pressing in the initial phase showed a 
significant interaction (F(3,28)=27.76, P<0.001) and Dunnett‟s post-hoc t-test revealed 
that haloperidol at 0.1 mg/kg significantly reduced the total lever pressing compared to 
vehicle-treated rats (P<0.001; table 4.3.3).  A one-way ANOVA also showed that 
haloperidol had a significant effect on total lever pressing in the reversal phase 
(F(3,28)=31.39), P<0.001) and Dunnett‟s t-test again revealed that the significant 
reduction in lever pressing occurred a dose of 0.1 mg/kg of haloperidol (P<0.001; table 
4.3).  
 
 
Table 4.3.3: The effect of haloperidol (0.025, 0.05, 0.1 mg/kg; i.p.) on the total number of lever presses 
in a reversal learning paradigm. Data are expressed as the mean  SEM total number of lever presses 
(n=6-8) per group) in the initial and reversal phase of the task. Significant reduction in lever pressing 
compared with vehicle group; ***P<0.001. 
Drug treatment     Initial phase   Reversal phase 
Vehicle      27.6 0.4     27.6 0.3 
0.025 mg/kg      27.3 0.5     28.1 0.3 
0.05 mg/kg      27.1 0.3     26.7 0.4 
0.1 mg/kg      17.3 2.0***     16.5 2.1*** 
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Figure 4.3.3a: The effect of haloperidol (0.025, 0.05, 0.1 mg/kg; i.p) on performance of the initial and 
reversal phases of the reversal learning task.  Data are shown as mean ± SEM percent correct responding 
(n=6-8).  Significant impairment in responding compared to vehicle group; *P<0.05. 
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Figure 4.3.3b: The influence of haloperidol (0.025, 0.05, 0.1 mg/kg; i.p) on performance of the initial 
and reversal phase of the reversal learning task. Data are shown as the mean total number of lever presses, 
correct responses are shown as clear bars and incorrect responses are shown as shaded bars (n=6-8). 
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4.3.2 Experiments with sub-chronic PCP 
 
Time-out experiment 
Paired t-tests showed a significant reduction in performance of the reversal phase in 
PCP-treated rats compared with the initial phase following a 2 min time-out (P<0.01; 
fig 4.3.4) and without the time-out period (P<0.001; fig 4.3.4).  Interestingly, a paired t-
test showed a reduction in performance of the reversal phase in vehicle-treated rats 
compared with the initial phase which approached statistical significance following the 
absence of the time-out period (P=0.06).  However, within the reversal phase, the 
performance of both sets of rats appears unaffected by the absence of the time-out cue.  
Paired t-tests comparing with and without the 2 min time-out in the reversal phase 
showed no significant difference in vehicle rats (P=0.13) or PCP rats (P=0.08).  Total 
lever pressing was unaffected (table 4.3.4).  
 
 
Table 4.3.4: The effect of sub-chronic PCP on total lever pressing with and without a 2 min time-out 
period (n=8 per group).  
Drug treatment     Initial phase   Reversal phase 
Vehicle + time out      27.5 0.2     28.9 0.4 
PCP + time out      27.5 0.3     28.6 0.3 
Vehicle + without time out      27.4 0.4     27.4 0.2 
PCP + without time out      27.4 0.2     27.9 0.3 
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Figure 4.3.4: The effect of sub-chronic PCP on performance of the reversal phase of the reversal learning 
task with and without a 2 min time-out period.  Data are shown as mean ± SEM percent correct 
responding (n=8).  Paired t-test showed a significant reduction in performance of the reversal phase 
compared with the initial phase (**P<0.01, ***P<0.001). 
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Extended reversal experiment 
Figure 4.3.5a shows the percent correct responding after 5 and 15 min of the reversal 
phase.  In the first 5 min of the reversal phase PCP produced a selective deficit in the 
reversal phase of the task, a paired t-test showed that percent correct responding was 
reduced in the reversal phase compared to the initial phase (P<0.01; fig 4.3.5a).  
However, after 15 min of the reversal phase this deficit in PCP-treated rats was no 
longer present (P=0.36).  Within the reversal phase of the task, performance of vehicle 
and PCP-treated rats improved with time.  Paired t-tests showed significant 
improvements after 15 min compared to 5 min in vehicle rats (P<0.01) and sub-chronic 
PCP-treated rats (P<0.001).  Vehicle rats also showed improved performance after 15 
min of the reversal phase compared to their initial phase performance (P<0.05).  
Following 15 min of the reversal phase although the PCP-treated rats had improved 
their level of responding up to that in the initial phase, vehicle-treated rats performed at 
a significantly higher level (P<0.01). 
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Figure 4.3.5a: The effect of sub-chronic PCP on performance of the reversal phase of the reversal 
learning task at 5 and 15 min.  Data are shown as mean ± SEM percent correct responding (n=8).  
Significant reduction in performance of the reversal phase compared with the initial phase; **P<0.01 
Paired t-test showed a significant deficit in the reversal phase after 5 min in the PCP-group compared to 
the initial phase.  
@
P<0.05 Paired t-test showed a significant improvement in the reversal phase after 15 
min in the veh-group compared to the initial phase.  Paired t-tests also showed significant improvements 
after 15 min compared to 5 min of the reversal phase 
##
P<0.01; 
###
P<0.001.  An independent t-test showed 
that PCP-treated rats were impaired compared to the vehicle group following 15 min of the reversal phase 
++
P<0.01. 
 
The temporal analysis of the percent correct responding data over every min of the 15 
min reversal phase show that PCP and vehicle rats both improve over time with vehicle 
and sub-chronic PCP-treated rats reaching 93% and 82% correct responding after 15 
min respectively (fig 4.3.5b).  The area under the curves (AUC) show reduced percent 
correct responding in PCP-treated rats over the 5 min extended reversal (P<0.05; fig 
4.3.5c) with an AUC of 193 compared to 290 in vehicle rats.  Following 15 min of the 
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extended reversal the AUC also showed a reduction in correct responding in PCP-
treated rats (P<0.01; fig 4.3.5c) with an AUC of 915 compared to 1189 in vehicle rats.   
The correct and incorrect lever presses shows at which point the rats begin to 
make more correct than incorrect responses.  As a result, in vehicle rats this cross-over 
point is reached before 1 min, while in sub-chronic PCP-treated rats this point is not 
reached until 4-5 min has elapsed (fig 4.3.5d). 
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Figure 4.3.5b: The effect of sub-chronic PCP on performance of the reversal phase of the reversal 
learning task at 1 min intervals for 15 min.  Data are shown as mean ± SEM percent correct responding 
(n=8). 
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Figure 4.3.5c: The effect of sub-chronic PCP on area under the curve of percent correct responding over 
a 15 min period.  Data are shown as mean ± SEM percent correct responding (n=8).  Significant reduction 
in PCP-treated rats; *P<0.05; **P<0.01 independent t-test. 
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Figure 4.3.5d: The effect of sub-chronic PCP on performance of the reversal phase of the reversal 
learning task at 1 min intervals for 15 min.  Data are shown as mean ± SEM for correct and incorrect 
responses (n=8). 
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Effect of double reversal 
There were no differences in performance of the initial phase (fig 4.3.6).  Paired t-tests 
showed that the PCP-treated group and the PCP-haloperidol rats were significantly 
impaired in reversal 1 compared to their initial phase performance (P<0.05 and P<0.01 
respectively; fig 4.3.6).  A one-way ANOVA in reversal 1 revealed a significant effect 
of drug treatment (F(5,49)=5.49, P<0.01).  Post-hoc Dunnett‟s test showed that clozapine 
(5.0 mg/kg), risperidone (0.2 mg/kg) and olanzapine (1.5 mg/kg) significantly reversed 
the sub-chronic PCP-induced deficit (P<0.05-0.01; fig 4.3.6).  Paired t-tests showed that 
the PCP-treated group, olanzapine-treated and haloperidol-treated rats were 
significantly impaired in reversal 2 compared to their initial phase performance (P<0.05; 
fig 4.3.6).  A one-way ANOVA in reversal 2 revealed a significant effect of drug 
treatment (F(5,49)=5.47, P<0.01).  Post-hoc Dunnett‟s test showed that clozapine (5.0 
mg/kg) and risperidone (0.2 mg/kg) significantly reversed the sub-chronic PCP-induced 
deficit (P<0.05 and P<0.01 respectively; fig 4.3.6).  However, olanzapine (1.5 mg/kg) 
no longer reversed the effect of PCP (P=0.86).  Furthermore, a paired t-test revealed that 
in reversal 2, performance was significantly impaired compared to reversal 1 in 
olanzapine-treated rats (P<0.05).  There were no significant effects on total lever 
pressing (table 4.3.6). 
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Table 4.3.6: The effect of clozapine (5.0 mg/kg; i.p.), risperidone (0.2 mg/kg; i.p.), olanzapine (1.5 
mg/kg) and haloperidol (0.05 mg/kg; i.p.) and sub-chronic PCP on the total number of lever presses in a 
reversal learning paradigm. Data are expressed as the mean  SEM total number of lever presses (n=8-10) 
in the initial and reversal phase of the task. 
Drug treatment Initial phase Reversal 
phase 1 
Reversal 
phase 2 
vehicle + vehicle 26.3 0.2 26.3 0.2 26.3 0.2 
vehicle + sub-chronic PCP 26.3 0.3 26.1 0.2 26.1 0.2 
Clozapine + sub-chronic PCP  26.4 0.2 26.0 0.3 26.3 0.3 
Risperidone + sub-chronic PCP 25.8 0.2 26.1 0.4 26.3 0.2 
Olanzapine + sub-chronic PCP 25.9 0.3 25.3 0.8 25.5 0.4 
Haloperidol + sub-chronic PCP 26.1 0.1 25.9 0.3 25.9 0.4 
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Figure 4.3.6: The effect of clozapine (5.0 mg/kg; i.p.), risperidone (0.2 mg/kg; i.p.), olanzapine (1.5 
mg/kg) and haloperidol (0.05 mg/kg; i.p.) on the deficit produced by sub-chronic PCP on performance of 
the reversal phase of the reversal learning task.  Data are shown as mean ± SEM percent correct 
responding (n=8-10).  Paired t-tests showed a significant deficit in the reversal phases compared to the 
initial phase; 
##
P<0.01,
 #
P<0.05.  Post-hoc Dunnett‟s t-test on each reversal phase showed a significant 
improvement following drug treatment compare to the PCP-veh group (**P<0.01, *P<0.05).  A paired t-
test showed that olanzapine-treated rats performed significantly worse in reversal 2 compared to reversal 
1 (
@
P<0.05). 
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4.4 Discussion 
 
4.4.1 Antipsychotics alone 
The present results demonstrate that vehicle-treated rats can be trained to an equivalent 
level of accuracy in both the initial and reversal phases of the reversal learning task.  In 
vehicle-treated rats clozapine and risperidone did not produce any impairment in 
percent correct responding.  The highest dose of each drug did, however, produce slight 
sedation measured by significantly reduced total lever pressing.  This was also observed 
at the highest dose of haloperidol.  Sedation induced by clozapine and risperidone could 
be due to affinity for histamine H1 receptors with Kd values of 3.1nM and 5.2nM 
respectively (see Richelson and Souder, 2000).  However, haloperidol does not have 
high affinity for the H1 receptor with a Kd value of 260nM (Richelson and Souder, 
2000), as a result sedation with haloperidol is more likely to be due to high D2 receptor 
affinity.   Haloperidol at 0.1 mg/kg reduced percent correct responding in the reversal 
phase indicative of cognitive impairment; this is supported by clinical data as patients 
treated with haloperidol have shown impaired performance in tests of working memory 
and executive function (Gilbertson and van Kammen, 1997). 
In contrast to these results with clozapine and risperidone, impairments have 
been shown in other studies; Didriksen and colleagues used low doses (0.63 and 1.3 
mg/kg) of clozapine for a reversal learning study, as a pilot study showed worsening of 
performance with higher doses of clozapine in combination with PCP (Didriksen et al., 
2007).  A recent study also showed that clozapine (2.5 mg/kg) but not haloperidol 
(0.025 mg/kg), disrupted performance in an attentional task in drug naïve rats (Martinez 
and Sarter, 2008).  Amitai and colleagues (2007) found that clozapine (3.0 mg/kg) and 
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risperidone (0.3 mg/kg) impaired performance, but haloperidol (0.05 mg/kg) did not, in 
the 5-choice serial reaction time task as measured by a decrease in the percent of correct 
responses.  These doses of clozapine and risperidone were shown to induce some 
sedation in the rats as measured by an increase in correct latency (Amitai et al., 2007).  
Although the doses of clozapine and risperidone used by Martinez and Sarter (2008) 
and Amitai and co-workers (2007) are comparable to present doses used, the dose at 
which an impairment was observed in haloperidol-treated rats was considerably higher 
(0.1 mg/kg) in the current experiment.  In summary, clozapine and risperidone in drug 
naïve rats did not impair reversal learning, in marked contrast, haloperidol at 0.1 mg/kg 
impaired performance in this reversal learning task. 
 
4.4.2 Sub-chronic PCP experiments 
Following treatment with sub-chronic PCP, rats continually demonstrated a reduction in 
responding which was selective for the reversal phase (chapter 3).  This is in agreement 
with other results from this laboratory (Abdul-Monim et al., 2006) and also this effect is 
observed following acute treatment with PCP (Abdul-Monim et al., 2003; Idris et al., 
2005a).  Sub-chronic PCP treatment did not affect total lever pressing, suggesting 
locomotor activity nor motivation were affected.  Results from other laboratories have 
also shown deficits in reversal learning following sub-chronic PCP administration 
(Jentsch and Taylor, 2001).  The use of sub-chronic PCP treatment is believed to more 
closely mimic cognitive deficits associated with schizophrenia compared to acute 
treatment (Jentsch and Roth, 1999). 
 In the time-out experiment sub-chronic PCP-treated rats were impaired 
following the time-out but were also equally impaired in the absence of the time-out.  
Vehicle-treated rats performed slightly worse without the time-out compared to with the 
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time-out, although this effect was not statistically significant (P=0.13).  This finding 
was also observed in the PCP-treated rats, but again was not statistically significant 
(P=0.08).  In vehicle rats in the experiment without the time-out, performance was 
impaired compared to the initial phase performance, and this affect was close to 
reaching significance (P=0.06).  Although the aforementioned differences were not 
statistically significant they do suggest that the 2 min time-out is needed as a cue.  The 
orbitofrontal cortex (OFC) is believed to control reversal learning ability (McAlonan 
and Brown, 2003).  There are several hypotheses regarding the role of the OFC in 
cognitive flexibility.  One explanation is that the OFC normally acts to inhibit prepotent 
responding that has become inappropriate after reversal (Jones and Mishkin, 1972).  
Animals lacking OFC function would therefore perseverate after reversal because they 
cannot inhibit the previous response.  A second account of the role of the OFC in 
reversal learning is that it drives behaviour according to associative information 
representing the significance of a particular cue (Rolls et al., 1996; Thorpe et al., 1983).  
An alternative explanation for the importance of OFC to reversal learning and to 
cognitive flexibility more generally, lies in its ability to signal the value of an expected 
outcome, rather than simply to drive behaviour based on the associative history of a 
particular cue.  Neuronal recordings and functional imaging in the OFC, have 
demonstrated that activity there tracks with and anticipates the value of rewarding or 
punishing outcomes (Blair et al., 2006; Feierstein et al., 2006; Furuyashiki et al., 2008; 
Roberts, 2006).  Under this hypothesis, OFC-lesioned animals would perseverate 
because they continue to encode the old contingencies, or fail to encode the new ones, 
in other associative learning areas.  The results in this chapter show that PCP affects 
reversal learning which is believed to be controlled by the OFC (McAlonan and Brown, 
2003), in future studies it would be beneficial to investigate the neurobioloical 
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differences in PCP-treated rats.  It would be advantageous to carry out lesions of the 
OFC in our reversal learning task to determine the brain region involved. 
 The differences in the vehicle-treated and sub-chronic PCP-treated rats with or 
without the time-out were not significant but suggest that the 2 min time-out could be 
important as a cue.  It was hypothesised that the lack of a time-out period would make 
the task much more difficult.  Though there was not an intentional time-out given in the 
no time-out experiment, to record the number of lever presses in the initial phase and to 
switch the active lever took approximately 15 sec.  Between food pellets the house-light 
is out for only 3 sec, in the no time-out experiment the house-light was out for 
approximately 15 sec, which may still have acted as a cue.  The rats are also very highly 
trained to perform reversals to achieve 90% correct, therefore this may be difficult to 
disrupt.  It may be advantageous to test the rats before they are so highly trained to 
observe the affect of removing the cue in the training phase. 
In the double reversal experiment, clozapine and risperidone were efficacious in 
reversing the sub-chronic PCP-induced deficit.  Clozapine was effective in attenuating 
the reversal learning deficit produced by sub-chronic PCP in both reversal 1 and 
reversal 2.  However, in chapter 3 clozapine did not significantly improve the 
performance of PCP rats despite restoring performance to the level of the vehicle group.  
The difference between the effects of clozapine in these two chapters may be that the 
PCP-induced deficit in this experiment impaired the rats‟ performance to 45% 
compared to 59% in chapter 3; therefore, there was more capacity for improvement as 
the PCP rats were performing to a lower level.  Olanzapine was also effective in 
reversing the deficit in reversal 1.  This is also supported by a recent study showing that 
the same dose (1.5 mg/kg) of olanzapine was effective in reversing the PCP-induced 
deficit (Abdul-Monim et al., 2006).  Olanzapine has been shown to improve cognition 
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in the clinic in schizophrenic patients (Stratta et al., 2005), and the dose used in this 
experiment (1.5 mg/kg) is clinically comparable in terms of D2 receptor occupancy 
(Kapur et al., 2003). As in chapter 2 the inability of haloperidol to reverse the PCP-
induced deficit may be due to its high D2 receptor affinity and minimal 5-HT2A receptor 
affinity (Siegfried et al., 2005).   
Following the second reversal phase the clozapine-treated rats performed 
slightly less well than in the first reversal, although this effect was not significantly 
different.  However, the olanzapine-treated rats performed significantly less well in the 
second reversal compared to the first reversal, suggesting that olanzapine is not as 
efficacious as clozapine or risperidone.  Olanzapine was also shown to impair 
responding at 2.0 mg/kg but this effect was only observed in the reversal phase, 
suggesting that rats were no longer attending to the task (Abdul-Monim et al., 2006).  
This could be similar to the effect observed in the second reversal in the current 
experiment.  A recent study showed that olanzapine was less efficacious than clozapine 
and risperidone in attenuating PPI deficits (Cilia et al., 2009).  It has been suggested in 
the clinic that risperidone is more effective in improving cognition than clozapine 
(Keefe et al., 2007).  Olanzapine has higher affinity for D1 receptors than clozapine and 
risperidone, and has comparable affinity for D2, 5-HT2A and 5-HT2C receptors (Siegfried 
et al., 2005; Hertel et al., 2007).  The main difference in receptor affinities between 
olanzapine and clozapine and risperidone appears to be olanzapine‟s lack of affinity for 
5-HT1A receptors (Siegfried et al., 2005; Hertel et al., 2007).  The 5-HT1A receptor may 
be important in reversal learning as buspirone, a partial 5-HT1A agonist, was shown to 
reverse the sub-chronic PCP-induced deficit in chapter 3.  Olanzapine may have been 
less efficacious than clozapine and risperidone in the second reversal due to its higher 
affinity for D1 receptors.  The results from the previous chapter showed that activation 
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of D1 receptors is effective in improving reversal learning performance, however, it has 
been suggested that over activation of D1 receptors can have a detrimental effect on 
cognition (Goldman-Rakic et al., 2000).  The second reversal phase may also 
incorporate an attention aspect of cognition as rats have to maintain attention on the task 
for a period that is longer than normal and following a longer (4 min) time-out.  This 
would therefore make the reversal learning task more difficult, and could provide a 
method of distinguishing between antipsychotics.  
From the temporal data in the extended reversal phase experiment, both the 
vehicle and the sub-chronic PCP-treated rats showed improved performance over time.  
PCP produces a selective deficit within the reversal phase over the first 5 min test 
period, however, after 15 min this deficit is no longer observed.  Previously in reversal 
learning experiments (chapter 3) data would only be obtained on the performance of the 
rats in the first 5 min of the reversal phase, and it would not be determined at which 
point the PCP loses its detrimental affect, or at which point antipsychotic compounds 
reverse the PCP-induced deficit.  The extended reversal phase used in the current 
experiment would also allow the investigation of the temporal effects of antipsychotics 
or selective compounds.   
During the first 5 min of the reversal phase it is evident that, in vehicle-treated 
rats, the curve of percent correct responding is steeper than that of the sub-chronic PCP-
treated rats, suggesting that vehicle-treated rats learn the new rule faster.  Pre-clinical 
time course data for antipsychotic drug effects is often shown as the effect on each day, 
or across training sessions (Li et al., 2007), and in reversal learning tasks is usually 
shown as trials to criterion or correct responding for a total reversal learning session 
(Boulougouris et al., 2008).  Analysis of the number of correct and incorrect responses 
reveals a “cross-over” point at which the rats begin to make more correct than incorrect 
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responses.  In vehicle-treated rats this cross-over point is reached before 1 min of the 
reversal phase, therefore the vehicle-treated rats have the ability to adapt to the new rule 
immediately.  In PCP-treated rats this point is not reached until 4-5 min has elapsed, 
which, when the reversal phase would normally be stopped after 5 min, would give a 
percent correct responding value of approximately 50%.  This is a novel measure that 
could potentially differentiate between the mechanism of action and efficacies of 
different antipsychotics. 
 
4.4.3 Conclusions 
In conclusion, the experiments in naïve rats suggest that the atypical antipsychotics 
clozapine and risperidone when given alone have no effect on reversal learning.  
Haloperidol when given to naïve rats impaired performance at the highest dose. 
Sub-chronic PCP administration impairs reversal learning ability as 
demonstrated by reduced percent correct responding in the reversal phase of the reversal 
learning task.  The 2 min time-out could be important as a cue for the reversal phase.  
Following a double reversal, olanzapine-treated rats lose the ability to switch between 
the rules, indicating it is not as efficacious as clozapine or risperidone in reversing the 
PCP-induced deficit.  Using double or even multiple reversals could provide an 
approach of distinguishing efficacy between antipsychotics. The extended reversal 
phase showed that PCP caused a deficit after 5 min but this effect was lost after 15 min.  
Using an extended reversal would also allow the investigation of the temporal effects of 
antipsychotics or selective compounds.   
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This chapter reiterates that this sub-chronic PCP dosage regime reliably produces 
cognitive deficits in this reversal learning task, and offers insight into the temporal 
profile of the PCP-induced deficit.  Having aimed to explore the mechanism of the 
behavioural deficit induced by sub-chronic PCP it is now necessary to investigate the 
nature of the PCP-induced neurobiological deficits that accompany the behaviour.  
These deficits will be explored using electrophysiology and immunohistochemistry in 
the PFC and hippocampus.  The PFC will encompass both the medial and orbital 
regions on which the behavioural tasks in chapters 2 and 3 (respectively) are based.  The 
hippocampus will be investigated as a control region for electrophysiology and it is a 
region implicated in learning and memory.  
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Chapter 5 
The effect of sub-chronic PCP 
on gamma oscillations and 
parvalbumin expression 
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5.1 Introduction 
Post mortem studies in patients with schizophrenia have revealed robust pathology 
involving GABAergic signalling (see chapter 1; Perry et al., 1979; Bird, 1985; Benes 
and Berretta, 2001; Reynolds et al., 2002; Zhang and Reynolds, 2002; Lewis et al., 
2005).  These GABAergic deficits are largely restricted to GABAergic interneurons 
containing the Ca
2+
 binding protein parvalbumin (PV; Lewis et al., 2005).  Importantly 
these interneurons have been shown to synapse onto pyramidal cells (Hendry et al., 
1989), and so are positioned to regulate pyramidal cell output (see figure 5.1).  This 
decrease in PV interneuron functionality would not only produce a decrease in 
inhibitory control over pyramidal cell activity (Olney and Farber, 1995), but would also 
reduce co-ordinated activity of brain networks.  Pyramidal cells drive oscillations 
among inhibitory neurons, which in turn modulate the firing rates of pyramidal cells, 
leading to synchronised activity.  Oscillations reflect this synchronised activity of 
neuronal populations and within the cortex and hippocampus there is emerging data 
suggesting the importance of fast-spiking interneurons in the generation of these 
oscillatory potentials (Whittington et al., 1995; Bartos et al., 2002; Freund and Katona, 
2007).  
Gamma-frequency oscillations (20-80 Hz) are prevalent in active cortical 
networks, and are important for cognition, learning and memory (Engel and Singer, 
2001).  Gamma oscillations arise from networks of PV interneurons in the middle 
cortical layers, whereas GABA neurons containing PV and calbindin give rise to theta 
frequency (4-7 Hz) oscillations (Blatow et al., 2003).  Theta and gamma oscillations 
induced in the prefrontal cortex during cognitive tasks, are reduced in patients with 
schizophrenia, who also perform poorly in these tasks (González-Hernández et al., 2003; 
Cho et al., 2006).  Patients with schizophrenia have shown reductions in gamma power, 
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which may reflect cognitive and negative symptoms, whereas positive symptoms may 
be related with increases in gamma power (Light et al., 2006).  
 
 
 
Figure 5.1: Simplified diagram of a neuronal circuit.  Pyramidal cells send excitatory (glutamatergic) 
projections to neighbouring pyramidal cells, other brain regions and local inhibitory interneurons.  These 
interneurons in turn send inhibitory (GABAergic) projections back to the pyramidal cells, enabling the 
generation of synchronous oscillations.  The basic pyramidal-interneuron- pyramidal circuit is shown in 
solid lines, other connections are shown by dashed lines.  Diagram taken from Spencer and McCarley, 
2006. 
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Following the discovery of suitable induction protocols it is now possible to 
induce gamma oscillation in in vitro slice preparations.  Gamma oscillations are mainly 
induced by 2 methods: (1) induction by electrical stimulation (Traub et al., 1996), 
which generates transient gamma oscillations, and (2) induction by pharmacologically 
activating muscarinic receptors (Fisahn et al., 1998) or kainate receptors (KARs) 
(Hormuzdi et al., 2001), which results in sustained gamma oscillations.  Genetic 
deletion of a receptor subtype contributing to the excitation of pyramidal neurons and/or 
interneurons prevents the induction of gamma oscillations by the respective agonists 
(Fisahn et al., 2004).  Kainate receptors are widely expressed in the hippocampus, with 
five subunits (GluR5-7 and KA1-2; Bureau et al., 1999).  While NMDA and AMPA 
receptors are predominantly post-synaptic, kainate receptors are also located pre-
synaptically at many synapses where they can modulate transmitter release (Lerma, 
2003).  Muscarinic receptors are widely expressed in the CNS; however, it is the M1 and 
M4 subtypes that are predominant in the frontal cortex and hippocampus (Levey et al., 
1991; Wei et al., 1994).  Gamma oscillations are generated in the CA3 region but not 
CA1 as the network architecture between pyramidal cells and interneurons is highly 
recurrent, thus generating strong rhythmic activity (Amaral et al., 1990).   
The aim of this study was to investigate whether the cognitive deficits induced 
by the sub-chronic PCP dosage regimen in chapters 2, 3 and 4 are underpinned by 
differences in gamma oscillations in the prefrontal cortex (PFC) and CA3 region of the 
hippocampus.  Expression of parvalbumin-containing interneurons will also be 
investigated to establish the role of GABAergic transmission in gamma oscillations and 
sub-chronic PCP-induced deficits in cognition.  A PCP sensitisation experiment will be 
carried out in order to establish that the sub-chronic PCP dosing regimen was effective. 
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5.2 Materials and Methods 
 
5.2.1 Subjects and sub-chronic PCP treatment 
Fifty-two adult female hooded-Lister rats (Charles River, UK) were housed in groups of 
four and weighed 190-240 g at the start of the experiment.  Animals were maintained 
under standard laboratory conditions at a temperature of 21°C (±1°C) and humidity of 
55±5%.  They were maintained on a 12 h/12 h light/dark cycle (lights on at 0700 h) and 
experimental procedures were performed during the light phase.  Rats had free access to 
food and water.  Experiments were conducted in accordance with the Home Office 
under the Animals (Scientific Procedures) Act, UK, 1986, and approved by the 
GlaxoSmithKline Procedure Review Panel. 
Rats were treated with 2 mg/kg PCP (n = 26) or vehicle (0.9 % saline; n = 26) by 
the intraperitoneal (i.p.) route in a volume of 1 ml/kg twice daily for seven days.  
Dosing with sub-chronic PCP or vehicle was followed by a washout period of a further 
seven days. 
 
5.2.2 Order of experiments (see figure 5.2.1) 
Following seven-day sub-chronic PCP treatment, 20 rats from the cohort (10 vehicle 
and 10 sub-chronic PCP-treated) were used for electrophysiology experiments, these 
were carried out following the seven day washout period.  Electrophysiology was 
carried out for approximately 6 weeks, using 1 rat on 3 days per week.   
Thirty-two rats (16 vehicle and 16 sub-chronic PCP-treated) were used to assess 
PCP sensitisation to ensure the sub-chronic PCP regimen as effective.  These 
experiments were carried out on days 17 and 18 (10 days after the final sub-chronic 
PCP dose).   
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Day     1              8              15            22          29            36             43           50             57   64
1-7
PCP dosing b.i.d
15-59
Electrophysiology
17-18
PCP sensitisation
 
Figure 5.2.1: Timeline of experiments carried out in one cohort of rats 
 
5.2.3 PCP sensitisation 
Thirty-two rats (16 vehicle and 16 sub-chronic PCP-treated) were used to assess PCP 
sensitisation to ensure the sub-chronic PCP regimen as effective.  Locomotor activity 
(LMA) response to a novel environment was monitored using automated photocell 
cages.  For details of LMA apparatus and software see chapter 2 (2.2.2).  Rats were 
placed in the LMA boxes for a period of 3 hours.  After 1 hour rats were either given an 
acute dose of PCP (2 mg/kg, i.p.) or vehicle (0.9% saline, i.p.) and were placed back in 
the LMA boxes immediately after dosing.  The acute dose of PCP was chosen based on 
a previous study showing that 2 mg/kg can produce cognitive deficits without affecting 
locomotor activity (Grayson, unpublished findings).  Therefore, there were 4 test groups 
(all n=8) sub-chronic vehicle-vehicle, sub-chronic vehicle-PCP, sub-chronic PCP-
vehicle, sub-chronic PCP-PCP.  Activity was monitored every 10 min over a 180-min 
period.   
 
5.2.4 Electrophysiology 
The remaining 20 rats from the cohort (10 vehicle and 10 sub-chronic PCP-treated) 
were used for electrophysiology experiments.  Rats were anesthetised with inhaled 
isoflurane (Abbott, UK), immediately followed by an intramuscular injection of ≥ 100 
mg/kg ketamine hydrochloride (Vetalar™, Pfizer, UK) and ≥ 10 mg/kg xylazine 
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hydrochloride (Rompun™, Bayer, UK).  Animals were perfused intracardially with ~50 
ml of modified sucrose-containing artificial CSF (aCSF), which was composed of the 
following (in mM): 189 sucrose, 25 KCl, 1.2 NaH2PO4, 26 NaHCO3, 5 MgCl2, 0.1 
CaCl2, and 10 glucose.  All salts were obtained from BDH Chemicals (Poole, UK).  
Although this was a terminal procedure through exsanguination, death was further 
confirmed by decapitation.  The brain was removed and submerged in cold (4–5°C) 
aCSF during dissection.  The dorsal surface of the brain was fixed to a cutting block 
with Vetbond (3M).  The cutting block was then lowered into the cutting chamber and 
submerged in ice cold sucrose-containing aCSF; the temperature was maintained at 
~3°C by a cooling unit (CU65, Microm).  Horizontal slices (400 μm) containing 
hippocampus and prefrontal cortex (PFC) were prepared using a Vibraslice (HM650 V, 
Microm) from vehicle and sub-chronic PCP-treated rats. 
Slices were cut and transferred to an interface recording chamber (Harvard 
apparatus, MA, USA; see figure 5.2.2).  Slices were placed on a layer of lens tissue in a 
Perspex trough within the chamber (see figure 5.2.3).  Oxygenated (95% O2/5% CO2) 
aCSF [containing the following (in mM): 124 NaCl, 3 KCl, 1 NaH2PO4, 26 NaHCO3, 2 
MgCl2 (for CA3, 1mM for PFC), 2 CaCl2, and 10 glucose] was continuously pumped 
into the chamber which was maintained at 30±1°C.  Slices were permitted to equilibrate 
for 1 hour before any recordings commenced.  CA3 slices were taken from bregma -6.8 
to -5.0 mm and PFC cortex slices were taken from bregma -4.0 to -2.5 mm.  Remaining 
slices were transferred to a holding chamber containing cold oxygenated (95% O2/5% 
CO2) aCSF.  If required, a slice from the holding chamber was transferred to the 
interface chamber and incubated as above before recording. 
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Figure 5.2.2: Photograph of the electrophysiology rig showing the interface chamber and headstages. 
 
 
Humidified gas
(95% O2, 5% CO2)
ACSF
Waste ACSFTissueBrain slice
 
Figure 5.2.3: Schematic diagram of the slice interface. 
 
 
Recording electrodes were pulled from borosilicate glass (Harvard Apparatus, Kent, UK) 
using a horizontal micropipette puller (DMZ-Universal Puller, Zeitz-Instrumente, 
Munich, Germany), filled with ACSF, and had resistances in the range of ~2MΩ.  The 
recording electrodes were fixed into the headstages (HS-2A headstage, Axon 
Microscope 
Slice Interface 
Headstage 
Waste aCSF 
Electrode 
Interface Chamber 
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Instruments, USA) and were connected to an Axoclamp 2B Amplifier (Axon 
Instruments, UK) by a silver chloride wire.  Electrodes were manually positioned using 
coarse control micro-manipulators (Narishige, Japan) on the surface of the CA3 and 
PFC in the position shown in red in figures 5.2.4 and 5.5.5.  A schematic diagram of the 
rig and recording equipment is shown in figure 5.2.6. 
 
 
 
 
Figure 5.2.4: Example of a section of horizontal prefrontal cortex used as a slice.  This example shows 
the PFC at Bregma -3.38mm (taken from Watson and Paxinos, 1998).  Electrodes were positioned in the 
region highlighted in red. FrA frontal association cortex, PrL prelimbic cortex, Cg2 cingulate cortex area 
2, IG indusium griseum, fmi forceps minor corpus callosum, cg cingulum. 
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Figure 5.2.5: Example of a section of horizontal hippocampus used as a slice.  This example shows the 
hippocampus at Bregma -5.32mm (taken from Watson and Paxinos, 1998).  Electrodes were positioned in 
the CA3 region, highlighted in red.  Lower left panel shown for clarity.  CA1, 2, and 3 fields of 
hippocampus, PoDG polymorph layer dentate gyrus, DG dentate gyrus, S subiculum, hf hippocampal 
fissure. 
 
 
The following drugs were added to the perfusion medium for various experimental 
conditions: kainic acid (KA, 100-400 nM), carbachol (10 µM).  Pilot experiments were 
carried out to determine the concentrations of the agonists required to induce gamma 
oscillations.  For CA3 slices gamma oscillations were induced with 100 nM KA and for 
PFC oscillations were induced by 400 nM KA and 10 µM carbachol.  In both cases 
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oscillations were permitted to stabilise (for approximately 3 hours) before 
measurements were taken.  
Peak frequency and peak power values were obtained from power spectra 
generated by Fast Fourier Transform (FFT) analysis in Spike2 version 6 (Cambridge 
Electronic Design).  The FFT generated a power spectrum at 0.512 sec which gave a 
resolution of 1.9 Hz.  Power was determined as the area under the peak in the power 
spectra between 20 and 80 Hz for gamma frequency oscillations.  All values are given 
as the mean ± S.E.M.  Power spectra were constructed offline from digitised data, using 
a 60 s epoch of recorded activity, the mean was taken over 5-10 min of recordings. 
 
Headstage
Amplifier
Signal Conditioner Humbug 50/60Hz
Noise eliminator
A/D Converter
Computer
Electrode
Brain slice
 
Figure 5.2.6: Schematic diagram of rig.  The recording electrodes were fixed into the headstages (HS-2A 
headstage, Axon Instruments) and were connected to an Axoclamp 2B Amplifier (Axon Instruments) by a 
silver chloride wire.  The signal was then further amplified or conditioned (Brownlee Precision model 
440).  50Hz noise was eliminated using a Humbug (Quest Scientific), and the analogue signal was then 
converted to digital (Micro 1401, Cambridge Electronic Design).  This is signal was then fed into the 
computer for analysis. 
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5.2.5 Drugs 
PCP hydrochloride (Sigma, UK) was dissolved in 0.9% saline and the dose was 
calculated at base equivalent.  Kainic acid (100-400 nM) and carbachol (10 µM), from 
Sigma (Poole, UK), were dissolved in distilled water. 
 
5.2.6 Immunohistochemistry 
In a separate cohort, 32 female hooded-Lister rats (Charles River, UK) were dosed with 
either PCP (n=16) or vehicle (n=16) for 7 days (see section 5.2.1).   
 
5.2.6.1 Brain preparation and fixation 
Two and eight weeks post sub-chronic PCP treatment, vehicle-treated (n=8) and sub-
chronic PCP-treated animals (n=8) were deeply anesthetised with sodium 
pentobarbitone (Euthatal, Merial Animal Health Ltd, Harlow, UK).  See figure 5.2.7 for 
the timeline of dosing and brain preparation.  Animals were then perfused intracardially 
with ~200 ml of phosphate buffered saline (PBS, Sigma, UK) followed by ~200 ml of 
4% paraformaldehyde (PFA, Sigma, UK), the brains were removed and cut into 2 large 
coronal sections and placed in 4% PFA prior to immunohistochemical analyses.  This 
was to prevent post-mortem brain changes in the tissue and to protect against shrinkage 
and distortion during dehydration, embedding and sectioning. 
 
Week     0              1               2              3        9
PCP dosing b.i.d
2 and 8 weeks post PCP dosing
Brains fixed with PFA
//
 
Figure 5.2.7: Timeline of PCP dosing and tissue collection for immunohistochemistry. 
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5.2.6.2 Wax embedding 
The brain samples were rinsed in distilled water four times.  The tissue was then 
dehydrated using increasing concentrations of ethanol: 50% (2 x 1 h), 70% (2 x 1 h), 
90% (2 x 1 h) and 100% (2 x 1 h).  Brains were then immersed in Histoclear clearing 
agent (Fisher Scientific, UK) overnight.  Subsequently the brain samples were placed in 
3 changes 60ºC heated paraffin wax (TissuePrep
®
2, Fisher Scientific, UK; MP=55-57ºC; 
1 x 2 h without pressure and 2 x 2 h under vacuum).  Samples were blocked 
individually in fresh wax.  Each brain section was placed face-down onto a plastic tray 
(3 x 2.5 x 0.5 cm deep) which was then partially filled with molten wax (shown in 
figure 5.2.8).  A perforated plastic holder was then positioned over the tray and molten 
wax added to attach the holder to the wax.  The trays were allowed to solidify overnight.  
The holder plus wax containing the brain section was then removed from the tray 
(shown in figure 5.2.8, bottom). 
 
 
5.2.6.3 Slide coating 
New microscope slides (Fisher Scientific, UK) were soaked in 10% Neutracon solution 
(Decon Laboratories Ltd, UK) at room temperature overnight.  Slides were then washed 
at with water at approximately 60ºC for 1 hour.  Slides were then rinsed with distilled 
water three times.  Slides were left to dry overnight at approximately 60ºC.  Clean slides 
were then immersed in a 10% Poly-L-Lysine solution (Sigma, UK) for 5 min to 
improve adherence of the paraffin embedded tissue sections onto the slides.  Slides were 
dried overnight at room temperature (18-26 ºC). 
Figure 5.2.8: Photograph of the plastic tray used to wax-embed brain sections (top).  The removed tissue 
holder plus wax containing the brain section is shown in the bottom of the picture. 
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5.2.6.4 Sectioning 
The excess wax was cleared from the outside of the plastic holder in which the tissue 
was embedded.  The sample was clamped into a microtome (Reichert-Jung, model 2030, 
MI, USA) and serial slices were cut coronally at 10 µm of the dorsal hippocampus 
(around Bregma -3.3 mm).  Samples were placed into a beaker of distilled water within 
a waterbath, and were then mounted onto slides coated with Poly-L-Lysine.  Samples 
were then left to dry overnight. 
 
5.2.6.5 Parvalbumin staining 
Sections were de-waxed in Histoclear for 5 min.  The sections were then re-hydrated for 
5 min in each of the following solutions: 100%, 90%, 70% ethanol and distilled water.   
 Antigen retrieval: Slides were placed in a 0.1 M sodium citrate solution (Sigma, 
UK) and were placed into a microwave for 15 min; at 5 min intervals the sodium 
citrate solution was topped up.  The solution was left to cool for 20 min.  
Antigen retrieval is needed with previously paraffin embedded tissue sections.  
Protein cross-links mask the antigenic sites in the tissue, thereby giving weak or 
false negative staining for detection of proteins.  Antigen retrieval breaks protein 
cross links, therefore unmasking the antigens and epitopes in paraffin embedded 
tissue sections, thus enhancing the staining intensity of the antibodies. 
 Peroxidase blocking: Sections were placed into a solution containing: 0.6% 
H2O2 (Sigma, UK), 10% methanol, 0.1% Triton X-100 (Fluka Biochemika, 
Switzerland), 8.8% phosphate buffer and 80.5% water.  The sections were 
incubated with this peroxidise block for 30 min and were then placed into a 0.01 
M phosphate buffer wash for 5 min.  Perioxidase blocking denatures 
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endogenous peroxidase enzymes which would otherwise lead to non-specific 
staining of the tissue.    
 Protein blocking: Sections were then placed into a protein block containing: 5% 
horse serum (Vector Laboratories, USA), 0.4% Triton X-100, 9.5% phosphate 
buffer and 85.1% water for 60 min.  Sections were then washed with 0.01 M 
phosphate buffer for 5 min.  This process blocks non-specific binding of 
immunoglobulin.   
 Primary antibody: Sections were then incubated with monoclonal anti-
parvalbumin (Swant, Switzerland) at a dilution of 1:5000 in 5% horse serum, 
0.4% Triton X-100, 9.5% phosphate buffer and 85.1% water for 36 hours at 4ºC.  
Sections were washed in 0.01 M phosphate buffer wash for 5 min twice.  See 
step 1 in figure 5.2.9. 
 Secondary antibody: The bound primary antibody is detected with a secondary 
antibody labelled with biotin.  Sections were incubated for 2 hours with 
secondary antibody, biotinylated anti-mouse IgG (Vector Laboratories, USA) at 
1:200 dilution in 2% horse serum, 0.1% Triton X-100, 9.7% phosphate buffer 
and 88.2% water.  Sections were washed in a 0.01 M phosphate buffer for 5 min.  
See step 2 in figure 5.2.9. 
 ABC Kit:  This is an immunoperoxidase procedure which increases the 
sensitivity of the staining.  The ABC Kit (Vector Laboratories, USA) contains 
avidin DH and a biotinylated enzyme complex.  Avidin has four binding sites 
for biotin.  The biotinylated enzyme forms a complex with the avidin before 
being added to the tissue.  Once added to the tissue the remaining biotin binding 
sites on the avidin molecule bind to the biotinylated secondary antibody that is 
already bound to the tissue.  This results in an amplification of the concentration 
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of enzyme at the antigenic site and therefore increases the staining intensity.  
The sections were processed by the ABC Kit for 2 hours at room temperature 
before being washed in 0.01 M phosphate buffer for 5 min.  See step 3 in figure 
5.2.9. 
 DAB Kit: The peroxidase was then visualised by incubation with a substrate for 
the enzyme.  In this case the chromagen diaminobenzadine (DAB) kit (Vector 
Laboratories, USA) was used.  Tissue sections were incubated for 15 min at 
room temperature and were then washed with distilled water before mounting.  
See step 4 in figure 5.2.9. 
 
 
Figure 5.2.9: Schematic diagram of parvalbumin staining detailed in section 5.2.6.5 (diagram from 
vectorlabs.com).    
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5.2.6.7 Counting and analysis 
Stained sections were scanned at 4x magnification using an Olympus BX51 microscope 
interfaced to an Image ProPlus (version 6.3) analysis system (Media Cybernetics, USA) 
via a JVC 3-CCD video camera.  Estimations of neuronal density (cells/mm
2
) were 
carried out in 6 sections per animal (~60 µm apart), using both images of left and right 
hippocampus.  Immunostained neurons were counted at a higher magnification in 
defined complete sub-fields of each region according to the Atlas of Paxinos and 
Watson (1998).  Within the hippocampal formation, the CA2 plus CA3 region was 
examined.  Images and cells were scanned and counted blind to the experimenter to 
avoid bias. 
 
5.2.7 Data and statistical analysis 
Area under the curve was calculated for the LMA data (for the 2 hour period following 
the acute challenge) using the trapezoid rule, and analysed using a one-way ANOVA 
followed by post-hoc Bonferroni‟s multiple comparison test.  For electrophysiology the 
area under the curve, peak power and peak frequency of the generated power spectra 
were analysed by Student‟s Independent t-tests.  Parvalbumin-containing cell density 
data is expressed as mean ± SEM. Differences between sub-chronic vehicle and PCP 
treated animals were statistically analysed by Student‟s Independent t-test. 
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5.3 Results 
 
5.3.1 PCP sensitisation 
Treatment had no effect on the habituation stage (first hour) of the sensitisation 
experiment.  A one-way ANOVA on the area under the curves and total LMA count 
over the 2 hour period following the acute challenge revealed a significant effect of 
treatment (F3,31=21.96, P<0.001) and (F3,31=20.46, P<0.001) respectively.  Bonferroni‟s 
multiple comparison test on the area under the curves (figure 5.3.1a) and the total LMA 
counts (figure 5.3.1b) showed that following an acute challenge with PCP (2 mg/kg) the 
PCP-PCP group was significantly more active compared to veh-veh, veh-PCP and PCP-
veh (P<0.001) groups.  There were no significant differences between any other groups. 
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Figure 5.3.1a Locomotor activity in vehicle or sub-chronic PCP-treated rats following acute challenge 
with PCP (2 mg/kg) measured over a 3 hour period at 10-min intervals.  
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Figure 5.3.1b: Locomotor activity in vehicle or sub-chronic PCP-treated rats following acute challenge 
with PCP (2 mg/kg) for the 2 hour period following the acute challenge (n=8).  Post-hoc Bonferroni‟s 
multiple comparison test showed that the PCP-PCP group was significantly more active compared to the 
veh-veh, veh-PCP and PCP-veh (***P<0.001) groups.  Acute administration of PCP in vehicle rats did 
not induce significant hyperactivity. 
 
5.3.2 Electrophysiology pilot studies 
Pilot studies were carried out in 6 rats dosed with saline (1 ml/kg, i.p.) for 7 days 
followed by a 7-day washout period.  Slices were discarded and were not included in 
the analysis if there was no apparent peak on the power spectrum.  Initially it was 
necessary to determine which concentration of the agonist would be required to evoke 
stable oscillations in the two regions of interest i.e. CA3 and PFC.  Increasing 
concentrations of kainate were bath applied to the slice until a maximum power was 
reached.  An example trace showing increasing power with increasing concentrations of 
kainate in the CA3 is shown in figure 5.3.2a and the power spectrum is shown in figure 
5.3.2b.  
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Figure 5.3.2a: Gamma oscillations driven by kainite recorded in the CA3.  The traces show recordings 
from 1 slice in response to increasing concentration of kainate. 
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Figure 5.3.2b: Power spectral analysis of gamma oscillations from 1 slice in the CA3 induced by 
increasing concentrations of kainate.   
 
The traces show that the power was increased at 200 nM kainite, however, these 
oscillations did not remain stable over a 3 hour period therefore a lower concentration of 
100 nM was used routinely in this region.   
 
The same procedure was repeated in PFC slices and it was determined that 400 nM 
kainate and 10 μM carbachol was required to induce stable oscillations, these 
experiments were conducted in different slices.  Increasing concentrations of kainate 
were bath applied to the slice until a maximum power was reached.  Following this 
carbachol was also bath applied in increasing concentrations.  An example trace 
showing increasing power with increasing concentrations of in kainate in the PFC is 
shown in figure 5.3.3a and the power spectrum is shown in figure 5.3.3b.  Once it was 
determined that 400 nM kainate was needed, increasing concentrations of carbachol 
were added, this example trace is shown in 5.3.4a and the power spectrum is shown in 
figure 5.3.4b. 
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Figure 5.3.3a: Gamma oscillations driven by kainate recorded in the PFC.  The traces show recordings 
from 1 slice in response to increasing concentrations of kainate and then 5 µM carbachol. 
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Figure 5.3.3b: Power spectral analysis of gamma oscillations from 1 slice in the PFC induced by 
increasing concentrations of kainate and then 5 µM carbachol.   
 
 
The traces show that the power was increased at 200 nM kainate, compared to 400 nM 
kainate alone, however, these oscillations did not remain stable over a 3 hour period.  
Whereas oscillations induced with 400 nM kainate did remain stable, therefore this 
concentration of 400 nM was used routinely in this region.  It also appeared that 
carbachol (5 µM) in combination with 400 nM kainate produced an enhancement of 
these oscillations; subsequently increasing concentrations of carbachol were tested. 
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Figure 5.3.4a: Gamma oscillations driven by 400 nM kainate and carbachol recorded in the PFC.  The 
traces show recordings from 1 slice in response to increasing concentrations of carbachol. 
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Figure 5.3.4b: Power spectral analysis of gamma oscillations from 1 slice in the PFC induced by 400 nM 
kainate and increasing concentrations of carbachol. 
 
In all cases the experiments were carried out blind to the treatment group to avoid bias.  
The treatment group remained blinded until the end of each day. 
Careful observation throughout the duration of the 6-week electrophysiology 
experiments revealed a differential effect of PCP over time.  Therefore, the data was 
analysed in 2 groups, with data from 2-5 weeks after PCP treatment, and then 6-8 weeks 
grouped together for CA3 and weeks 3-5 and 6-8 were grouped together for PFC.  
Experiments in week 2 (following PCP treatment) were not carried out in the PFC as the 
second rig was in the process of being developed. 
 
5.3.3. Gamma Oscillations in CA3 
Gamma oscillations were obtained from 39/39 slices from the vehicle-treated group, and 
40/44 slices from the PCP-treated group.  Power spectra were generated between 20 and 
80 Hz.  The power spectra for weeks 2-5 are shown in figure 5.3.5a and weeks 6-8 are 
shown in weeks 5.3.5.b.  The difference between the time bins in vehicle-treated rats is 
shown in figure 5.3.6a and figure 5.3.6b shows the difference in PCP-treated rats.  
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Representative traces of the oscillations are shown in figure 5.3.7.  The traces selected 
were form the slice with largest oscillations in all cases. 
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Figure 5.3.5a:  Power spectra for vehicle and PCP-treated rats between 20 and 80 Hz for weeks 2-5 in the 
CA3.  Solid lines show the mean and dotted lines show the SEM.  
 
Week 6-8
20 40 60 80
0
50
100
150
PCP
Veh
Frequency (Hz)
P
o
w
e
r 
( 
V
2
/H
z)
 
Figure 5.3.5b:  Power spectra for vehicle and PCP-treated rats between 20 and 80 Hz for weeks 6-8 in 
the CA3.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.6a:  Power spectra between 20 and 80 Hz for vehicle-treated rats in the CA3, comparing 
weeks 2-5 with weeks 6-8.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.6b:  Power spectra between 20 and 80 Hz for PCP-treated rats in the CA3, comparing weeks 
2-5 with weeks 6-8.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.7:  Representative traces showing oscillations in the CA3 in vehicle and PCP-treated rats in 
weeks 2-5 and 6-8. 
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The area under the curve of the power spectrum is shown in figure 5.3.8a.  Independent 
t-tests on the area under the curve of the power spectra in weeks 2-5 showed that PCP-
treated rats were significantly lower than vehicle-treated rats (P<0.05), and in weeks 6-8 
PCP-treated rats were significantly higher compared to the vehicle group (P<0.05).  
This effect is also shown by the power spectra in figures 5.3.5a and 5.3.5b.  There was 
no significant difference in area under the curve between vehicle-treated rats in weeks 
2-5 compared to weeks 6-8 (P=0.54), however, in PCP-treated rats there was a 
significant increase in the area under the curve of the power spectra in weeks 6-8 
compared to weeks 2-5 (*P<0.001; figure 5.3.8a).  This effect is also clear from the 
power spectrum in figure 5.3.6b. 
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Figure 5.3.8a:  Area under the curve of the power spectra for vehicle and PCP-treated rats.  Recordings 
taken from the CA3.  Data is shown as mean ± SEM.  Independent t-tests showed that PCP-treated rats 
were significantly different to the vehicle group (*P<0.05).  
###
P<0.001 indicates a significant difference 
in PCP-treated rats between 2-5 weeks and 6-8 weeks. 
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There were no significant differences in peak frequency of the power spectra between 
vehicle and PCP-treated rats at weeks 2-5 or weeks 6-8, P=0.89 and P=0.49 respectively 
(figure 5.3.8b).  There were also no differences between the time points in vehicle or 
PCP-treated rats, P=0.70 and P=0.10 respectively.   
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Figure 5.3.8b: Peak frequency of the power spectra for vehicle and PCP-treated rats.  Recordings taken 
from the CA3.  Data is shown as mean ± SEM. Independent t-tests revealed no significant differences. 
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The peak power of the power spectra is shown in figure 5.3.8c.  Independent t-tests on 
the peak power in weeks 2-5 showed no significant difference between vehicle and 
PCP-treated rats (P=0.07), however in weeks 6-8 PCP-treated rats had significantly 
higher power compared to the vehicle group (P<0.05).  There was no significant 
difference in peak power between vehicle-treated rats in weeks 2-5 compared to weeks 
6-8 (P=0.92), however, in PCP-treated rats there was a significant increase in the peak 
power of the power spectra in weeks 6-8 compared to weeks 2-5 (P<0.001; figure 
5.3.8c).   
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Figure 5.3.8c: Peak power of the power spectra for vehicle and PCP-treated rats.  Recordings taken from 
the CA3.  Data is shown as mean ± SEM.  Independent t-tests showed that PCP-treated rats were 
significantly different to the vehicle group at weeks 6-8 (*P<0.05), and that there was a significant 
difference in PCP-treated rats between 2-5 weeks and 6-8 weeks (
###
P<0.001). 
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5.3.4. Gamma Oscillations in PFC 
Gamma oscillations were obtained from 21/22 slices from the vehicle-treated group, and 
34/34 slices from the PCP-treated group.  Power spectra were generated between 20 and 
80 Hz.  The power spectra for weeks 3-5 are shown in figure 5.3.9a and weeks 6-8 are 
shown in weeks 5.3.9b.  The difference between the time bins in vehicle-treated rats is 
shown in figure 5.3.10a and figure 5.3.10b shows the difference in PCP-treated rats.  In 
all cases there were no significant differences between vehicle and PCP-treated rats, and 
no differences between the time points.  Figure 5.3.11 show representative traces of the 
oscillations.  The traces selected were form the slice with largest oscillations in all cases. 
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Figure 5.3.9a: Power spectra for vehicle and PCP-treated rats between 20 and 80 Hz for weeks 3-5 in the 
PFC.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.9b: Power spectra for vehicle and PCP-treated rats between 20 and 80 Hz for weeks 6-8 in the 
PFC.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.10a: Power spectra between 20 and 80 Hz for vehicle-treated rats in the PFC, comparing 
weeks 3-5 with weeks 6-8.  Solid lines show the mean and dotted lines show the SEM.  
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Figure 5.3.10b: Power spectra between 20 and 80 Hz for PCP-treated rats in the PFC, comparing weeks 
3-5 with weeks 6-8.  Solid lines show the mean and dotted lines show the SEM.  
 
 206 
 
 
-40u
V
M
E
3
 0:00.2
hms
-40u
V
M
E
2
16
 0:00.2
hms
-40u
V
M
e
m
o
r
y
m1
 0:00.2
hms
PCP
Veh
Week 3-5
PCP
Veh
Week 6-8
-40u
V
M
e
m
o
r
y
m1
 0:00.2
hms
200 ms
40 μV
u
V
M
E
3
u
V
M
E
2
u
V
M
e
m
o
r
y
u
V
M
e
m
o
r
y
 
 
Figure 5.3.11:  Representative traces showing oscillations in the PFC in vehicle and PCP-treated rats in 
weeks 2-5 and 6-8. 
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The area under the curve of the power spectrum is shown in figure 5.3.12a.  The peak 
frequency is shown in figure 5.3.12b and the peak power is shown in figure 5.3.12c.  
Independent t-tests revealed no significant difference between treatment groups or time 
points in vehicle or PCP-treated rats.  
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Figure 5.3.12a: Area under the curve of the power spectra for vehicle and PCP-treated rats.  Recordings 
taken from the PFC.  Data is shown as mean ± SEM. 
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Figure 5.3.12b: Peak frequency of the power spectra for vehicle and PCP-treated rats.  Recordings taken 
from the PFC.  Data is shown as mean ± SEM. 
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Figure 5.3.12c: Peak power of the power spectra for vehicle and PCP-treated rats.  Recordings taken 
from the PFC.  Data is shown as mean ± SEM. 
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5.3.5 Immunohistochemistry for parvalbumin 
Following the in vitro electrophysiology, it was decided to examine parvalbumin 
expression in the CA2/3 region of the hippocampus.  Figure 5.3.13 shows the 
distribution of parvalbumin immunoreactivity in a coronal section of the region at 4× 
magnification.  In vitro analysis of rat brains 2 weeks post PCP treatment showed a 
reduction in parvalbumin immunoreactive cell density in the CA2/3 region of the 
hippocampus of PCP-treated rats (P=0.058; figure 5.3.14).  This reduction was not 
observed 8 weeks following sub-chronic PCP treatment (P=0.981).  There were no 
differences between the vehicle groups at 2 and 8 weeks (P=0.777) nor in the PCP-
treated groups (P=0.141).   
 
 
Figure 5.3.13: Parvalbumin immunoreactivity in the CA2/3 region of the hippocampus. Brightfield 
photomicrograph of a coronal section showing the distribution of parvalbumin immunoreactivity 
throughout the region at 4× magnification. 
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Figure 5.3.14: Relative density (cells/mm
2
) of parvalbumin immunoreactive neurons in the CA2/3 region 
of the hippocampus of vehicle and sub-chronic PCP-treated rats at 2 and 8 weeks post treatment. Data are 
expressed as mean density ± SEM.  Week 2: vehicle n = 6, PCP-treated n = 7, week 8: vehicle n = 5, 
PCP-treated n = 6.  N indicates the number of rats (means were calculated from 6 sections per animal).  P 
values indicate the results of independent t-tests. 
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5.4 Discussion 
The principal findings from this chapter are that sub-chronic PCP treatment has no 
effect on gamma oscillations in the PFC.  In the CA3 region of the hippocampus, 
oscillations were initially significantly reduced in the sub-chronic PCP group compared 
to the vehicle-treated group; however, in the second half of the experiment there was a 
significant increase in gamma oscillations compared to the vehicle group.  Following 
the in vitro electrophysiology results, it was decided to investigate parvalbumin 
immunoreactive (IR) cell density in the CA2/3 region of the hippocampus.  It was found 
that sub-chronic PCP-treated rats showed reduced parvalbumin IR cell density at 2 
weeks following PCP treatment, however, cell density was unchanged 8 weeks 
following PCP treatment. 
 
5.4.1 PCP sensitisation 
Following an acute challenge with PCP, an increase in locomotor activity in the sub-
chronic PCP treated rats was observed, with no effect in vehicle treated animals. 
Previous studies in male rats, using similar treatment regimes at comparable doses have 
reported similar findings (Kalinichev et al., 2008).  This sensitisation in the sub-chronic 
PCP treated animals may be related to the disruption of GABAergic interneurons in the 
medial prefrontal cortex (Abekawa et al., 2007) leading to dysregulation of the striatal 
dopaminergic system (see Jentsch and Roth, 1999).  Taken together these results 
indicate that the sub-chronic PCP regimen was successful in producing behavioural 
changes in these animals thus validating the treatment prior to electrophysiology 
experiments. 
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5.4.2 PCP effects on gamma oscillations in the CA3 region of the hippocampus 
Gamma oscillations are generated in the CA3 region but not the CA1 region of the 
hippocampus, which lacks recurrent connectivity and the high level of kainate receptors 
(KAR) expression in area CA3 (Bureau et al., 1999; Fisahn, 1999).  It has been widely 
reported that gamma oscillations are decreased in patients with schizophrenia, and 
stimulation or working memory load-dependent increases in gamma oscillations in 
healthy controls are absent in patients during cognitive tasks (see Başar and Günterkin, 
2008).  However, it has been suggested that gamma band activity in schizophrenia 
patients is complex, region-dependent and symptom specific.  It has further been 
suggested that negative symptoms are associated with decreases in left hemisphere 
synchrony, while positive symptoms were found to be associated with increased gamma 
band power in right hemisphere regions (Lee et al., 2003a, b).   
The results presented in this chapter demonstrate that in the CA3 region of the 
hippocampus oscillations were initially reduced in the sub-chronic PCP group, however, 
in the second half of the experiment there was a significant increase in gamma 
oscillations.  The rodent data investigating PCP and gamma oscillation is minimal.  
However, studies have been performed using other NMDA antagonists, with varying 
results.  To our knowledge this is the first study to examine the effects of sub-chronic 
PCP on gamma oscillations and this is also the first slice preparation experiment in 
animals to carry out a time-course experiment following PCP treatment. 
It was shown in vivo using EEG recordings that rats which were pre-treated with 
acute PCP or methamphetamine exhibited increased gamma band power in the 
hippocampus 2 hours following drug administration (Ma and Leung, 2000).  It has been 
postulated that acute block of NMDA receptors will dampen the activity of interneurons 
(Homayoun and Moghaddam, 2007) and thereby disinhibit pyramidal neurons (Grunze 
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et al., 1996).  Consistent with this theory firing rates of pyramidal neurones were 
potentiated in the PFC in freely moving rats following acute treatment with MK-801 
(Jackson et al., 2004).  Chronic ketamine was shown to reduce power and amplitude of 
gamma oscillations in the PFC; slices were prepared following the final dose of 
ketamine (Zhang et al., 2008).  These authors attribute this effect to a different 
mechanism that reduced GAD67 (Zhang et al., 2008; Lisman et al., 2008).  The 
downregulation of GAD67 produced by ketamine is associated with accumulation of 
superoxide; inhibition of the superoxide-synthesising enzyme prevents the loss of 
GAD67 immunoreactivity in parvalbumin interneurons (Behrens et al., 2007).  Taken 
together the results from rodent studies with NMDA antagonists are inconsistent, but 
the alteration in gamma oscillations could depend on whether the treatment with 
NMDA antagonists is acute or sub-chronic.  All of the aforementioned studies have 
used different species of rats and have been males; therefore, differences in the present 
data may be observed due to the use of female hooded-Lister rats, and also due to the 
seven day sub-chronic PCP dosage regimen. 
Studies involving transgenic mouse models of psychiatric disorders have also 
been carried out.  Alterations in gamma oscillations have been reported in Alzheimer‟s 
disease (Koenig et al., 2005; Uhlhaas and Singer, 2006).  Mice over-expressing human 
amyloid precursor protein (APP) exhibited a reduction in hippocampal gamma activity 
at 8 months of age compared to age-matched wild-type mice (Driver et al., 2007).  
Sensorimotor-gating deficits and neurochemical changes resembling those in 
schizophrenia are observed in lysophosphatidic acid 1 receptor (LPA-1) knock-out mice 
(Harrison et al., 2003).  Lysophosphatidic acid 1 receptor (LPA-1) knock-out mice were 
shown to have reduced gamma oscillations and a decrease in parvalbumin neurons in 
the medial entorhinal cortex (Cunningham et al., 2006). 
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5.4.3 PCP effects on gamma oscillations in the PFC 
Sub-chronic PCP treatment had no apparent effect on gamma oscillations in the PFC, 
and there were no significant differences over time in either the vehicle or sub-chronic 
PCP-treated rats.  In another study, chronic ketamine was shown to reduce power and 
amplitude of gamma oscillations in the PFC (Zhang et al., 2008).  Gamma oscillations 
in the present study in the PFC were approximately 5 times smaller than in the CA3 
region of the hippocampus.  Due to this very small signal, it may not have been possible 
to observe a difference between the treatment groups.  The majority of the literature 
concerning gamma oscillations is focused on the hippocampus; this is likely due to the 
network architecture between pyramidal cells and interneurons being highly recurrent, 
thus generating strong rhythmic activity (Amaral et al., 1990).  As the architecture is 
less recurrent in the PFC it may be more beneficial to investigate gamma oscillation in 
vivo rather than in a slice preparation.  This was also the first study to be carried out 
using prefrontal slices in the laboratory; therefore, it may be that the method of inducing 
the oscillations needs improvement.  For example, the method of inducing the 
oscillations may need refinement, and/or the location of the electrode placement may 
need altering.  
 
5.4.4 PCP effects on parvalbumin IR cell density in the CA2/3 region of the 
hippocampus 
Following the in vitro electrophysiology results, it was decided to investigate 
parvalbumin immunoreactive (IR) cell density in the CA2/3 region of the hippocampus.  
Post mortem studies in patients with schizophrenia have revealed robust pathology 
involving GABAergic signalling (see section 5.1).  Benes et al. (1998) reported a 
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reduced density of GABA interneurons in the CA2/3 region of the hippocampus, the 
same region in which a reduction in parvalbumin IR cell density was observed in sub-
chronic PCP treated rats.  Calcium binding proteins (CBP), namely parvalbumin (PV), 
calbindin (CB) and calretinin (CR) have been used as markers of specific 
subpopulations of non-overlapping GABAergic interneurons in the brain.  The 
GABAergic deficits found in schizophrenia are largely restricted to the PV-containing 
neurons (Lewis et al., 2005).  Deficits in PV IR cells have been reported in both the 
frontal cortex (Beasley and Reynolds, 1997; Beasley et al., 2002) and hippocampus 
(Zhang and Reynolds, 2002) in schizophrenia.  Whether these studies reflect deficits in 
the density of PV interneurons or that the interneurons are present but PV is not 
expressed was unanswered.  In a more recent study, it was reported that, at the cellular 
level, a decrease in signal intensity for PV mRNA was attributable
 
principally to a 
reduction in PV mRNA expression per neuron
 
rather than by a decreased density of PV 
mRNA-positive neurons (Hashimoto et al., 2003).  Furthermore, it was reported that 
treatment of PV interneurons in culture with ketamine resulted in a concentration 
dependent decrease in PV, and at the highest concentration of ketamine cell death was 
not observed (Kinney et al., 2006). 
The results presented here show a reduction in parvalbumin IR cell density in 
sub-chronic PCP-treated rats at 2 weeks following PCP treatment.  These results are 
supported by other studies using a sub-chronic PCP treatment regime that have reported 
deficits in PV-immunoreactive neurons in the hippocampus; these reductions have 
occurred alongside cognitive and behavioural alterations (Abdul-Monim et al., 2006; 
Jenkins et al., 2008).  Deficits in the attentional set-shifting task following acute PCP 
treatment were also accompanied by a reduction in PV mRNA in the reticular thalamus 
with no change in the prefrontal cortex (Egerton et al., 2005).  However, using a regime 
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of chronic intermittent exposure to PCP, Cochran and co-workers (2003) reported 
decreases in PV mRNA expression in both the rat prefrontal cortex and reticular nucleus 
of the thalamus.  A recent study found that repeated PCP administration (10 mg/kg for 
10 days) impaired performance in a working memory test and reduced PV mRNA 
expression in the PFC (Thomsen et al., 2009).  Furthermore, it was shown that co-
administration of SSR180711, an α7 nAChR agonist, prevented the PV and behavioural 
deficits (Thomsen et al., 2009).  Other studies using the NMDA antagonists MK-801 
and ketamine have also showed deficits in PV interneurons in the hippocampus 
(Keilhoff et al., 2001; Braun et al., 2007; Rujesca et al., 2006).  It is also important to 
note that deficits in PV-immunoreactive neurons are also observed in 
neurodevelopmental models of schizophrenia such as post-natal administration of PCP 
(Wang et al., 2008), the MAM model (Penschuck et al., 2006) and isolation rearing 
(Harte et al., 2007).   
 
5.4.5 Time-dependent changes in the PCP-induced effects on gamma oscillation and 
parvalbumin IR cell density in the CA2/3 region of the hippocampus  
The literature is lacking data studying the time-course effects of PV and gamma 
oscillations, therefore it is difficult to postulate how these effects could be changed over 
time.  Parvalbumin IR cell density was unchanged at 8 weeks post PCP treatment, 
suggesting a compensatory mechanism could be increasing PV.  A previous study in our 
laboratory found reductions in PV IR cell density at 6 weeks post PCP treatment in the 
CA2/3 region (Abdul-Monim et al., 2007).  It is not clear from immunohistochemistry 
whether these studies initially reflected a decreased number of interneurons or that the 
interneurons were present but PV was not detectable.  It was reported that treatment of 
PV interneurons in culture with ketamine resulted in a concentration-dependent 
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decrease in PV, and at the highest concentration of ketamine cell death was not 
observed (Kinney et al., 2006).  Therefore, it is suggested that blocking NMDA 
receptors on interneurons changes the phenotype of the neurons.  If the PV interneurons 
are still present but are not expressing parvalbumin, this may allow PV expression to be 
increased with time due to compensatory mechanisms, such a mechanism may involve 
the increase in NMDA receptors or NMDA receptor subunits.  PV expression is thought 
to be activity dependent (Philpot et al., 1997); therefore, an increase in functional 
NMDA receptors could result in an increase in PV expression and so increase release of 
GABA and glutamate within the network.  This could also account for the increase in 
gamma oscillations, as the system would be more synchronous.  Although the gamma 
oscillations began to increase over time, the fact that oscillations were increased 
compared to vehicle-treated rats still represents an abnormal system of firing.  Gamma 
oscillations may be further increased to above a normal level because NMDA receptors 
could also be increased on pyramidal cells which could also disrupt the synchronicity of 
the system.  It is also unclear whether the levels of parvalbumin return to normal (as in 
vehicle-treated rats) or whether these levels are further increased, as 
immunohistochemistry only allows us to count whether the cells express PV or not, it 
does not quantify the levels of PV within each neuron. 
Although the effects in this study appear to be time-dependent, the evidence here 
and in the literature does suggest a role of GABAergic neurotransmission in 
schizophrenia.  It should be an aim of antipsychotic treatment to reverse the deficits in 
PV expression.  In a rodent model of schizophrenia using chronic PCP treatment it was 
shown that clozapine reversed the PCP-induced deficits in PV expression (Cochran et 
al., 2003). Furthermore, it was shown that co-administration of SSR180711, an α7 
nAChR agonist, prevented the PV and behavioural deficits (Thomsen et al., 2009).  
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Indeed, the GABAA receptor could be a novel target for cognitive dysfunction 
associated with schizophrenia.  For example the positive allosteric modulator of 
GABAA receptors, MK-0777, was shown to have high selectivity for the α2/α3 subunits 
and was found to improve working memory in schizophrenia patients; furthermore it 
was also shown to increase gamma power during the Preparing to Overcome 
Prepotency task (Lewis et al., 2008).  This cognitive task is a cued stimulus-response 
reversal paradigm that requires increases in cognitive control through the maintenance 
and use of context information to overcome prepotent response tendencies (Cho et al., 
2006). 
 
5.4.6 Conclusions 
There was no difference in gamma oscillations at either time point in the PFC.  The 
results from this chapter demonstrate a reduction in gamma oscillations in the CA3 
region of the hippocampus following PCP treatment that was paralleled by a deficit in 
parvalbumin IR cell density, at a similar time point (2-5 weeks post PCP-treatment).  In 
contrast, a time-dependent increase in gamma oscillations was observed (6-8 weeks post 
PCP-treatment), at which point parvalbumin IR cell density was unchanged.  To our 
knowledge this is the first study to investigate the effects of sub-chronic PCP on gamma 
oscillations in vitro.  These experiments demonstrate a link between altered gamma-
frequency oscillations and abnormalities in parvalbumin interneurons, which may 
underlie some of the cognitive deficits previously reported in this animal model of 
schizophrenia. 
 
This chapter demonstrates differences in gamma oscillations in the CA3 region of the 
hippocampus; however, the behavioural tasks employed in this thesis are believed to be 
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primarily based on the PFC.  Due to the small signal obtained from the PFC, it could be 
concluded that this protocol is not the ideal method for exploring changes in the PFC.  
Therefore, the next chapter will aim to investigate differences in the PFC using in vivo 
microdialysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 220 
 
 
 
 
 
 
Chapter 6 
Effect of sub-chronic PCP on dopamine 
release in the prefrontal cortex during a 
novel object recognition test 
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6.1 Introduction 
 
The previous chapters have principally explored two behavioural tests of cognition, i.e. 
the attentional set-shifting task and the reversal learning test.  The current chapter aims 
to utilise a quicker, more ethologically relevant task, namely the novel object 
recognition task. 
 
6.1.1 Novel object recognition (NOR) task 
As early as 1950, Berlyne found that rats spent significantly more time exploring a 
novel object than two familiar objects (Berlyne, 1950).  Subsequently the novel object 
recognition (NOR) task was developed, based on the natural propensity of rats to 
explore novel objects (Ennaceur and Delacour, 1988).  It is a non-rewarded, 
ethologically relevant, relatively simple test (Puma et al., 1998).  Rats would be 
expected typically to respond to changes in their environment, in this case this would be 
shown by preferential exploration of a novel object compared to a familiar object.  Such 
tests are increasingly being used to study and screen potential novel antipsychotic drugs.   
Indeed, NOR has been listed by the TURNS initiative as relevant for studying visual 
learning and memory deficits in schizophrenia (TURNS.ucla.edu).  This model is 
relevant to the disease since visual recognition memory is impaired in schizophrenic 
patients (Calkins et al., 2005).   
It has been shown that female rats can perform better in NOR compare to males, 
and that there is no effect of stage of oestrus cycle on ability to perform in the NOR task 
(Sutcliffe et al., 2007).   Sub-chronic PCP has previously been reported to induce a long 
lasting robust deficit in novel object recognition, an effect which can be reversed by the 
atypical antipsychotics clozapine and risperidone (Grayson et al., 2007).  The NOR task 
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may therefore provide a relatively quick and simple means of evaluating novel therapies 
for aspects of cognition in schizophrenia.  Furthermore, the efficacy of the atypical 
antipsychotics clozapine, risperidone, sertindole, and the ampakine, farampator, was 
demonstrated in this model against PCP (Grayson et al., 2007; Neill et al., 2007; Idris et 
al., 2009).   
 
6.1.2 Brain regions involved in NOR 
Studies of primates and rodents have shown the importance of the parahippocampal 
regions of the temporal lobe (namely perirhinial, entorhinal, and inferior temporal 
cortices) in visual object recognition memory (Gilbert and Kesner, 2003; Murray et al., 
2000).  Excitotoxic lesions of the perirhinal cortex in rats have been shown to disrupt 
object recognition memory (Aggleton et al., 1997; Liu and Bilkey, 2001).  Furthermore, 
additional studies in rats and primates have suggested that it is cortical rather than 
hippocampal neurons that are involved in object recognition tasks (Brown and Aggleton, 
2001; Wan et al., 1999; Xiang and Brown, 1999).  However, some human and primate 
studies have shown that hippocampal lesions result in impaired object recognition 
memory (Beason-Held et al., 1999; Cave and Squire, 1991; Reed and Squire, 1997; 
Zola et al., 2000).  It is thought that the brain regions involved in object recognition 
memory depend upon the length of the inter-trial interval.  Rats with hippocampal 
lesions exhibited impairments in object recognition following long inter-trial intervals 
(>15 min), but not short intervals of <15 min (Clark et al., 2000).  In support of this, 
intra-hippocampal administration of the NMDA antagonist, APV, was reported to 
impair object recognition memory with a long (3 hour), but not short (5 min) inter-trial 
interval (Baker and Kim, 2002). 
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 Though much of the evidence indicates a critical role of the perirhinal cortex in 
object recognition memory (Gaffan and Murray, 1992; Meunier et al., 1993; Ennaceur 
et al., 1996; Brown and Aggleton, 2001; Hannesson et al., 2004), evidence also 
suggests that the medial PFC may also contribute to recognition memory.  PFC neurons 
have been shown to carry information concerning the relative familiarity of individual 
stimuli (Miller et al., 1996; Xiang and Brown, 2004), and damage to this area has been 
shown to impair recognition memory tasks (Bachevalier and Mishkin, 1986; Kolb et al., 
1994).  Therefore, recognition memory following a short inter-trial interval may involve 
a large network of cortical connections that include the perirhinal cortex and the 
prefrontal cortex. 
 
6.1.3 NMDA receptor antagonists and the role of dopamine 
It is suggested that interaction with novelty may activate rewarding mechanisms in rats, 
and that novelty seeking behaviour is controlled by the dopaminergic system (Besheer 
et al., 1996; Peters et al., 2007; Rebec et al., 1997).  As yet, the role of dopamine in 
object recognition remains less well established.  Thus, it would be particularly useful to 
gain an insight into dopaminergic changes in vivo during the novel object recognition 
task.   
Several lines of evidence suggest that current antipsychotics have one common 
factor regarding their mechanism of action, in that they all interfere with the 
dopaminergic system in the brain (see Arnt and Skarsfeldt, 1998).  Dopamine 
hypofunction in the PFC is thought to have a major role in the aetiology of negative 
symptoms and cognitive dysfunction of schizophrenia (Abi-Dargham and Moore, 2003; 
Stone et al., 2007).  It has been shown that the atypical antipsychotics, sertindole and 
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risperidone, increase extracellular dopamine in the rat mPFC and nucleus accumbens 
(Mork et al., 2009).  
There are several studies which demonstrate that NMDA antagonists produce 
psychotic and neurocognitive disturbances similar to those observed in schizophrenia 
(Enomoto et al., 2007; Javitt, 2007; Krivoy et al., 2008; Stone et al., 2007; Tan et al., 
2007).  Moreover, PCP has been shown to disturb dopamine levels in the PFC and 
nucleus accumbens (Jentsch et al., 1997).  The reduction of dopamine levels in the PFC 
is associated with negative and cognitive symptoms of schizophrenia (Jentsch et al., 
1999), while an increase in dopamine in the nucleus accumbens is associated with 
hyperlocomotion often seen in PCP-treated animals (Jentsch et al., 1998).  Acute dosing 
with PCP has limitations in modelling the chronic psychotic illness or the persistent 
cognitive deficits of schizophrenic patients.  Alternatively, as previously discussed in 
prior chapters, repeated sub-chronic exposure to PCP is believed to mimic 
schizophrenia more accurately than acute dosing (Jentsch and Roth, 1999).  Examples 
of these changes include reduced frontal blood flow and glucose utilisation (Hertzman 
et al., 1990; Wu et al., 1991) and reduced dopamine utilisation in the PFC (Jentsch et al., 
1997).  These data indicate that dopamine function is significantly altered in the PFC by 
sub-chronic treatment with PCP.   
It has been suggested that the brain areas involved in recognition memory 
include the PFC and perirhinal cortex (Miller et al., 1996; Xiang and Brown, 2004; 
Winters and Bussey, 2005).  In addition, there is also evidence that the effects of 
NMDA receptor antagonists are more robust in the PFC compared with other regions 
having major dopaminergic innervation (Verma and Moghaddam, 1996).  Although a 
single injection of MK-801 has been reported to increase extracellular levels of 
glutamate in the mPFC (Lopez-Gil et al., 2007; Zuo et al., 2006), repeated 
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administration of MK-801 has been shown to decrease glutamate levels in the mPFC 
(Zho et al., 2006).  Furthermore, basal dopamine levels seem to be reduced in the rat 
PFC following sub-chronic PCP administration (Jentsch and Roth, 1999).     
 
6.1.4 Control anxiety testing 
As the NOR task involves rats being placed in an open arena it would be valuable to 
assess whether there were any differences in anxiety between vehicle and sub-chronic 
PCP treated rats, which could then confound results in the NOR task.  Therefore, rats 
were tested in two anxiety-like behaviour tests, namely the elevated plus maze (Pellow 
et al., 1985) and open field (Walsh and Cummins, 1976) tests.  The elevated plus-maze 
(Pellow et al., 1985) involves placing a naive rat in the centre of an elevated plus-maze 
with two open and two enclosed arms and allowing it to freely explore (Rodgers and 
Cole, 1993).  It has been suggested that the reluctance of rats to explore the open arms 
of the maze is caused by fear of open spaces rather than the novelty of the maze or its 
height (Pellow et al., 1985).  The open-field test is also a frequently used test of anxiety 
(Gray, 1979). Both tests have been pharmacologically validated with anxiolytic 
compounds increasing and conversely anxiogenic compounds decreasing the percentage 
of time spent in the open areas (Pellow et al., 1985; Gentsch et al., 1987; Cole et al., 
1995). 
 
6.1.5 Aims 
The aim of this chapter was to investigate the role of prefrontal dopamine in specific 
phases of the novel object recognition (NOR) task using in vivo microdialysis during the 
behavioural task.  Predominantly, in our laboratory the NOR task is carried out using a 
1 min inter-trial interval; however, due to the methodological constraints of 
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microdialysis these experiments were carried out using a 10 min inter-trial interval.  In 
addition, as a control experiment, anxiety tests were carried out to ensure that any 
differences in novel object recognition in PCP-treated rats were not due to anxiety or 
neophobia. 
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6.2 Materials and Methods 
 
The main technique used in this chapter was in vivo microdialysis.  The development of 
brain sampling techniques was limited by the large sample previously required for the 
identification and quantification of neurotransmitters.  The development of highly 
sensitive analytical techniques, such as HPLC, has made it possible for the development 
of micro-collection techniques such as in vivo microdialysis (Benveniste and 
Huttemeier, 1990; Ungerstedt, 1984).  An important advantage of high-liquid 
performance chromatography (HPLC) is rapid separation, which takes minutes rather 
than hours for each sample unlike previous methods of detection.   
Microdialysis is a technique that allows both administration and collection of 
substances from remote brain regions with a high level of accuracy.  Sampling can be 
done on a continuous basis in freely moving animals, limited only by the amount of 
time needed to fill the sample loop of the HPLC injector.  Microdialysis is based on the 
principal of dialysis, in which a semi-permeable membrane separating two solutions 
allows some diffusion to occur.  The movement of fluid through the probe carries the 
substance of interest to the sampling site for analysis. 
 
6.2.1 Experiment 1: PCP and anxiety 
 
6.2.1.1 Subjects and drug treatment 
Forty adult female hooded-Lister rats weighing 200-250 g were housed in groups of five 
in standard laboratory conditions with free access to food and water.  Light intensity in 
the holding and behavioural testing rooms was 400-500 lx. All experimental procedures 
were carried out in accordance with the Animals (Scientific Procedures) Act, UK (1986) 
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and were approved by the University of Bradford ethical review process.  At adulthood 
20 rats received sub-chronic PCP (2 mg/kg) and 20 rats received vehicle (0.9% saline, 1 
ml/kg) as previously detailed in chapter 2. 
 
6.2.1.2 Locomotor activity (LMA)  
The LMA response to a novel environment was monitored using automated photocell 
cages.  The movement of each animal was monitored in a Plexiglas chamber (16 x 26 x 
19 cm) covered with a compatible Plexiglas lid using AM1052 Activity Monitor 
(Linton Instrumentation).  Rats were habituated to the cages for 2 hours on the day prior 
to testing.  On the test day, rats were either given an acute dose of PCP (2 mg/kg, i.p.) 
or vehicle (0.9% saline, i.p.) and were placed in the LMA boxes immediately after 
dosing.  The acute dose of PCP was chosen based on a previous study showing that 2 
mg/kg can produce cognitive deficits without affecting locomotor activity (Grayson, 
unpublished findings).  Therefore, there were 4 test groups (all n=10) sub-chronic 
vehicle-vehicle, sub-chronic vehicle-PCP, sub-chronic PCP-vehicle, sub-chronic PCP-
PCP.  Counts were recorded by AmLogger software (supplied by GSK, Harlow, UK) by 
means of photo beam interruptions within the chamber.  Activity was monitored every 
5min over a 120 min period.  Rats were challenged to ensure that the sub-chronic PCP 
regimen was effective.  The rats that did not receive the PCP challenge (veh-veh (n=10) 
and PCP-veh (n=10)) then went on to be tested in the elevated plus maze and open field 
paradigms.   
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6.2.1.3 Elevated plus maze 
The elevated plus maze (constructed in house) consisted of four arms elevated 50 cm 
above the floor and is shown in figure 6.2.1.3.  Each arm (12 cm wide, 46 cm long) was 
joined to the others by a central square (12 cm ×12 cm) in a cross-like disposition.  A 
wall (12 cm in height) enclosed two opposite arms, while the other two arms were open.  
Placing the rat on the platform facing an open arm started the test.  The arms of the 
maze were cleaned between the tests.  The experimenter monitored the movements of 
the rats via a video camera (JVC, TK/C1480E) mounted above the maze, and recordings 
were scored using Hindsight version 1.  During the 10 min test session, the number of 
entries into the open or closed-arms and the time spent in the open or closed-arms were 
recorded. The rats were considered to have entered an arm when all four limbs were 
located in an arm of the maze.  The latency to enter the open arm was also scored. 
 
 
 
Figure 6.2.1.3: The elevated plus maze 
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6.2.1.4 Open field  
The open field arena (constructed in house) consisted of an open box (52 cm wide by 40 
cm high by 52 cm long) with black Perspex sides, a white Perspex base and black grid 
lines dividing the arena into 9 equally sized squares (see figure 6.2.1.4).  No additional 
illumination was placed on the box and the box was placed in the experimental room in 
such a position where no shadows fell.  Placing the rat in the centre square started the 
test.  The arena was cleaned in between tests.  The experiment was recorded and scored 
as described previously for the elevated plus maze.  During the 10 min test session, the 
number of entries into the centre square and the time spent in the centre square were 
recorded.  The rats were considered to have entered a square when all four limbs were 
located in that square of the arena. 
 
 
 
Figure 6.2.1.4: The open field arena 
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6.2.1.5 Data and statistical analysis 
Area under the curve was calculated for the LMA data using the trapezoid rule, and 
analysed using post-hoc Bonferroni‟s multiple comparison test.  Independent Student‟s 
t-tests were carried out on the elevated plus maze and open field data between the 
vehicle and PCP treated groups. 
 
6.2.2 Experiment 2: novel object recognition and microdialysis 
 
6.2.2.1 Subjects and drug treatment 
Twelve adult female hooded-Lister rats (Charles River, UK) were housed in groups of 
two to three and weighed 200-220 g at the start of the experiment.  Animals were 
maintained under standard laboratory conditions at a temperature of 20°C (±1°C) and 
humidity of 50±5%.  They were maintained on a 12-h/12-h light/dark cycle (lights on at 
0700 hours) and experimental procedures were performed during the light phase.  Rats 
had free access to food and water.  Rats were treated with 2 mg/kg PCP (n = 5) or 
vehicle (0.9 % saline; n = 7), twice daily for 7 days.  All experiments were performed 
with appropriate project and personal license authority under the Animals (Scientific 
Procedures) Act, 1986, and with approval of the University of Leicester Animal Ethics 
Committee. 
 
6.2.2.2 Surgery 
Prior to surgery rats were administered buprenorphine (0.05 mg/kg, s.c; Vetergesic®, 
Reckitt Benckiser, UK).  Rats were anaesthetised using isoflurane (3% isoflurane in O2: 
1 litre/min) in an induction chamber.  Once fully anaesthetised, the head was shaved and 
swabbed with an iodine solution and the animal was mounted in a Kopf stereotaxic 
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frame, incorporating a gaseous anaesthetic delivery mask (Stoelting, USA), and was 
maintained at 1-2% isoflurane in 1 litre/min oxygen.  Exhaust gas was filtered through a 
scavenger unit (Fluovac Aldasorber, Aldred and Co, UK).  The head was positioned 
such that the incisor bar was 3.3 mm below the intra-aural line (Paxinos and Watson, 
1998).  Blunt ear bars were used to minimise trauma to the ear canal, and a topical local 
anaesthetic (EMLA cream containing 25 mg lidocaine and 25 mg prilocaine, 
AstraZeneca, UK) was applied to the ear bars before insertion into the ear canal; an 
ocular lubricant (Lacri-lube, Allergan, UK) was placed onto the eyes.   
The skin overlying the surface of the skull was removed to reveal the area to be 
covered by the cap.  A midline incision was made in the pericranium overlying the skull, 
which was scraped away laterally and removed to fully expose the bone.  The horizontal 
and transverse stereotaxic coordinates of bregma were recorded.  The coordinates of the 
implants were then calculated and the position marked on the skull surface (PFC: H, 
+3.2; Tr, -0.5 and NAc: H, +1.6; Tr, +1.4, relative to bregma; (Paxinos and Watson, 
1998)).  Holes were drilled in the skull using a hand-held drill (bit size 1.18 mm 
diameter) at the locations of the implants and two additional holes in the left and right 
parietal bones.  Anchor screws (3.2 mm shaft length, 1.57 mm shaft diameter, 2.5 mm 
head diameter Plastics One, USA) were inserted into the holes in the parietal bones.  
The stainless steel guide cannulae (o.d., 890 μm; i.d., 685 μm; length 10 mm: Coopers 
Needle Works, Birmingham, UK) were mounted onto an implanter device and were 
then lowered into their respective holes until the surface of the brain was reached.  At 
this point the vertical coordinate was recorded and the vertical position of the implanted 
cannula was calculated (PFC: V, -1.4; NAc: V, -6.0, relative to dura).  The guide 
cannula was raised and the dura was pierced with a needle before the cannula could be 
lowered into position.  The guide cannula was then secured in place using dental acrylic 
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(DuraLay, BAS, UK).  Once dry, the implanter was raised leaving the guide in position.  
This was repeated for the other region.  Stainless steel stylettes (10 mm length, o.d., 
0.64 μm, top 2 mm bent over) were then inserted into the guides and secured in place 
with a small amount of silicon rubber compound (Hombase, UK).  Rats received 2-3 
sutures below the cap using FS-3 coated vicryl polyglactin (Ethicon®, Johnson and 
Johnson, Belgium).  Finally, a topical antibiotic (cloxacilin benzathine, Orbenin dry 
cow®, Pfizer, UK) was applied around the wound to aid healing.  Following surgery 
animals were singly housed in order not to cause damage to each others implants and 
were fed a mixture of standard chow and chow softened by pre-soaking for 2 hours.  
Animals were closely monitored until behavioural testing, they were weighed daily, and 
the amount of food and water intake was recorded. 
After recovery from surgery (≥7 days), animals were again anaesthetised with 
isoflurane and the stylettes mounted in the silicon rubber were removed.  The dialysis 
probes (see below) were inserted into the guide cannulae to lie in the PFC (tip position 
H, +3.2; Tr, -0.5; V, -5.4) and NAC (tip position H, +1.6; Tr, +1.4; V, -8.5).  The probes 
were then fixed in place using dental acrylic.  Following the insertion of the probes the 
wire rack lid of the home-cage was replaced with a clear Perspex lid with holes for 
ventilation, to ensure that the probes were not damaged. 
 
6.2.2.3 Microdialysis probes 
Microdialysis probes were constructed in house (by Dr Andrew Young) as previously 
described (Young et al., 1998).  The dialysis membrane (o.d. 350 μm; Cuprophan, 
COBE laboratories, Gloucester, UK), sealed at one end with epoxy resin and with two 
fused silica capillaries (o.d. 170 μm, SGE, Milton Keynes, UK) inserted, was mounted 
into a stainless steel tube (o.d. 640 μm, Coopers Needle Works, Birmingham, UK) with 
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a 2.5 or 4.0 mm length of membrane exposed.  The open ends of the capillaries were 
each inserted into a 6 mm length of stainless steel tube (o.d. 640 μm) with a 5 mm 
length of silicon rubber tube on the other end to act as a connector.  The joint was 
secured with epoxy resin.  A schematic diagram of the probe is shown in figure 6.2.2.3.  
All probes used in the experiments were checked for flow rate integrity and leaks before 
implantation.  The recovery of the probes in vitro was 10-15%. 
 
4 mm
Perfusate in Perfusate out
Epoxy resin
Epoxy resin
Epoxy resin
Stainless
steel tube
Dialysis tube
Vitreous
silica tube
Brain tissue
 
Figure 6.2.2.3: A schematic diagram of the microdialysis probes used for the PFC. 
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6.2.2.4 Delivery system 
Delivery tubes comprised four 20 cm lengths of „Portex‟ polythene tubing (o.d. 0.61 
mm, Anachem, Luton, UK), mounted in a 17 cm length of stainless steel spring 
(Plastics One, USA).  Two tubes (inlet) were connected via a two channel liquid swivel 
(Eicom, Japan), to a two channel syringe pump (CMA, Sweden).  The other two tubes 
(output) went from the top end of the spring into the collector tubes mounted on the 
spring, such that they rotated with the animal.  The length of the output line was 
adjusted to give a 30 min dead time from probe tip to collection at a flow rate of 2 
μl/min.  Custom built gantry was curved to allow movement (20 gauge steel wire).  The 
delivery system set-up is shown with NOR apparatus in figures 6.2.2.4a and b. 
 
NOR box
Delivery systemGantrySyringe pump
Position of home-cage  
Figure 6.2.2.4a:  Labelled photograph of the delivery system set-up shown attached to the NOR box 
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Figure 6.2.2.4b:  Labelled photograph of the delivery system, the gantry was attached to the NOR box 
and the spring leads to the implanted probes 
 
 
6.2.2.5 Microdialysis procedure during NOR 
At least one hour after implantation of the probe, animals were connected up for 
microdialysis, and perfusion with artificial cerebrospinal fluid (mM: NaCl, 145; KCl, 
3.3; MgSO4, 2.4; KH2PO4, 1.25; CaCl2, 1.85: 2 μl/min) commenced immediately.  
Following equilibration for 1 hour, dialysate samples were collected consecutively for 
10 min into 2 μl of 1.0 M H3PO4 (to minimise oxidation).  The details of sample 
collection throughout the experiment are shown in table 6.2.2.5.  The first four samples 
(40 min) were used to determine basal dopamine levels in the dialysates. 
 
 237 
 
Table 6.2.2.5: Shows the collection time points of the samples.  Collection was offset 
by 30 min to allow for 30 min dead time within the tubes.  
Time (min) Behaviour Sample 
0 Home cage 
Clearing dead volume 10 Home cage 
20 Home cage 
30 Home cage 
Dialysis 
Equilibration 
40 Home cage 
50 Home cage 
60 Baseline in home cage 
70 Baseline in home cage 
80 Baseline in home cage 
90 Baseline in home cage S1     - Baseline 
100 Habituation in NOR box S2     - Baseline 
110 Acquisition in NOR box S3     - Baseline 
120 ITI S4     - Baseline 
130 Retention test S5     - Habituation 
140 Re-baseline in home cage S6     - Acquisition 
150 Re-baseline in home cage S7     - ITI 
160 Re-baseline in home cage S8     - Retention 
170 
Remain in home cage and 
continue perfusion 
S9     - Re-baseline 
180 S10  - Re-baseline 
190 S11  - Re-baseline 
 
 
Dopamine content in every sample (S1-11) was assessed by high performance liquid 
chromatography (HPLC) with electrochemical detection.  On completion of the dialysis 
collection, animals were disconnected from the delivery tubes and returned to their 
home cage.  At the end of the collection period, animals were killed by anaesthetic 
overdose (sodium pentobarbitone 400 mg, JML, Southampton, UK) and cervical 
dislocation, and the brains were removed and stored in 4% formalin for subsequent 
histological verification of cannulae placement.   
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6.2.2.6 Microdialysis probe location - Cresyl Violet staining 
Brain samples were embedded in wax (see chapter 5 section 5.2.6.2).  Samples were 
sectioned (see chapter 5 section 5.2.6.4) as the probe location was observed, and were 
then mounted onto slides coated with Poly-L-Lysine (see chapter 5 section 5.2.6.3).  
Samples were then left to dry overnight.  Sections were de-waxed in Histoclear clearing 
agent (Fisher Scientific, UK) for 10 min.  The sections were then re-hydrated for 5 min 
in each of the following solutions: 100%, 90%, 70% ethanol and distilled water.  The 
tissue was then stained with cresyl violet acetate (Fluka Biochemika, Switzerland) for 
10 min.  Slides were washed with distilled water until the water ran clean.  Sections 
were then subjected to the same process as re-hydration in reverse, i.e. 5 min in each of 
the following: distilled water, 70%, 90%, 100% ethanol.  Sections were then placed into 
Histoclear for 5 min.  Slides were then mounted in DPX (BDH, UK) and covered with a 
coverslip. 
 
6.2.2.7 NOR apparatus 
The apparatus consisted of an open box made of Plexiglas (52 cm L; 52 cm W; 31 cm H) 
and was positioned 60 cm above the floor on a table.  The tube delivery system was 
mounted on one side of the box.  The NOR box is shown in figure 6.2.2.7a.  The walls 
of the box were black and the objects to be discriminated (in triplicate) were cola cans 
or Frijj® bottles.  The size of the objects was similar (8-10 cm) and they were heavy 
enough not to be displaced by the animals, to achieve this, the bottles were filled with 
NaCl.  The objects used in these experiments are shown in figure 6.2.2.7b.  Objects 
were positioned away from the walls of the box, in opposite corners.  After each trial, 
10% ethanol was used to clean the objects in an attempt to remove any lingering 
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olfactory cues on the objects and in the box.  The familiar and novel objects were 
counterbalanced to the left and right position to prevent bias for a particular location.   
 
 
Figure 6.2.2.7a: Photograph of the NOR box          Figure 6.2.2.7b: Objects used in the NOR task 
 
 
6.2.2.8 Habituation 
During the week prior to the first behavioural testing procedure, all rats were handled 
daily.  For three days prior to behavioural testing, rats were given daily 30 min 
exploration periods in the NOR box to ensure habituation to the empty apparatus and 
test room environment. 
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6.2.2.9 Behavioural testing 
The order of testing is shown in appendix 2.  The test was divided into 3 phases, the 
acquisition trial, an inter-trial interval and a retention trial proceeded by a 10 min 
habituation.   
 Acquisition trial: each rat was placed into the NOR box and exposed to two 
identical objects (A1 and A2) for a period of 10 min.   
 Inter-trial interval: the rats were then returned to their home cage for a 10 min 
inter-trial interval.  Both objects were removed and the entire NOR box was then 
cleaned. 
 Rats were returned to the NOR box to explore a familiar (a triplicate of those 
used in the acquisition phase to minimise olfactory cues) and a novel object (B) 
for a 10 min retention trial.  The location of the novel object in the retention trial 
was randomly assigned for each rat. 
All experiments were video recorded (JVC, TK/C1480E) for subsequent blind 
behavioural analysis.  Object exploration was defined as the rats sniffing, licking or 
touching the objects with forepaws whilst sniffing but not by leaning against, turning 
around, standing or sitting on the objects.  The exploration time (s) of each object in 
each trial was recorded manually using two stopwatches and the following factors were 
calculated. 
 Discrimination index (DI) = (time exploring the novel object (s) – time 
exploring the familiar object) / total time exploring both novel and familiar 
objects.  A value above zero indicates that the rats have explored the novel 
object more than the familiar object.  A value below zero indicates that the rats 
have explored the familiar object more than the novel object.   
 The total exploration time of objects in both the acquisition and retention trials.   
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Locomotor activity (LMA) was also recorded; this was evaluated by scoring the total 
number of sectors or line crossings by the animal in both acquisition and retention trials.  
The rat was only considered to have crossed the line once all four paws had crossed the 
line.  A schematic diagram of the task is shown in figure 6.2.2.9. 
 
ITI
 
Figure 6.2.2.9: Schematic diagram of the novel object recognition task.  The left panel shows the position 
of the objects in the acquisition trial followed by the inter-trial internal, and then the position of the 
familiar and novel objects in the retention trial.   
 
6.2.2.10 HPLC detection of dopamine 
After collection, dialysate samples were analysed to determine the dialysate 
concentration of dopamine in each sample by HPLC with electrochemical detection.  
Samples (15 μl) were injected onto the column using a Spark Triathlon refrigerated 
autosampler (Presearch, UK).  The mobile phase (75 mM NaH2PO4, 1.1 mM 
octanesulfonic acid, 1 mM EDTA, 10% methanol, pH 3.7), was pumped at 110 μl/min 
using a Rheos 4000A pump (Presearch, UK), and separation was achieved with a 150 
mm × 1.0 mm LUNA C18(2) 5 µm column (Phenomenex, UK).  The separation was 
previously optimised for dopamine (see appendix 3).  Dopamine, with a retention time 
of approximately 12.1 min was clearly separated from the other main constituents of the 
samples which had the following retention times (min): DOPAC, 5.9; 5-hydroxyindole 
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acetic acid, 10.2; HVA, 14.4.  The concentrations were measured using an ANTEC 
Intro electrochemical detector incorporating a VT-03 low volume flow cell (Presearch, 
UK) with the working electrode set at 700 mV relative to a silver/silver chloride 
reference electrode, and data were collected and analysed using Chrom Perfect Analysis 
v5.5.4 (Justice laboratories, NJ, USA) PC-based integrator.  The detection limit for 
dopamine under these conditions was 4.5 fmol per injection (equivalent to 15 μl 
injection of 0.3 nM).  All chemicals were supplied by Sigma Chemicals (Poole, UK) 
and were HPLC grade.   
 
6.2.2.11 Data and statistical analysis 
The NOR data are expressed as mean ± SEM. Student‟s paired t-test was performed to 
compare the effect of treatment on the time spent exploring the familiar versus the novel 
object. LMA data are expressed as mean ± SEM of the total number of lines crossed 
during the acquisition and retention trials.  Analysis of the total exploration values, 
LMA and DI data were performed using unpaired t-tests. 
Dopamine concentrations were calculated with reference to standards at 1, 10, 
and 100 nM.  Data are expressed as concentrations (nM) in the dialysates and percent of 
basal.  The basal value was calculated from the four samples taken prior to behavioural 
testing.  Microdialysis data were analysed using repeated measures two-way ANOVA 
with stage of task as a within subjects factor (basal, habituation, acquisition, ITI, 
retention, 3 post-test) and treatment (vehicle or PCP) as a between subjects factor.  This 
was followed by post-hoc Bonferroni pair-wise comparisons.  All statistical analyses 
were performed in SPSS (version 15).  The DI from the NOR data and the percent of 
basal dopamine in the retention stage were assessed for correlation using Pearson‟s 
correlation (Graph Pad, Prism version 5).  
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6.3 Results 
 
6.3.1 Experiment 1: Verification of PCP dosing regimen and anxiety tests 
Bonferroni‟s multiple comparison test on the area under the curves (figure 6.3.1a) and 
the total LMA counts (figure 6.3.1b) showed that the PCP-PCP group was significantly 
more active compared to veh-veh (P<0.05), veh-PCP (P<0.01) and PCP-veh (P<0.01) 
groups.  There were no significant differences between the other groups.   
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Figure 6.3.1a: Locomotor activity in vehicle or sub-chronic PCP-treated rats (2 mg/kg twice daily for 
seven days) following acute challenge with PCP (2 mg/kg) measured over a 2-hour period at 5-min 
intervals (n=10).  Post-hoc Bonferroni multiple comparison test on the area under the curves showed that 
the PCP-PCP group was significantly more active compared to veh-veh (P<0.05), and veh-PCP and PCP-
veh (P<0.01) groups.  
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Figure 6.3.1b: Locomotor activity in vehicle or sub-chronic PCP-treated rats (2 mg/kg twice daily for 
seven days) following acute challenge with PCP (2 mg/kg) measured over a 2-hour period (n=10).  Post-
hoc Bonferroni multiple comparison test showed that the PCP-PCP group was significantly more active 
compared to veh-veh (P<0.05), and veh-PCP and PCP-veh (P<0.01) groups.  
 
 
Rats which had received an acute dose of vehicle were then tested in the behavioural 
paradigms (vehicle and PCP n=10).  Rats were excluded from the elevated plus maze 
study if they did not remain on the maze for the full test session, therefore groups sizes 
for the elevated plus maze experiment were n=8.  Behaviour in the open field and on the 
elevated plus maze was unaffected by sub-chronic PCP with no significant differences 
observed between groups in time spent in the open/closed arms and number of entries 
into the arms, or time spent and entries into the centre square of the open field (table 
6.3.1a).  The ratio of open/closed arm duration and entries were calculated and are 
shown in table 6.3.1b; these also showed no significant effect of PCP treatment. 
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Table 6.3.1a: Behaviour of vehicle and PCP-treated rats on the elevated plus maze and 
open field tests. 
Behaviour Vehicle PCP P value 
    
Elevated plus maze    
    Open arm duration (s) 109.8 ± 11.3 94.2 ± 10.0 0.31 
    Closed arm duration (s) 377.5 ± 18.0 368.9 ± 14.3 0.71 
    Centre duration (s) 112.7 ± 22.2 131.0 ± 7.9 0.45 
    Open arm entries 6.8 ± 0.7 6.6 ± 0.5 0.89 
    Closed arm entries 12.9 ± 0.7 15.5 ± 1.1 0.07 
    Centre entries 19.8 ± 1.3 22.3 ± 1.3 0.20 
    Open arm latency (s) 28.8 ± 6.8 17.4 ± 7.0 0.26 
    
Open field test    
    Centre square duration (s) 25.2 ± 5.9 27.1 ± 4.9 0.80 
    Centre square entries 9.1 ± 1.5 11.1 ± 1.8 0.32 
    Line crossings 111.4 ± 5.9 111.1 ± 8.1 0.98 
 
Table 6.3.1a:  Behaviour of vehicle and sub-chronic PCP-treated rats on the elevated plus maze (n=8) 
and open field tests (n=10).  Data are means ± SEM.  P values were obtained from Independent Student‟s 
t-test comparing PCP to vehicle-treated group. 
 
 
 
Table 6.3.1b: Ratios of open/closed arm duration and number of entries on the elevated 
plus maze in vehicle and PCP-treated rats. 
 Open/closed ratio  
Behaviour Vehicle PCP P value 
Duration (s) 0.29 ± 0.03 0.27 ± 0.04 0.59 
Entries 0.53 ± 0.05 0.44 ± 0.03 0.14 
 
Table 6.3.1b:  Ratios of open/closed arm duration and number of entries on the elevated plus maze in 
vehicle and PCP-treated rats (n=8).  Data are means ± SEM.  P values were obtained from Independent 
Student‟s t-test comparing PCP to vehicle-treated group. 
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6.3.2 Experiment 2: Microdialysis and NOR 
Initially the groups consisted of 5 vehicle-treated and 5 PCP-treated rats (2 vehicle rats 
were excluded during behavioural testing).  Bodyweights were monitored for a week 
following surgery.  This data is shown in figure 6.3.2, day 0 represents the day of 
surgery.  A two-way repeated measures ANOVA with day as the within factor and 
treatment as the between factor revealed no significant interaction (F(1,8)=0.27; P=0.62). 
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Figure 6.3.2: The bodyweights of sub-chronic vehicle and PCP-treated rats following surgery to insert 
the guide cannulae (n=5).  Day 0 represents the day of surgery.  There was no significant difference 
between the vehicle and PCP-treated groups. 
 
 
6.3.2.1 NOR results 
Animals were excluded if there was a lack of exploration in the behavioural task.  
Therefore, the groups for behaviour were vehicle (n=5) and PCP (n=5).  The total time 
spent exploring both objects in the acquisition and retentions trials is shown in table 
6.3.2.1.  Student‟s independent t-test showed that there was no significant difference 
between vehicle and PCP-treated rats on total object exploration in the acquisition 
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(P=0.56) and retention trials (P=0.44).  Paired t-tests revealed that there was no 
significant difference in the time spent exploring the two identical objects during the 
acquisition trial in either vehicle (P=0.83) or PCP-treated rats (P=0.73; figure 6.3.2.1a).  
In the retention trial (figure 6.3.2.1b), vehicle-treated rats explored the novel object 
more than the familiar object, although this effect was not significant (P=0.11; there was 
no difference in exploration of the novel and familiar objects in sub-chronic PCP-treated 
rats (P=0.09).  An independent t-test revealed a significant difference in the 
discrimination index (DI, P<0.05).  The DI for the PCP-treated group was significantly 
reduced to 0.25 from 0.65 in the vehicle treated group (Fig 6.3.2.1c).  There was no 
effect on locomotor activity assessed by the number of line crossings in the acquisition 
and retention trials (P=0.45; Fig 6.3.2.1d). 
 
Table 6.3.2.1: Total exploration time (sec) in the acquisition and retention trials for 
vehicle (n=5) and PCP-treated (n=5) rats. 
 Total exploration time (sec) 
  Acquisition Trial Retention Trial 
Vehicle 40.5 ± 11.2 30.7 ± 13.3 
PCP 49.0 ± 7.0 44.2 ± 9.4 
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Figure 6.3.2.1a: The effect of treatment with vehicle or sub-chronic PCP (2 mg/kg, twice daily for 7 days, 
i.p.) in the acquisition phase of the novel object recognition task.  Data are shown as mean ± s.e.m of time 
spent exploring the objects (n=5 per group). 
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Figure 6.3.2.1b:  The effect of treatment with vehicle or sub-chronic PCP (2 mg/kg, twice daily for 7 
days, i.p.) in the retention phase of the novel object recognition task.  Data are shown as mean ± s.e.m of 
time spent exploring the objects (n=5 per group). 
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Figure 6.3.2.1c: The effect of treatment with vehicle or sub-chronic PCP (2 mg/kg, twice daily for 7 days, 
i.p.) in the novel object recognition task.  Data are shown as mean DI ± s.e.m (n=5 per group).  The DI for 
the PCP-treated group was significantly impaired compared to the vehicle group (*P<0.05). 
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Figure 6.3.2.1d: The effect of treatment with vehicle or sub-chronic PCP (2 mg/kg, twice a day for 7 
days, i.p.) on locomotor activity (line crossings) in the novel object recognition task.  Data are shown as 
mean line crossings ± s.e.m (n=5 per group).  
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6.3.2.2 Dopamine results 
Following the behavioural experiments, HPLC was carried out, therefore the groups for 
dopamine analysis were vehicle (n=5) and PCP (n=5).  The raw values obtained for 
each rat over the baseline measurements and in the retention trial of the NOR task are 
shown in table 6.3.2.2a, the data expressed as percent of basal are shown in table 
6.3.2.2b.  An example chromatogram for the baseline values of a vehicle and PCP rats is 
shown in appendix 4. 
 
 
Table 6.3.2.2a: Raw values of relative dopamine concentrations (nM) in the PFC for 
vehicle and sub-chronic PCP-treated rats.  The data shows the mean basal 
concentrations and retention trial concentrations. 
 Dopamine concentration (nM) 
 Vehicle PCP 
Rat Mean basal Retention Mean basal Retention 
1 0.260 0.198 3.229 3.437 
2 10.391 6.109 4.223 4.587 
3 4.897 38.173 3.844 4.148 
4 0.354 0.741 2.290 4.162 
5 0.456 1.509 1.020 0.617 
Mean 3.272 9.346 2.921 3.390 
SEM 1.812 6.658 0.577 0.717 
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Table 6.3.2.2b: Retention trial PFC dopamine data expressed as percent of basal for 
vehicle and sub-chronic PCP-treated rats.  The data shows the mean basal 
concentrations and retention trial concentrations. 
Rat Vehicle PCP 
1 76.1 106.5 
2 58.8 108.6 
3 779.6 107.9 
4 209.2 181.7 
5 330.8 60.5 
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The mean of the 4 baseline concentrations prior to behavioural testing was calculated 
and data in figure 6.3.2.2a were expressed as percent of basal.  A two-way repeated 
measures ANOVA with stage of test as the within subjects factor and treatment as the 
between subjects factor revealed no significant interaction (F(7,56)=1.26; NS).  However, 
planned pair-wise Bonferroni comparisons revealed a selective and significant increase 
in dopamine levels in vehicle treated rats in the retention phase (P<0.01), however, this 
effect was not found in PCP-treated rats. 
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Figure 6.3.2.2a: Relative concentrations of dopamine in the PFC expressed as percent basal in vehicle 
and sub-chronic PCP-treated rats in each stage of the behavioural task.  Data are shown as mean 
concentration ± S.E.M (n=5). **P<0.01 significant increase in dopamine in the retention phase compared 
to baseline levels. 
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The line of best fit was plotted for the DI and percent of basal dopamine in the retention 
stage (figure 6.3.2.2b), and a correlation analysis revealed that the line was not 
significant from zero (P=0.18). 
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Figure 6.3.2.2b: Plot of DI and percent basal dopamine in the retention trial in NOR with the line of best 
fit plotted.  Correlation analysis revealed a correlation coefficient of 0.47 and a coefficient of 
determination of 0.22; this was not significant from zero. 
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6.3.2.3 Microdialysis probe placement 
Following Cresyl violet staining, the locations of the probes were verified.  All probes 
were located within the PFC at Bregma 2.7 to 3.2 mm.  An example image of probe 
location is shown in figure 6.3.2.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.2.3:  Microdialysis probe 
placement.  Top: coronal image from 
Watson and Paxinos (1998), Bregma 
2.7 mm showing PFC regions.  Bottom: 
Photograph taken at x4 magnification 
following Cresyl violet staining. The 
solid shaded rectangle represents the 
position of the cannula; the dotted line 
represents the tip position. 
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6.4 Discussion 
 
6.4.1 PCP sensitisation and anxiety 
A component of this study examined whether sub-chronic PCP would induce anxiety-
like behaviour in the adult rat.  Sub-chronic PCP had no effect on behaviour in the open 
field or elevated plus maze.  Following an acute challenge with PCP, there was an 
observed increase in locomotor activity in the sub-chronic PCP treated rats, with no 
effect in vehicle treated animals.  This effect was also seen in chapter 5.  Previous 
studies in male rats, using similar treatment regimes at comparable doses have reported 
similar findings (Kalinichev et al., 2008). This sensitisation in the sub-chronic PCP 
treated animals may be related to the disruption of GABAergic interneurons in the 
medial prefrontal cortex (Abekawa et al., 2007).  Taken together these results indicate 
that the sub-chronic PCP regimen was successful in producing behavioural changes in 
these animals thus validating the treatment prior to testing in the anxiety paradigms. 
In the present study there were no significant differences between vehicle and 
PCP-treated rats in time spent in each arm or number of entries on the elevated plus 
maze.  There were also no differences in open field behaviour with rats spending a 
similar duration in the centre square and making a similar number of entries into the 
centre.  These data suggest that sub-chronic PCP does not have an anxiogenic effect as 
assessed by the elevated plus maze or open field test.  These findings are supported by 
studies using a perinatal (du Bois et al., 2008) and sub-chronic pubertal (Schwabe et al., 
2006) regimen of PCP dosing which showed no difference in elevated plus maze 
behaviour in adult female and male rats respectively, suggesting that these PCP regimes 
do not produce anxiety-like behaviour.  However, these data are in contrast with a 
recent study by Audet and co-workers.  They found that sub-chronic PCP followed by a 
week washout period resulted in male rats spending less time in the lit area of a brightly 
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lit/dark arena (Audet et al., 2007).  However, it should be noted that they used a 
different strain and sex of rat and a higher dosing regimen of 5 mg/kg twice daily for 7 
days, compared to our regimen of 2 mg/kg twice daily for the same duration in female 
rats.  It is important to note that results concerning anxiety and neophobia vary between 
laboratories and differences are observed between sexes (see Toufexis et al., 2006) and 
strains (Hall et al., 2000; Rex et al., 2004). 
 
6.4.2 Novel object recognition 
In the NOR task, the time spent exploring both objects in the acquisition trial was not 
significantly different between vehicle and PCP-treated rats.  There was also no 
significant difference in total exploration between the groups in the retention trial; this 
suggests that neither group of rats were experiencing neophobia when confronted with a 
novel object in the retention trial or that PCP rats found the open field anxious.  This 
result is in agreement with previous results from our laboratory (Grayson et al., 2007 
Grayson et al., 2008; Idris et al., 2009). 
In the acquisition trial of the NOR task, there was no difference in the 
exploration time of the two identical objects in either vehicle or PCP-treated rats.  In the 
retention trial, the discrimination index revealed that vehicle-treated rats could 
discriminate the novel from familiar object in the retention trial, suggesting they 
recognised the familiar object.  In the PCP-treated rats, the discrimination index 
revealed that rats could not distinguish between the novel and familiar objects, 
suggesting that PCP-treated rats did not remember the familiar object.  Although the 
time exploring the novel and familiar objects in the retention trial was not significant, 
this is likely to be due to the low numbers in the group (vehicle n=5 and PCP n=5).  
Previous studies in this laboratory have shown a significant deficit with sub-chronic 
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PCP in NOR when using 8-10 rats (Grayson et al., 2007; Grayson et al., 2008; Idris et 
al., 2009).  These results have also been supported by Hashimoto et al., (2005) who 
showed that a sub-chronic PCP dosing regimen of 10 mg/kg, s.c. once daily for 10 days, 
administered on days 1-5 and 8-12 produced a deficit in NOR, and that clozapine (5 
mg/kg) but not haloperidol (0.1 mg/kg) when administered once daily for 2 weeks, 
attenuated the deficit in object recognition in mice.  Additionally, in mice, it has been 
shown that PCP (10 mg/kg) administration for 14 days produced a deficit in NOR, an 
effect which was ameliorated by single (1 mg/kg) and repeated (0.3 and 1 mg/kg, for 7 
days) treatment with the antipsychotic aripiprazole (Nagai et al., 2009).  Furthermore, 
the attenuating effect of aripiprazole to reverse the PCP-induced deficit in object 
recognition memory was blocked by co-treatment with dopamine D1 receptor antagonist, 
SCH23390, and the serotonin 5-HT1A receptor antagonist, WAY-100635 (Nagai et al., 
2009).  Results from our laboratory have also suggested a role of D1 receptors, in that 
the D1 receptor agonist, SKF-38393, was shown to improve a PCP-induced deficit in the 
NOR task (Idris et al., 2009b).  The mechanism for this effect of PCP is not established 
yet, however, recent work in our laboratory showed that the PCP-induced deficit is 
maintained following a 1 hour inter-trial interval and may be due to increased 
susceptibility to distraction during the inter-trial interval (Grayson et al., 2008). 
 
6.4.3 Dopamine levels during NOR 
The concentration of dopamine in the PFC revealed that the basal levels in vehicle and 
PCP-treated rats were similar.  The concentrations were also comparable in all stages of 
the NOR task with the exception of the retention trial, in which a large increase in 
dopamine was observed in the vehicle treated group.  This increase was absent in the 
PCP-treated group.  This finding is comparable with the percent of basal data, where in 
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the retention trial; dopamine in vehicle rats was increased to 225% of baseline, an 
increase which was statistically significant from the basal level.  In comparison, the 
PCP-treated rats remained at 113% of baseline.  Correlation analysis, however, did not 
reveal a significant correlation between the discrimination index and percent of basal 
dopamine in the retention phase. 
 These results demonstrate a significant increase in dopamine observed during 
the retention trial of the NOR task in vehicle-treated rats.  This result is supported by 
similar data showing a significant increase in dopamine during the retention trial of the 
task (Snigdha et al., sfn abstract).  The increase in dopamine in the current study was 
selective for the retention trial.  It must be noted that within the vehicle treated group 
there is one very high value that may be skewing the data; more animals would be 
needed to confirm this finding.  This may suggest that the act of recalling the familiar 
object and therefore recognising the novel object as new is accompanied by an increase 
in dopamine in the PFC.  Thus, PCP-treated rats do not recruit prefrontal dopamine in 
the retention trial of the task and therefore perform poorly.  This study implies that a 
lack of prefrontal dopamine when required may underlie the observed cognitive deficit 
in novel object recognition.  It has been suggested that the negative and cognitive 
symptoms of schizophrenia may arise from a dopaminergic deficit in the prefrontal 
cortex (hypofrontality), whereas the positive symptoms may be related to 
hyperdopaminergic activity in mesolimbic dopaminergic neurones (Davis et al., 1991; 
Laruelle et al., 2003; this will be further discussed in chapter 7). 
This requirement for prefrontal dopamine is supported by a previous study from 
our laboratory showing that the sub-chronic PCP-induced deficit in NOR was fully 
attenuated by the dopamine D1 receptor agonist SKF-38393 (Idris et al., 2009).  
Additionally, the dopamine D1 receptor agonist, SKF-81297, has been shown to 
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improve object recognition following a 4 hour delay (Hotte et al., 2005).  Furthermore, 
chronic PCP treatment (5 mg/kg for 14 days) was shown to dramatically decrease the 
D1 dopamine receptor agonist-mediated activation of G-proteins in the PFC, indicating 
a dysfunction of D1 receptors in the PFC in chronic PCP treated rats (Guo et al., 2009).  
As previously described in chapter 3, D1 receptors are coupled to adenylyl cyclase, 
which results in an increase in cAMP and activation of protein kinase A (PKA).  Hotte 
and coworkers (2006) attribute the improvement in object recognition memory to an 
increase in the level of phosphorylation of both cAMP response element binding protein 
(CREB) and DARPP-32 in the prefrontal cortex.  CREB is a transcription factor 
believed to be important in the cascade produced by activation of D1 receptors 
(Lamprecht, 1999; Liu and Graybiel, 1996).  DARPP-32 is a major downstream target 
for dopamine signaling and PKA activation, and has been established as a crucial 
mediator of the biochemical, electrophysiological, and behavioural effects of dopamine 
(Svenningsson et al., 2004). 
 
 
6.4.4 Limitations 
It was originally planned to also measure dopamine from the nucleus accumbens (NAc) 
during the NOR task.  However, there were several methodological issues with the NAc 
data.  Firstly, in two of the rats the probes were not in the correct region and in other 
rats there were problems with the flow through the probe on the day of the experiment.  
Problems with the HPLC were also encountered with the NAc samples.  Subsequently, 
there was insufficient data to report the NAc results. 
Two vehicle-treated rats were excluded for behavioural reasons i.e. one rat 
jumped out of the NOR box and one rat did not explore the objects, these rats were 
subsequently also excluded from the bodyweight and HPLC analysis as the data was to 
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be analysed for a correlation between the DI and dopamine levels in the retention trial.  
The final number of rats (5 vehicle and 5 PCP) used in the microdialysis experiment is 
also a limitation of the study.  It would have been more useful to include more rats; 
however, due to time constraints this was not possible. 
The NOR task was performed using 10 min trials and a 10 min inter-trial 
interval.  This was to ensure that an adequate sample volume (20 µL) could be collected 
for detection by HPLC (15 µL injected onto the column).  In our laboratory this task is 
usually carried out using 3 min trials with a 1 min inter-trial interval, as generally most 
object exploration occurs within the first 2 min.  In the microdialysis experiment, 
potential increases in dopamine caused by novel object exploration may have been 
undetected within the sample as it was likely that this exploration occurred within the 
first 2-3 min; therefore there was potentially another 7-8 min of collection time in which 
dopamine levels may have returned to normal, thus diluting any increase in dopamine in 
the sample.  Sampling has been carried out over 1 min periods previously (Young et al., 
2004); however, this method was considered too complex to carry out within the 
behavioural experiments detailed in this current study. 
Probe in vitro recovery was found to be 10-15%, which merely provides an 
indication of how the probe was functioning in vitro.  It is not appropriate to apply this 
in vitro recovery as a conversion factor to calculate the concentration of dopamine in 
vivo as the probe is possibly acting differently in an in vivo situation.  Therefore, 
concentrations can only be compared to that animals‟ baseline thus these concentrations 
remain relative, and do not give an accurate measure of the actual brain concentrations 
in vivo.   
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6.4.5 Conclusions 
In summary, the novel object recognition task is a test of short term episodic memory, a 
cognitive function which was impaired (as measured by the DI) following sub-chronic 
PCP treatment.  These data demonstrate an increase in dopamine during the retention 
trial in vehicle rats which was not observed in PCP-treated rats, suggesting recruitment 
of prefrontal dopamine may be necessary for object recognition memory; however, 
more animals would be required to confirm this proposal.  This is impaired in PCP-
treated rats providing good validation of the sub-chronic PCP model for cognitive 
dysfunction in schizophrenia.  
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Chapter 7 
General Discussion 
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7.1 General Discussion 
The work presented in this thesis forms part of a larger effort by researchers working on 
schizophrenia to identify an animal model that mimics the behavioural aspects of the 
disorder and also aims to investigate the underlying neurobiology.  One of these models 
is the sub-chronic PCP model in rodents which induces disruption in behavioural tasks 
of relevance to schizophrenia.  The data presented here describes robust and 
reproducible sub-chronic PCP-induced deficits in rodent cognitive tasks.  Furthermore, 
studies were then undertaken to investigate the neurobiological changes produced by 
sub-chronic PCP in an attempt to develop an understanding of the circuit dysfunction 
underpinning the disorder. 
A summary of the behavioural results with sub-chronic PCP in this thesis are 
shown in table 7.1.1.  The effect of isolation rearing in attentional set-shifting was also 
examined.  The principal findings show that isolation reared rats exhibit impaired set-
shifting ability when compared with socially reared controls (see chapter 2).  Thus 
isolates required significantly more trials to reach criterion selectively at the EDS phase 
of testing, when compared with socially housed animals indicative of a selective deficit 
in set-shifting ability.  However, the deficits produced by sub-chronic PCP were more 
robust than the deficit produced by isolation rearing; therefore this model was further 
investigated.  Following on from the behavioural tasks, the results shown from in vitro 
electrophysiology, ex vivo immunohistochemistry and in vivo microdialysis are shown 
in table 7.1.2. 
 
 
 
 
 264 
 
Table 7.1.1: Effects of sub-chronic PCP on behaviour. 
Paradigm Chapter Brain Region Result 
Attentional set-shifting 2 mPFC 
Deficits in EDS with 
PCP 
Reversal learning 3, 4 PFC, orbital 
Deficit in reversal phase 
with PCP 
Novel object 
recognition 
6 
PFC, perirhinal 
cortex, entorhinal 
cortex 
Deficit in novel object 
recognition during the 
retention trial in PCP-
treated rats. 
Elevated plus maze 6 
Limbic structures 
e.g. amygdala 
No effect of PCP 
Open field 6 
Limbic structures 
e.g. amygdala 
No effect of PCP 
 
 
 
Table 7.1.2: Effects of sub-chronic PCP in non-behavioural techniques. 
Technique Chapter 
Brain 
Region Result 
Electrophysiology  
(in vitro) 
5 CA3, PFC 
Reduction in gamma oscillations 
2 weeks following PCP 
treatment in the CA3.  Increase 
in gamma oscillations 8 weeks 
following PCP treatment.  No 
change in PFC at either time 
point.  
Immunohistochemistry 
(ex vivo) 
5 CA2/3 
Reduction in parvalbumin IR 
cell density in the CA2/3 2 
weeks post PCP treatment.  No 
difference 8 weeks following 
PCP treatment. 
Microdialysis (in vivo) 6 PFC 
Vehicle rats show an increase in 
dopamine during the retention 
trial of the NOR task.  This 
increase in dopamine was absent 
in PCP-treated rats. 
 
 
The chief findings are summarised below:- 
(1) Sub-chronic PCP produces more pronounced effects in female rats compared to 
male rats; this may be due to differing sensitivity to PCP.  Sub-chronic PCP 
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administration was shown to impair set-shifting performance selectively in the EDS 
phase, a deficit which was significantly attenuated by sub-chronic administration of 
clozapine (2.5 mg/kg) and risperidone (0.2 mg/kg), but not haloperidol (0.05 mg/kg).  A 
deficit in set-shifting ability was also observed in isolation reared rats.  This chapter 
demonstrated that deficits in attentional set-shifting ability can be produced by sub-
chronic PCP administration and isolation rearing.  However, the deficits produced by 
PCP were more robust than the deficit produced by isolation rearing.  Therefore, the 
sub-chronic PCP model was pursued in other cognitive tests. 
(2) Sub-chronic PCP administration impairs reversal learning ability as demonstrated by 
reduced percent correct responding in the reversal phase of the reversal learning task.  It 
was found that D1 agonists, 5-HT1A partial agonists, 5-HT2C antagonists and positive 
modulators of the α7 nACh receptor are able to reverse the sub-chronic PCP-induced 
deficit in reversal learning.  Although many antipsychotics have affinity for muscarinic 
M1 and histamine H1 receptors, selective agents at these receptors were not able to 
improve the PCP-induced deficit.  From previous experiments in the literature it is 
possible that these agents may improve cognition via increasing dopamine or 
acetylcholine levels in the prefrontal cortex (see fig 7.2), the region thought to be 
involved in reversal learning ability.  For detailed discussion of the receptor 
pharmacology refer to chapter 3. 
(3) The results from chapter 4 show that the atypical antipsychotics, clozapine and 
risperidone, when given alone to naïve rats have no effect on reversal learning.  
Haloperidol when given to naïve rats impaired performance at the highest dose (0.1 
mg/kg).  Sub-chronic PCP was again found to impair reversal learning performance.  
The differences in the vehicle-treated and sub-chronic PCP-treated rats with or without 
the 2 min time-out were not significant but suggested that the 2 min time-out could be 
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important as a cue.  Following a double reversal, olanzapine-treated rats lose the ability 
to switch between the rules, possibly indicating it is not as efficacious as clozapine or 
risperidone in reversing the PCP-induced deficit.  The extended (15 min) reversal phase 
showed that PCP caused a deficit after 5 min but this effect was lost after 15 min.  
Using an extended reversal would also allow the investigation of the time-course effects 
of antipsychotics or selective compounds.   
(4) The studies presented in chapter 5 found a reduction in gamma oscillations 
following sub-chronic PCP treatment (2-5 weeks post treatment) that was paralleled by 
a deficit in parvalbumin immunoreactive cell density, at a similar time point (2 weeks 
post treatment).  In contrast, a time-dependent increase in gamma oscillations was 
observed (6-8 weeks post treatment), at which point parvalbumin IR cell density was 
unchanged (8 weeks post treatment).  These studies demonstrate a link between altered 
gamma-frequency oscillations and abnormalities in parvalbumin interneurons, which 
may underlie some of the cognitive deficits previously reported in this animal model of 
schizophrenia. 
(5) Sub-chronic PCP treatment impaired rats to distinguish between a novel and a 
familiar object following a 10 min inter-trial interval (chapter 6).  In vehicle-treated rats 
an increase in dopamine was observed in the PFC during the retention trial of the 
behavioural task.  In PCP-treated rats the levels of dopamine were unchanged in the 
retention trial.  This study may suggest that the recruitment of prefrontal dopamine is 
needed to distinguish between the novel and familiar objects. 
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7.2 The validity of the sub-chronic PCP model to mimic cognitive dysfunction 
observed in patients with schizophrenia and the relevance of the cognitive 
behavioural tasks 
Animal models are critical in understanding the mechanisms underlying many human 
diseases, and in particular psychiatric disorders.  However, an animal model of 
schizophrenia has proved to be very difficult to develop as it is mainly a thought 
disorder involving complex cortical processes which may not be expected to be found in 
lower mammals.  It is therefore unrealistic to expect a single animal model to mimic all 
aspects of schizophrenia; however, it is possible to mimic certain symptom clusters.  
Table 7.1.3 summarises the behavioural changes induced by different PCP dosage 
regimens and their relation to the clinical symptoms of schizophrenia. 
 
Table 7.1.3: Comparison of clinical symptoms of schizophrenia with the schizophrenia-
like behaviour induced by PCP (table adapted from Lipska and Weinberger, 2000). 
Clinical symptom Behavioural change Reference 
Psychotic symptoms 
An increase in locomotor 
activity 
See chapters 5 and 6 
Stereotyped behaviours 
Repetitive sniffing, face 
washing etc 
Sams-Dodd, 1998; Linn 
et al., 2007 
Vulnerability to stress 
Changes in locomotor activity 
or behaviour induced by stress 
Jentsch et al., 1998 
Information processing 
deficits 
Deficits in PPI Egerton et al., 2008 
Attentional deficits 
Deficits in 5-choice serial 
reaction time task 
Amitai et al., 2007; 
Amitai and Markou, 
2009 
Cognitive deficits 
Deficits in attentional set-
shifting, reversal learning and 
novel object recognition 
memory 
See chapters 2,3 and 6 of 
this thesis 
Social withdrawal Deficits in social interaction 
Sams-Dodd, 1998; 
Snigdha and Neill, 
2008a,b 
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Whilst impairments have been reported across all of the cognitive domains identified by 
the MATRICS initiative (see chapter 1), impairments in executive function have long 
been considered to be a core feature of schizophrenia (Elvevag and Goldberg, 2000; 
Nuechterlein and Dawson, 1984; Sullivan et al., 1994).  One aspect of executive 
function is the ability to modify behaviour in response to the changing relevance of a 
stimulus; this is commonly assessed in patients using the Wisconsin Card Sorting Test 
(WCST) (Berg, 1948).  The attentional set-shifting task represents a rat analogue of the 
human Wisconsin Card Sorting Task (WCST, Berg, 1948) and CANTAB ID/ED task 
(Downes et al., 1989) in which patients with schizophrenia exhibit impaired set-shifting 
(Kolb and Wishaw, 1983; Haut et al., 1996; Pantelis et al., 1999; Tyson et al., 2004).  It 
was shown that clozapine and risperidone, but not haloperidol reversed the sub-chronic 
PCP-induced deficit in the EDS phase of the attentional set-shifting task (chapter 2).  It 
was also shown that clozapine, olanzapine (chapter 4) and risperidone (chapters 3 and 4) 
reversed the PCP-induced deficit in the reversal learning task.  Effective performance in 
the reversal learning task requires intact cognitive ability; thus animals are required to 
demonstrate flexibility, attention, motivation, and ability to suppress a previously 
learned response and implement a new one (Jones et al., 1991).  Both the reversal 
learning and attentional set-shifting tasks have been identified by the TURNS initiative 
as tests that can be used to determine the reasoning and problem solving deficits 
described in the MATRICS cognitive battery (www.turns.ucla.edu). 
Deficits in the novel object recognition task (Ennaceur and Delacour, 1988) 
were also observed following sub-chronic PCP treatment.  The MATRICS initiative 
categorised the novel object recognition task as relevant to visual learning and memory.  
It has been shown that visual recognition memory is impaired in patients with 
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schizophrenia (Calkins et al., 2005).   Data in this thesis may suggest a role for 
dopamine in object recognition memory as an increase in prefrontal dopamine was 
found in the retention trial of the task in vehicle-treated rats (chapter 6); however, more 
animals would be required to confirm this proposal.  The effect of antipsychotics was 
not investigated in this study, but other results from our laboratory have found clozapine 
and risperidone to improve the PCP-induced deficit (Grayson et al., 2007).  Furthermore, 
it was shown that clozapine and risperidone increased dopamine acetylcholine in the 
mPFC, but only sertindole increased glutamate levels (see Mork et al., 2009). 
The results from this thesis suggest that the sub-chronic PCP model is able to 
induce cognitive deficits similar to those seen in patients with schizophrenia.  Sub-
chronic PCP has also altered gamma oscillations and parvalbumin IR cell density, 
suggesting GABAergic deficits, as well as dopamine hypofunction in the PFC during 
the novel object recognition task.  It was also shown that atypical but not typical 
antipsychotics were able to reverse the PCP-induced deficits in attentional set-shifting 
and reversal learning, therefore providing predictive validity.  However, the Clinical 
Antipsychotic Trials of Invention Effectiveness (CATIE) study revealed that atypical 
antipsychotics, such as clozapine, show little improvement compared to typical 
antipsychotics, against cognitive symptoms (Lieberman, 2006; Keefe et al., 2007).  
Although this is a valid concern, it is important to note that this study did not 
incorporate young patients or patients with first episode psychosis.  Therefore, it may be 
possible that atypical antipsychotics could show improvement if given early.  It is also 
important to remember that we are using animals to mimic aspects of a uniquely human 
condition; humans who may have a genetic and neurodevelopmental predisposition for 
the disorder.  Patients are also prescribed a considerable amount of medication and are 
abusing numerous psychoactive agents, including being avid smokers and have varied 
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and often traumatic life experiences.  In marked contrast, our animals have no genetic 
predisposition (unless transgenic mice are used), no previous drug history and no 
current drug abuse.  Instead they are genetically identical (if using an inbred strain) and 
live in optimum conditions (lighting, noise level, humidity etc) for that species with 
minimum stress.  Subsequently this makes them ideal for our research but also makes it 
even harder to fully mimic a human disorder (particularly a psychiatric disorder) and 
this caveat is important to recognise.   
 
7.3 The possible mechanism of action of PCP 
The behavioural deficits in this thesis are possibly due to decreased dopamine in the 
PFC.  In particular, this was demonstrated in the novel object recognition study.  
Treatment with NMDA antagonists induces disruption of the glutamatergic system.  
However, unlike acute treatment which increases glutamate release in the brain, sub-
chronic treatment with NMDA antagonists induces a decrease in glutamate release in 
the frontal cortex (Zuo et al., 2006).  In addition, sub-chronic PCP treatment produces 
hypofunction of mesocortical dopamine neurons and hyperactivity of mesolimbic 
dopamine neurons (Jentsch et al., 1998).  Similar changes in the dopaminergic and 
glutamatergic systems have been found in schizophrenia patients (Kim et al., 1980; Tsai 
et al., 1995; Breier et al., 1997).  The mechanism by which prolonged or sub-chronic 
PCP treatment leads to dopaminergic dysfunction is currently unknown, but it is 
suggested that subcortical efflux of dopamine along with cortical dopamine 
hypofunction is responsible for the cognitive deficits induced by NMDA receptor 
antagonists such as PCP and ketamine (Jentsch et al., 1997).  It has been suggested that 
acute PCP increases dopamine via the GABAergic disinhibition of dopaminergic and 
glutamatergic neurons (see figure 7.1 bottom panel).  Sub-chronic PCP is then thought 
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to show reduced levels of dopamine and glutamate due to compensatory changes, such 
as alteration in postsynaptic receptor density (see Jentsch and Roth, 1999).  In addition 
to the dopaminergic and glutamatergic systems, PCP has also been shown to affect the 
serotonergic system.  Systemic administration of acute PCP was shown to increase 5-
HT release in the nucleus accumbens (Millan et al., 1999), suggesting that PCP (acutely) 
can enhance the serotonergic function, which can subsequently be blocked by 5-HT2A 
receptor antagonist (Idris et al., 2008); an important pharmacological aspect of 
antipsychotics (Schmidt et al., 1995; Meltzer, 1989).  It has also been shown that 
repeated PCP administration results in an increase in 5-HT utilisation in the PFC under 
stress (Noda et al., 2000).  Results from this thesis (chapter 3) have shown that 
serotonergic compounds improved the sub-chronic PCP-induced deficit in reversal 
learning.  The discussion of chapter 3 suggests that these compounds improve cognition 
by increasing dopamine in the PFC and nucleus accumbens (Ichikawa and Meltzer, 
1990; Di Matteo et al., 2001), which would presumably reverse the changes induced by 
sub-chronic PCP in figure 7.1 (bottom panel). 
Results from chapter 5 showed significant decreases in both gamma frequency 
oscillations and parvalbumin IR cell density in the CA2/3 region of the hippocampus at 
2-5 weeks and 2 weeks following PCP treatment respectively.  In a normal brain these 
interactions between interneurons and pyramidal cells are perfectly balanced and 
synchronised.  Reductions in gamma oscillations and parvalbumin IR density are also 
observed in patients with schizophrenia (Benes and Berretta, 2001; Reynolds et al., 
2002; Zhang and Reynolds, 2002; Lewis et al., 2005; González-Hernández et al., 2003; 
Cho et al., 2006).  Therefore, it could be suggested that these neurobiological changes 
induced by sub-chronic PCP may underly the cognitive deficits also observed in 
schizophrenia and the sub-chronic PCP animal model.  The cognitive deficits observed 
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in our animal model are apparant up to 6 months post PCP treatment (Grayson and Idris, 
personal communication).  However, the gamma oscillations at 6-8 weeks post PCP 
treatment were increased compared to the vehicle-treated group, and this was 
accompanied by no change in parvalbumin IR cell density at 8 weeks post PCP 
treatment.  This suggests that a time-dependent compensatory mechanism is possibly 
recovering the gamma oscillations and parvalbumin IR cell density.  It is suggested that 
blocking NMDA receptors on interneurons changes the phenotype of the neurons.  If 
the PV interneurons are still present but are not expressing parvalbumin, this may allow 
PV expression to be increased with time due to compensatory mechanisms, such a 
mechanism may involve the increase in NMDA receptors or NMDA receptor subunits.  
It is also not possible to say whether the levels of expression return to normal because 
we can only measure whether expression is there or not, rather than quantifying the 
levels. 
Though gamma oscillations were found to increase over time, this may still 
cause cognitive deficits, as it still represents an unsynchronised network of GABA 
interneurons and pyramidal cells.  Indeed, it has been shown that both decreases and 
increases in gamma oscillations are found in patients with schizophrenia (Light et al., 
2006).  In this thesis it was shown that there was a reduction in parvalbumin IR cell 
density in the CA2/3 region of the hippocampus at 2 weeks following PCP treatment; 
however cell density was unchanged at 8 weeks following PCP.  Immunohistochemistry 
does not allow us to determine whether these reductions are due to a diminished number 
of PV-containing interneurons or a down-regulation of parvalbumin expression, i.e. 
rendering the neurons in a less excitable state (Kohr et al., 1991).  If the latter case was 
true it may be possible for this functionality to return over time.  
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If these deficits in GABAergic neurotransmission are underpinning the cognitive 
deficits observed in our model, then another mechanism must also be producing 
cognitive deficits in order for the deficits in cognition to be observed 6 months 
following PCP treatment.  This could be the lack of prefrontal dopamine recruitment 
during the cognitive task.   
 Results from this thesis also suggest a role for dopamine in cognition.  The D1 
receptor agonist SKF-38393 was shown to improve the PCP-induced deficit in reversal 
learning.  Furthermore, it was found that in vehicle-treated rats performing the NOR 
task there was a significant increase in dopamine in the PFC which was selective for the 
retention phase of the task i.e. dopamine was only increased when the rats were exposed 
to the novel object.  This increase in prefrontal dopamine during the retention trial was 
absent in the PCP-treated rats.  Therefore, this data may suggest a role for dopamine in 
NOR memory.  This lack of dopamine recruitment may be due to disinhibition of the 
GABAergic system, which initially increases dopamine and glutamate, but sub-chronic 
PCP induces compensatory reduction in glutamate and dopamine in the frontal cortex.  
The GABAergic deficits in this thesis were found to recover after time, but it was not 
determined whether the dopaminergic deficit in the PFC recovered.  It would be 
interesting to determine whether these deficits persist along with the behavioural 
impairments. 
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Figure 7.1 
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Figure 7.1: Schematic diagram of the findings in this thesis in vehicle-treated rats 
(top) and PCP-treated rats (bottom): a proposed mechanism of action.  Top: (1) 
Depolarisation of neuronal membrane which results in (2) Mg
2+
 blockade of the NMDA 
receptor being removed, allowing (3) Ca
2+
 efflux is required for GABA neurons to 
function. (4) Parvalbumin IR cell density is normal in the CA2/3 region of the 
hippocampus. (5) Synchronous firing between interneurons and pyramidal cells 
produces gamma oscillations. (6)  GABA inhibits the release, therefore controlling the 
levels of DA and Glu in the frontal cortex, resulting in normal behaviour. (7) In vivo 
microdialysis revealed an increase in DA in the PFC during the retention trial of the 
NOR task.  Bottom: (1) Depolarisation of neuronal membrane which results in (2) Mg
2+
 
blockade of the NMDA receptor being removed, following which (3) PCP binds to its 
site, (4) preventing Ca
2+
 efflux required for GABA neurons to function. (5) Parvalbumin 
IR cell density was reduced in the CA2/3 region of the hippocampus. (6) Lack of 
synchronous firing between interneurons and pyramidal cells produced a time-
dependent reduction, then increase in gamma oscillations. (7) Dysfunction of GABA 
transmission results in disinhibition and therefore increased excitatory transmission, 
thus increasing DA and Glu following acute PCP. (8) Reduced DA and Glu levels are 
thought to be due to compensatory changes leading to a hypofunctional state resulting in 
the cognitive deficits described in this thesis. (9) An example of this is the lack of 
prefrontal DA recruitment in the retention trial of the NOR task. 
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7.4 The mechanisms of action of antipsychotics 
From the experiments in the chapter 3 it is evident that D1 receptor agonists, 5-HT1A 
receptor partial agonists, 5-HT2C receptor antagonists and positive modulators of the 
alpha 7 nACh receptor are able to reverse the sub-chronic PCP-induced deficit in 
reversal learning.  Although many antipsychotics have affinity for muscarinic M1 and 
histamine H1 receptors, selective agents at these receptors were not able to improve the 
PCP-induced deficit.  From previous experiments in the literature it is possible that 
these agents may improve cognition via increasing dopamine or acetylcholine levels in 
the prefrontal cortex (see fig 7.2). 
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Figure 7.2: Summary diagram of the possible mechanisms involved in the attenuation of the sub-chronic 
PCP-induced deficit.  Abbreviations: acetylcholine (ACh), dopamine (DA), prefrontal cortex (PFC); 
nucleus accumbens (NAcc), substantia nigra (SN), ventral tegmental area (VTA). Solid lines indicate 
agonism or activation, dotted lines indicate antagonism.  Red highlights increases in ACh and blue 
highlights increases in DA. 
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Although the effects in the gamma oscillations and parvalbumin studies (chapter 5) 
appear to be time-dependent, the evidence here and in the literature does suggest a role 
of GABAergic neurotransmission in schizophrenia.  It should be an aim of antipsychotic 
treatment to reverse the deficits in PV expression.  In a rodent model of schizophrenia 
using chronic PCP treatment it was shown that clozapine reversed the PCP-induced 
deficits in PV expression (Cochran et al., 2003). Furthermore, it was shown that co-
administration of SSR180711, an α7 nAChR agonist, prevented the PV and behavioural 
deficits (Thomsen et al., 2009).  Indeed, the GABAA receptor could be a novel target for 
cognitive dysfunction associated with schizophrenia.  For example the positive 
allosteric modulator of GABAA receptors, MK-0777, was shown to have high 
selectivity for the α2/α3 subunits and was found to improve working memory in 
schizophrenia patients; furthermore it was also shown to increase gamma power during 
the Preparing to Overcome Prepotency task (Lewis et al., 2008).  This cognitive task is 
a cued stimulus-response reversal paradigm that requires increases in cognitive control 
through the maintenance and use of context information to overcome prepotent response 
tendencies (Cho et al., 2006). 
 
7.5 Future Studies 
The attentional set-shifting studies revealed that a single dose of the atypical 
antipsychotics reversed the PCP-induced deficit.  However, if receptor selective 
compounds were to be used a dose-response would need to be carried out.  This task is 
not ideal for carrying out multiple doses due to the time taken to carry out the 
experiments.  Therefore, it would be advantageous to carry out a quicker experiment in, 
for example, the novel object recognition task to obtain an efficacious dose to carry 
forward to be tested in attentional set-shifting.  Isolation rearing also produced a 
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significant deficit in the EDS phase of the attentional set-shifting task; however, the 
data were more consistent using the sub-chronic PCP model.  It may be interesting to 
combine these two models in order to obtain a cognitive deficit that is more difficult to 
reverse.  This would also combine a pharmacological model with a neurodevelopmental 
model, which may more closely mimic the brain disturbances observed in schizophrenia. 
The attentional set-shifting task has been shown to be dependent on the medial 
PFC (Birrell and Brown, 2000).  However, lesion studies have not been carried out in an 
operant reversal learning task.  Therefore, it would be beneficial to carry out lesion 
studies (possibly of the OFC) in our operant reversal learning task to determine which 
region is involved in the task.  From the results in chapter 4, it may be possible to 
distinguish between antipsychotics efficacies by using the extended reversal learning 
phase or the double reversal.  Thus, the experiments in chapter 3 using selective 
compounds could be repeated with the aim that it could be determined how quickly the 
drugs begin to reverse the PCP-induced deficit.  In addition, the use of the double 
reversal (or even multiple reversal) task could differentiate antipsychotics in that the 
more efficacious drugs would be able to continue reversing the deficit when the rule is 
repeatedly switched.  All of the experiments carried out in the reversal learning task, 
tested compounds acutely.  More studies utilising long-term treatment regimes with 
testing post-dosing could provide a better insight into the effects of drugs that are more 
likely to result in molecular/pathological changes and that could abolish cognitive 
dysfunction in the long-term and provide a real benefit for patients.  
The in vitro electrophysiology data revealed a time-dependent effect of sub-
chronic PCP on gamma oscillations in the CA2/3 region of the hippocampus.  There 
was no observed effect in the PFC; however, this was probably due to the small signal.  
Gamma oscillations are more prevalent in regions with recurring architecture, other 
 279 
 
regions to be studied for gamma oscillations include the entrorhinal and perirhinal 
cortices, and it has been suggested that these parahippocampal regions are involved in 
object recognition memory (Aggleton et al., 1997).  Studies could also be carried out 
using antipsychotics or selective receptor compounds to investigate whether the PCP-
induced reduction in gamma oscillations (observed in weeks 2-5) could be restored.  
Studies could also be carried out using cognitive enhancers such as α7 nACh receptor 
agonists or positive allosteric modulators to see if the gamma oscillations in vehicle or 
drug-naive rats can be enhanced.  The role of specific GABAA receptor subunits could 
also be investigated as these are altered in schizophrenia (Hashimoto et al., 2008). 
In the in vivo microdialysis experiment, due to methodological problems, the 
final number of rats (5 vehicle and 5 PCP) was a limitation of the study.  It would have 
been beneficial to include more rats; however, due to time constraints this was not 
possible.  Future studies using in vivo microdialysis may also include the use of 
antipsychotics to elucidate whether the lack of prefrontal dopamine in PCP-treated rats 
could be restored; this would help to identify the mechanistic properties of 
antipsychotics.  The NOR task was performed using 10 min trials and a 10 min inter-
trial interval.  This was to ensure that an adequate sample volume (20 µL) could be 
collected for detection by HPLC (15 µL injected onto the column).  In our laboratory 
this task is usually carried out using 3 min trials with a 1 min inter-trial interval, as 
generally most object exploration occurs within the first 2 min.  Although 1 min 
sampling has been carried out (Young et al., 2004), it may also be interesting to utilise 
in vivo fast-cyclic voltametry to measure bursts of dopamine activity.  Additional 
utilisation of in vivo microdialysis could be extended to the reversal learning task, 
although, this would require 5 min sampling, unless the extended reversal phase was 
used. 
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It is noteworthy that the sub-chronic PCP model in adults does not account for 
the developmental aspects of schizophrenia.  This is perhaps a limitation of the sub-
chronic PCP model.  In chapter 2, an isolation rearing model was utilised to examine 
differences in attentional set-shifting ability; however, although deficits were induced in 
the relevant stage of the task, this deficit was not as robust as in the sub-chronic PCP 
model.  It may be useful to produce a pharmacological early insult, such as a neo-natal 
PCP model to investigate whether the cognitive deficits observed in adults would differ 
and indeed to ascertain whether behavioural deficits emerge only after puberty.  Studies 
have been carried out using a neonatal PCP regimen in attentional set-shifting (Broberg 
et al., 2008; 2009). 
 
7.6 Conclusions 
Schizophrenia remains a disorder caused by largely unknown factors including 
susceptibility genes, dysfunction of multiple neurotransmitter systems, and 
environmental factors.  One or several of these factors presents diverse clinical 
symptoms.  The complexity of schizophrenia has presented the scientific research 
community with a complicated challenge to develop a valid animal model of the 
disorder. 
The behavioural and neurobiological data presented in this thesis strongly argue 
for considerable validity of a sub-chronic PCP dosage regimen in female rats as an 
effective model of schizophrenia.  This model may, therefore, provide an excellent 
research tool into the mechanisms underpinning cognitive dysfunction observed in 
schizophrenia.  Furthermore, the model may potentially predict the clinical response and 
functional outcome of schizophrenic patients to novel antipsychotic pharmacological 
therapies.     
 281 
 
Appendix 1 – Attentional Set-shifting score sheet 
 
 
TRAINING 
 
1.  5 min habituation to empty test box. 
 
2.  Shaping to dig 
 a)  bowls + reward         
 b)  bowls + reward on 1 cm media    
 c)  bowls + reward on 1cm media under thin layer    
 d)  bowls + reward on 1cm media under thick layer      
 
3.  SD - Medium 
  
Trial L R Correct Trial L R Correct 
1 M2 M1  13 M2 M1  
2 M1 M2  14 M1 M2  
3 M1 M2  15 M2 M1  
4 M2 M1  16 M1 M2  
5 M1 M2  17 M1 M2  
6 M2 M1  18 M1 M2  
7 M2 M1  19 M2 M1  
8 M1 M2  20 M2 M1  
9 M2 M1  21 M1 M2  
10 M2 M1  22 M1 M2  
11 M1 M2  23 M2 M1  
12 M1 M2  24 M1 M2  
 
4.  SD - Odour 
 
Trial L R Correct Trial L R Correct 
1 O2 O1  13 O2 O1  
2 O1 O2  14 O1 O2  
3 O1 O2  15 O2 O1  
4 O2 O1  16 O1 O2  
5 O1 O2  17 O1 O2  
6 O2 O1  18 O1 O2  
7 O2 O1  19 O2 O1  
8 O1 O2  20 O2 O1  
9 O2 O1  21 O1 O2  
10 O2 O1  22 O1 O2  
11 O1 O2  23 O2 O1  
12 O1 O2  24 O1 O2  
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      SD  Relevant Dimension:  Media  Correct Exemplar:  M1 Rat   Date  Total Time 
      
               
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 M1  M2    40 M1  M2    
M1 M2  18 M1  M2    41 M1  M2    
M2 M1  19 M2  M1    42 M2  M1    
M2 M1  20 M2  M1    43 M1  M2    
M1 M2  21 M1  M2    44 M2  M1    
Set-shifting 22 M1  M2    45 M2  M1    
Trial L R Correct Both 23 M2  M1    46 M1  M2    
1 M2  M1    24 M1  M2    47 M2  M1    
2 M1  M2    25 M2  M1    48 M2  M1    
3 M1  M2    26 M2  M1    49 M1  M2    
4 M2  M1    27 M1  M2    50 M1  M2    
5 M1  M2    28 M2  M1    51 M2  M1    
6 M2  M1    29 M2  M1    52 M1  M2    
7 M2  M1    30 M1  M2    53 M2  M1    
8 M1  M2    31 M1  M2    54 M1  M2    
9 M2  M1    32 M2  M1    55 M2  M1    
10 M2  M1    33 M1  M2    56 M2  M1    
11 M1  M2    34 M2  M1    57 M2  M1    
12 M1  M2    35 M1  M2    58 M1  M2    
13 M2  M1    36 M1  M2    59 M1  M2    
14 M1  M2    37 M1  M2    60 M2  M1    
15 M2  M1    38 M2  M1     
Abort if >60 trials needed = failed set 
16 M1  M2    39 M2  M1    
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      CD  Relevant Dimension:  Media Correct Exemplar:  M1 +O1/O2 Rat  Date  Total time 
 
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 M1 ,O1 M2 ,O2   40 M1 ,O2 M2 ,O1   
M2 ,O2 M1 ,O1  18 M1 ,O2 M2 ,O1   41 M1 ,O1 M2 ,O2   
M1 ,O2 M2 ,O1  19 M2 ,O2 M1 ,O1   42 M2 ,O2 M1 ,O1   
M1 ,O1 M2 ,O2  20 M2 ,O2 M1 ,O1   43 M1 ,O2 M2 ,O1   
M2 ,O1 M1 ,O2  21 M1 ,O2 M2 ,O1   44 M2 ,O1 M1 ,O2   
Set-shifting 22 M1 ,O1 M2 ,O2   45 M2 ,O2 M1 ,O1   
Trial L R Correct Both 23 M2 ,O2 M1 ,O1   46 M1 ,O2 M2 ,O1   
1 M2 ,O2 M1 ,O1   24 M1 ,O2 M2 ,O1   47 M2 ,O2 M1 ,O1   
2 M1 ,O2 M2 ,O1   25 M2 ,O1 M1 ,O2   48 M2 ,O1 M1 ,O2   
3 M1 ,O1 M2 ,O2   26 M2 ,O2 M1 ,O1   49 M1 ,O1 M2 ,O2   
4 M2 ,O2 M1 ,O1   27 M1 ,O2 M2 ,O1   50 M1 ,O2 M2 ,O1   
5 M1 ,O2 M2 ,O1   28 M2 ,O2 M1 ,O1   51 M2 ,O2 M1 ,O1   
6 M2 ,O1 M1 ,O2   29 M2 ,O1 M1 ,O2   52 M1 ,O1 M2 ,O2   
7 M2 ,O2 M1 ,O1   30 M1 ,O1 M2 ,O2   53 M2 ,O1 M1 ,O2   
8 M1 ,O2 M2 ,O1   31 M1 ,O2 M2 ,O1   54 M1 ,O2 M2 ,O1   
9 M2 ,O2 M1 ,O1   32 M2 ,O2 M1 ,O1   55 M1 ,O1 M2 ,O2   
10 M2 ,O1 M1 ,O2   33 M1 ,O1 M2 ,O2   56 M1 ,O2 M2 ,O1   
11 M1 ,O1 M2 ,O2   34 M2 ,O1 M1 ,O2   57 M2 ,O2 M1 ,O1   
12 M1 ,O2 M2 ,O1   35 M1 ,O2 M2 ,O1   58 M2 ,O2 M1 ,O1   
13 M2 ,O2 M1 ,O1   36 M1 ,O1 M2 ,O2   59 M1 ,O2 M2 ,O1   
14 M1 ,O1 M2 ,O2   37 M1 ,O2 M2 ,O1   60 M1 ,O1 M2 ,O2   
15 M2 ,O1 M1 ,O2   38 M2 ,O2 M1 ,O1    
Abort if >60 trials needed = failed set 
16 M1 ,O2 M2 ,O1   39 M2 ,O2 M1 ,O1   
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      R1  Relevant Dimension:  Media Correct Exemplar:  M2 +O1/O2 Rat  Date  Total time   
  
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 M1 ,O1 M2 ,O2   40 M1 ,O2 M2 ,O1   
M2 ,O2 M1 ,O1  18 M1 ,O2 M2 ,O1   41 M1 ,O1 M2 ,O2   
M1 ,O2 M2 ,O1  19 M2 ,O2 M1 ,O1   42 M2 ,O2 M1 ,O1   
M1 ,O1 M2 ,O2  20 M2 ,O2 M1 ,O1   43 M1 ,O2 M2 ,O1   
M2 ,O1 M1 ,O2  21 M1 ,O2 M2 ,O1   44 M2 ,O1 M1 ,O2   
Set-shifting 22 M1 ,O1 M2 ,O2   45 M2 ,O2 M1 ,O1   
Trial L R Correct Both 23 M2 ,O2 M1 ,O1   46 M1 ,O2 M2 ,O1   
1 M2 ,O2 M1 ,O1   24 M1 ,O2 M2 ,O1   47 M2 ,O2 M1 ,O1   
2 M1 ,O2 M2 ,O1   25 M2 ,O1 M1 ,O2   48 M2 ,O1 M1 ,O2   
3 M1 ,O1 M2 ,O2   26 M2 ,O2 M1 ,O1   49 M1 ,O1 M2 ,O2   
4 M2 ,O2 M1 ,O1   27 M1 ,O2 M2 ,O1   50 M1 ,O2 M2 ,O1   
5 M1 ,O2 M2 ,O1   28 M2 ,O2 M1 ,O1   51 M2 ,O2 M1 ,O1   
6 M2 ,O1 M1 ,O2   29 M2 ,O1 M1 ,O2   52 M1 ,O1 M2 ,O2   
7 M2 ,O2 M1 ,O1   30 M1 ,O1 M2 ,O2   53 M2 ,O1 M1 ,O2   
8 M1 ,O2 M2 ,O1   31 M1 ,O2 M2 ,O1   54 M1 ,O2 M2 ,O1   
9 M2 ,O2 M1 ,O1   32 M2 ,O2 M1 ,O1   55 M1 ,O1 M2 ,O2   
10 M2 ,O1 M1 ,O2   33 M1 ,O1 M2 ,O2   56 M1 ,O2 M2 ,O1   
11 M1 ,O1 M2 ,O2   34 M2 ,O1 M1 ,O2   57 M2 ,O2 M1 ,O1   
12 M1 ,O2 M2 ,O1   35 M1 ,O2 M2 ,O1   58 M2 ,O2 M1 ,O1   
13 M2 ,O2 M1 ,O1   36 M1 ,O1 M2 ,O2   59 M1 ,O2 M2 ,O1   
14 M1 ,O1 M2 ,O2   37 M1 ,O2 M2 ,O1   60 M1 ,O1 M2 ,O2   
15 M2 ,O1 M1 ,O2   38 M2 ,O2 M1 ,O1    
Abort if >60 trials needed = failed set 
16 M1 ,O2 M2 ,O1   39 M2 ,O2 M1 ,O1   
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      IDS  Relevant Dimension:  Media Correct Exemplar:  M3+O3/O4 Rat  Date  Total time 
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 M4,O4 M3,O3   40 M4,O3 M3,O4   
M3,O3 M4,O4  18 M4,O3 M3,O4   41 M4,O4 M3,O3   
M4,O3 M3,O4  19 M3,O3 M4,O4   42 M3,O3 M4,O4   
M4,O4 M3,O3  20 M3,O3 M4,O4   43 M4,O3 M3,O4   
M3,O4 M4,O3  21 M4,O3 M3,O4   44 M3,O4 M4,O3   
Set-shifting 22 M4,O4 M3,O3   45 M3,O3 M4,O4   
Trial L R Correct Both 23 M3,O3 M4,O4   46 M4,O3 M3,O4   
1 M3,O3 M4,O4   24 M4,O3 M3,O4   47 M3,O3 M4,O4   
2 M4,O3 M3,O4   25 M3,O4 M4,O3   48 M3,O4 M4,O3   
3 M4,O4 M3,O3   26 M3,O3 M4,O4   49 M4,O4 M3,O3   
4 M3,O3 M4,O4   27 M4,O3 M3,O4   50 M4,O3 M3,O4   
5 M4,O3 M3,O4   28 M3,O3 M4,O4   51 M3,O3 M4,O4   
6 M3,O4 M4,O3   29 M3,O4 M4,O3   52 M4,O4 M3,O3   
7 M3,O3 M4,O4   30 M4,O4 M3,O3   53 M3,O4 M4,O3   
8 M4,O3 M3,O4   31 M4,O3 M3,O4   54 M4,O3 M3,O4   
9 M3,O3 M4,O4   32 M3,O3 M4,O4   55 M4,O4 M3,O3   
10 M3,O4 M4,O3   33 M4,O4 M3,O3   56 M4,O3 M3,O4   
11 M4,O4 M3,O3   34 M3,O4 M4,O3   57 M3,O3 M4,O4   
12 M4,O3 M3,O4   35 M4,O3 M3,O4   58 M3,O3 M4,O4   
13 M3,O3 M4,O4   36 M4,O4 M3,O3   59 M4,O3 M3,O4   
14 M4,O4 M3,O3   37 M4,O3 M3,O4   60 M4,O4 M3,O3   
15 M3,O4 M4,O3   38 M3,O3 M4,O4    
Abort if >60 trials needed = failed set 
16 M4,O3 M3,O4   39 M3,O3 M4,O4   
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     R2  Relevant Dimension:  Media Correct Exemplar:  M4+O3/O4 Rat  Date  Total time 
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 M4,O4 M3,O3   40 M4,O3 M3,O4   
M3,O3 M4,O4  18 M4,O3 M3,O4   41 M4,O4 M3,O3   
M4,O3 M3,O4  19 M3,O3 M4,O4   42 M3,O3 M4,O4   
M4,O4 M3,O3  20 M3,O3 M4,O4   43 M4,O3 M3,O4   
M3,O4 M4,O3  21 M4,O3 M3,O4   44 M3,O4 M4,O3   
Set-shifting 22 M4,O4 M3,O3   45 M3,O3 M4,O4   
Trial L R Correct Both 23 M3,O3 M4,O4   46 M4,O3 M3,O4   
1 M3,O3 M4,O4   24 M4,O3 M3,O4   47 M3,O3 M4,O4   
2 M4,O3 M3,O4   25 M3,O4 M4,O3   48 M3,O4 M4,O3   
3 M4,O4 M3,O3   26 M3,O3 M4,O4   49 M4,O4 M3,O3   
4 M3,O3 M4,O4   27 M4,O3 M3,O4   50 M4,O3 M3,O4   
5 M4,O3 M3,O4   28 M3,O3 M4,O4   51 M3,O3 M4,O4   
6 M3,O4 M4,O3   29 M3,O4 M4,O3   52 M4,O4 M3,O3   
7 M3,O3 M4,O4   30 M4,O4 M3,O3   53 M3,O4 M4,O3   
8 M4,O3 M3,O4   31 M4,O3 M3,O4   54 M4,O3 M3,O4   
9 M3,O3 M4,O4   32 M3,O3 M4,O4   55 M4,O4 M3,O3   
10 M3,O4 M4,O3   33 M4,O4 M3,O3   56 M4,O3 M3,O4   
11 M4,O4 M3,O3   34 M3,O4 M4,O3   57 M3,O3 M4,O4   
12 M4,O3 M3,O4   35 M4,O3 M3,O4   58 M3,O3 M4,O4   
13 M3,O3 M4,O4   36 M4,O4 M3,O3   59 M4,O3 M3,O4   
14 M4,O4 M3,O3   37 M4,O3 M3,O4   60 M4,O4 M3,O3   
15 M3,O4 M4,O3   38 M3,O3 M4,O4    
Abort if >60 trials needed = failed set 
16 M4,O3 M3,O4   39 M3,O3 M4,O4   
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    EDS  Relevant Dimension:  Odour Correct Exemplar:  O5+,M5/M6 Rat  Date  Total time 
 
 
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 O6,M6 O5,M5   40 O6,M5 O5,M6   
O5,M5 O6,M6  18 O6,M5 O5,M6   41 O6,M6 O5,M5   
O6,M5 O5,M6  19 O5,M5 O6,M6   42 O5,M5 O6,M6   
O6,M6 O5,M5  20 O5,M5 O6,M6   43 O6,M5 O5,M6   
O5,M6 O6,M5  21 O6,M5 O5,M6   44 O5,M6 O6,M5   
Set-shifting 22 O6,M6 O5,M5   45 O5,M5 O6,M6   
Trial L R Correct Both 23 O5,M5 O6,M6   46 O6,M5 O5,M6   
1 O5,M5 O6,M6   24 O6,M5 O5,M6   47 O5,M5 O6,M6   
2 O6,M5 O5,M6   25 O5,M6 O6,M5   48 O5,M6 O6,M5   
3 O6,M6 O5,M5   26 O5,M5 O6,M6   49 O6,M6 O5,M5   
4 O5,M5 O6,M6   27 O6,M5 O5,M6   50 O6,M5 O5,M6   
5 O6,M5 O5,M6   28 O5,M5 O6,M6   51 O5,M5 O6,M6   
6 O5,M6 O6,M5   29 O5,M6 O6,M5   52 O6,M6 O5,M5   
7 O5,M5 O6,M6   30 O6,M6 O5,M5   53 O5,M6 O6,M5   
8 O6,M5 O5,M6   31 O6,M5 O5,M6   54 O6,M5 O5,M6   
9 O5,M5 O6,M6   32 O5,M5 O6,M6   55 O6,M6 O5,M5   
10 O5,M6 O6,M5   33 O6,M6 O5,M5   56 O6,M5 O5,M6   
11 O6,M6 O5,M5   34 O5,M6 O6,M5   57 O5,M5 O6,M6   
12 O6,M5 O5,M6   35 O6,M5 O5,M6   58 O5,M5 O6,M6   
13 O5,M5 O6,M6   36 O6,M6 O5,M5   59 O6,M5 O5,M6   
14 O6,M6 O5,M5   37 O6,M5 O5,M6   60 O6,M6 O5,M5   
15 O5,M6 O6,M5   38 O5,M5 O6,M6    
Abort if >60 trials needed = failed set 
16 O6,M5 O5,M6   39 O5,M5 O6,M6   
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     R3  Relevant Dimension:  Odour Correct Exemplar:  O6+M5/M6 Rat  Date  Total time 
 
 
Discovery trials Trial L R Correct Both Trial L R Correct Both 
L R Done 17 O6,M6 O5,M5   40 O6,M5 O5,M6   
O5,M5 O6,M6  18 O6,M5 O5,M6   41 O6,M6 O5,M5   
O6,M5 O5,M6  19 O5,M5 O6,M6   42 O5,M5 O6,M6   
O6,M6 O5,M5  20 O5,M5 O6,M6   43 O6,M5 O5,M6   
O5,M6 O6,M5  21 O6,M5 O5,M6   44 O5,M6 O6,M5   
Set-shifting 22 O6,M6 O5,M5   45 O5,M5 O6,M6   
Trial L R Correct Both 23 O5,M5 O6,M6   46 O6,M5 O5,M6   
1 O5,M5 O6,M6   24 O6,M5 O5,M6   47 O5,M5 O6,M6   
2 O6,M5 O5,M6   25 O5,M6 O6,M5   48 O5,M6 O6,M5   
3 O6,M6 O5,M5   26 O5,M5 O6,M6   49 O6,M6 O5,M5   
4 O5,M5 O6,M6   27 O6,M5 O5,M6   50 O6,M5 O5,M6   
5 O6,M5 O5,M6   28 O5,M5 O6,M6   51 O5,M5 O6,M6   
6 O5,M6 O6,M5   29 O5,M6 O6,M5   52 O6,M6 O5,M5   
7 O5,M5 O6,M6   30 O6,M6 O5,M5   53 O5,M6 O6,M5   
8 O6,M5 O5,M6   31 O6,M5 O5,M6   54 O6,M5 O5,M6   
9 O5,M5 O6,M6   32 O5,M5 O6,M6   55 O6,M6 O5,M5   
10 O5,M6 O6,M5   33 O6,M6 O5,M5   56 O6,M5 O5,M6   
11 O6,M6 O5,M5   34 O5,M6 O6,M5   57 O5,M5 O6,M6   
12 O6,M5 O5,M6   35 O6,M5 O5,M6   58 O5,M5 O6,M6   
13 O5,M5 O6,M6   36 O6,M6 O5,M5   59 O6,M5 O5,M6   
14 O6,M6 O5,M5   37 O6,M5 O5,M6   60 O6,M6 O5,M5   
15 O5,M6 O6,M5   38 O5,M5 O6,M6    
Abort if >60 trials needed = failed set 
16 O6,M5 O5,M6   39 O5,M5 O6,M6   
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Appendix 2: The order of microdialysis experiments 
 
 Rat number Rat number 
Week 1 2 3 4 5 6 7 8 9 10 
1 2mg/kg PCP(1ml/kg): twice daily i.p. 1ml/kg saline : twice daily i.p. 
2 7-day washout 7-day washout 
3         Surgery Surgery 
           
           
          Habituation 
         Habituation Habituation 
4 Surgery Surgery Surgery   Surgery   Habituation Habituation 
         Habituation Test 
         Test  
 Habituation          
 Habituation Habituation         
5 Habituation Habituation  Surgery  Habituation Surgery    
 Test Habituation Habituation  Surgery Habituation  Surgery   
  Test Habituation   Habituation     
   Habituation Habituation  Test     
   Test Habituation   Habituation    
6    Habituation Habituation  Habituation    
    Test Habituation  Habituation Habituation   
     Habituation  Test Habituation   
     Test   Habituation   
        Test   
7 Analysis Analysis 
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Appendix 3 – Optimisation of dopamine detection 
using HPLC 
 
Results of using 1.2 mM OSA 
Figure 1 shows the chromatograms of a 100 nM mixed standard (DA, DOPAC, HVA 
and 5-HIAA) and the individual standards at 100 nM.  Figure 1A shows the following 
retention time (min): DOPAC, 4.53; 5-HIAA, 7.88; HVA 10.41; DA, 10.96. The 
identity of the peaks was determined following the individual standards shown in 
figures 1B-1E showing the respective retention times: DOPAC, 4.44; 5-HIAA, 7.77; 
HVA, 10.34; DA, 10.92.  The separation of the peaks was insufficient to measure DA.  
Therefore, the OSA concentration was reduced from 1.2 mM to 1.0 mM. 
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Figure 1:  Chromotgrams at 1.2 mM OSA. (A) shows the following retention time (min): DOPAC, 4.53; 
5-HIAA, 7.88; HVA 10.41; DA, 10.96. (B) shows the DOPAC peak at 4.44 min. (C) shows the 5-HIAA 
peak at 7.77 min. (D) shows the HVA peak at 10.34 min. (E) shows the DA peak at 10.92 min.   
 
 
Results of using 1.0 mM OSA 
Figure 2 shows the chromatograms of a 100 nM mixed standard (DA, DOPAC, HVA 
and 5-HIAA) and the individual standards at 100 nM.  Figure 2A shows the following 
retention time (min): DOPAC, 4.70; 5-HIAA, 8.07; HVA 11.22; DA, 9.11. The identity 
of the peaks was determined following the individual standards shown in figures 2B-2E 
showing the respective retention times: DOPAC, 4.84; 5-HIAA, 8.48; HVA, 11.53; DA, 
9.53.  The separation of the peaks was again insufficient to measure DA.  Therefore, the 
OSA concentration was increased from 1.0 mM to 1.1 mM. 
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A Mixed standard 100 nM
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D HVA 100 nM
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Figure 2:  Chromotgrams at 1.0 mM OSA. (A) shows the following retention time (min): DOPAC, 4.70; 
5-HIAA, 8.07; HVA 11.22; DA, 9.11. (B) shows the DOPAC peak at 4.84 min. (C) shows the 5-HIAA 
peak at 8.48 min. (D) shows the HVA peak at 11.53 min. (E) shows the DA peak at 9.53 min.  
 
 
Results of using 1.1 mM OSA 
Figure 3 shows the chromatograms of a 100 nM mixed standard (DA, DOPAC, HVA 
and 5-HIAA) and the individual standards at 100 nM.  Figure 3A shows the following 
retention time (min): DOPAC, 4.63; 5-HIAA, 7.66; HVA 10.92; DA, 8.68. The identity 
of the peaks was determined following the individual standards shown in figures 3B-3E 
showing the respective retention times: DOPAC, 4.59; 5-HIAA, 7.55; HVA, 10.74; DA, 
9.61.  The separation of the peaks was now sufficient to measure DA.  Therefore, the 
OSA concentration was maintained at 1.1 mM. 
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A Mixed standard 100 nM
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D HVA 100 nM
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Figure 3:  Chromotgrams at 1.1 mM OSA. (A) shows the following retention time (min): DOPAC, 4.63; 
5-HIAA, 7.66; HVA 10.92; DA, 8.68. (B) shows the DOPAC peak at 4.59 min. (C) shows the 5-HIAA 
peak at 7.55 min. (D) shows the HVA peak at 10.74 min. (E) shows the DA peak at 9.61 min.  
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Appendix 4 – Example chromatograms from HPLC 
 
Figure 1A shows an example chromatogram from a vehicle rat during the baseline 
phase.  Figure 1B shows an example chromatogram from a PCP rat during the baseline 
phase. 
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Figure 1: Example chromatograms from (A) a vehicle-treated rats and (B) a sub-chronic PCP-treated rat. 
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